1  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 NC T  03839459 
P ro to co l  ve r s ion /D a te :  
P ro to co l  # :  UMM Y18121  
Re fe ren ce  #  20187179 
T I T L E :  Deno sum ab  fo r  Smo lde r in g  Mu l t ip le  M ye lom a 
S tud y  Ch a i r : B r e a  L ip e ,  MD  
Un i v e r s i t y  o f  Ro ch e s t e r 
601  E lmwood  A v e ,  Bo x  704 
Ro ch e s t e r  N Y  14642 
IND  Numbe r : Deno sum ab : 
S tud y  Co l l abo r a to r : And r e a  B a r an ,  M S  b io s t a t i s t i c i an 
P ro to co l  Ve r s ion :  6 D a te :  15 Ju l2021 
Th i s  do cum en t  i s  a  con f id en t ia l  commun i ca t ion  o f  th e  Un i v e r s i t y  o f  Ro ch e s t e r .  A c c ep tan c e  o f  th i s  
do cum en t  con s t i tu t e s  ag r e em en t  b y  th e  r e c ip i en t  tha t  no  unpub l i sh ed  in fo rma t ion  con ta in ed  h e r e in  sha l l  
b e  pub l i sh ed  o r  d i s c lo s ed  w i thou t  p r io r  w r i t t en  app ro va l ,  e x c ep t  tha t  th i s  do cum en t  ma y  b e  d i s c lo s ed  to  
th e  app rop r ia t e  In s t i tu t iona l  R e v i ew  Boa rd s /  Ind ep end en t  E th i c s  Comm i t t e e s  und e r  th e  cond i t ion  tha t  th e y  
k e ep  i t  con f id en t ia l . 
2  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 T  A  B  L  E  O  F  C  O  N  T  E  N  T  S 
S TUD Y  S YNOP S I S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 
1 .  B a c k g round . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11 
1 .1SMM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11 
1 .2Bon e  D i s e a s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12 
1 .3E xp lo r a to r y  endpo in t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 
1 .4S tud y  d ru g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14 
1 .4 .1Ph a rm a co k in e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15 
1 .4 .2D eno sum ab  Do s e  S e l e c t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15 
1 .5H ypo th e s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15 
2OB J EC T IV E S  AND  ENDPO IN T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 
2 .1P r im a r y  Ob j e c t i v e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 
2 .2S e cond a r y  Ob j e c t i v e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 
3E L IG IB I L I T Y  CR I T ER IA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 
3 .1 In c lu s ion  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17 
3 .2E x c lu s ion  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17 
4S TUD Y  D E S IGN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 
4 .1O v e r v i ew  o f  S tud y  D e s i gn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 
4 .2R e g i s t r a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21 
4 .3D i s con t inu a t ion  f rom  S tud y  T r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21 
4 .4C r i t e r i a  fo r  S tud y  t e rm in a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21 
5S TUD Y  A S S E S SM EN T S  AND  TR EA TM EN T  SCH EDU L E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22 
6A g en t  Adm in i s t r a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24 
6 .1D eno sum ab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24 
6 .1 .1Fo rm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 
6 .1 .2S to r a g e  and  S t ab i l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 
6 .1 .3P r ep a r a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 
6 .1 .4Adm in i s t r a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 
6 .1 .5O rd e r in g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 
6 .1 .6S a f e t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26 
3  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 6 .1 .7D e s t ru c t ion  and  R e tu rn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27 
6 .1 .8Do s a g e  ad ju s tm en t s  and  d i s con t inu a t ion  o f  d eno sum ab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 
6 .2con com i t an t /  e x c lud ed  M ed i c a t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 
7M EA SUR EM EN T  O F  E F F EC T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 
7 .1M e thod  o f  A s s e s sm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 
7 .1 .1S e rum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 
7 .1 .2F r e e  L i gh t  Ch a in  T e s t in g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 
7 .1 .3U r in e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 
7 .1 .4Bon e  M a r row  E x am in a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 
7 .1 .5DXA  s c an s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 
7 .1 .6A s s e s sm en t  o f  r e spon s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 
8S TA T I S T ICA L  CON S ID ERA T ION S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 
8 .1d e s i gn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32 
8 .2P a t i en t  D i spo s i t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 
8 .3P a t i en t  D emo g r aph i c s  and  B a s e l in e  Ch a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 
8 .4E x t en t  o f  E xpo su r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 
8 .5S t a t i s t i c a l  An a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 
9SA F E T Y  R EPOR T ING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .34 
9 .1Ad v e r s e  E v en t  Ch a r a c t e r i s t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35 
9 .2D e f in i t ion s  o f  Ad v e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35 
9 .3Ad v e r s e  E v en t s  (A E s )  and  T r e a tm en t  Em e r g en t  Ad v e r s e  E v en t s  ( T EA E s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36 
9 .4Ad v e r s e  E v en t s / S e r iou s  Ad v e r s e  E v en t  C au s a l i t y  A s s e s sm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36 
9 .4 .1H and l in g  o f  Ad v e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36 
9 .5S e r iou s  Ad v e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 
9 .5 .1D e f in i t ion s  o f  S e r iou s  Ad v e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 
9 .5 .2S e r iou s  Ad v e r s e  E v en t  R epo r t in g  b y  In v e s t i g a to r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38 
9 .6R e co rd in g  o f  Ad v e r s e  E v en t s  and  S e r iou s  Ad v e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 
9 .6 .1P e r s i s t en t  o r  R e cu r r en t  Ad v e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 
9 .6 .2D e a th s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 
9 .6 .3Ho sp i t a l i z a t ion ,  P ro lon g ed  Ho sp i t a l i z a t ion ,  o r  Su r g e r y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 
9 .7S a f e t y  R epo r t in g  to  Am g en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40 
T ab le  9 .7 .1 .   E xped i ted  Repo r t in g  Requ i remen t s  fo r  In te r ven t ion a l  S tud ie s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 
4  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 T ab le  9 .7 .2 .  A g g re g a te  Repo r t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 
10C L IN ICA L  DA TA  CO L L EC T ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41 
10 .1Am endm en t s  to  th e  P ro to co l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41 
10 .2F in an c i a l  D i s c lo su r e s  and  E th i c a l  Con s id e r a t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41 
10 .3 IRB  and  R e gu l a to r y  app ro v a l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41 
10 .4 In fo rm ed  Con s en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42 
10 .5Con f id en t i a l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42 
10 .6S tud y  Do cum en t a t ion  and  S to r a g e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 
10 .7D a t a  Co l l e c t ion  and  S a f e t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .44 
10 .8Pub l i c a t ion  Po l i c y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .45 
11P l ann ed  co r r e l a t i v e  an a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .45 
12R E F ER ENC E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46 
13App end i x  A :  IMWG  r e spon s e  c r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50 
14App end i x  B :  Abb r e v i a t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .53 
5  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 S TUD  Y  S YNOP  S I S 
P ro to co l  no . 
S tud y  T i t le Deno sum ab  fo r  Smo lde r in g  Mu l t ip le  M ye lom a 
P r in c ip le  
In ve s t i g a to r  and  
S tud y  Ch a i r B r e a  L ip e ,  MD 
W i lmo t  C an c e r  In s t i tu t e ,  Un i v e r s i t y  o f  Ro ch e s t e r ,  Ro ch e s t e r  N Y  U SA 
S tud y  S i te  &  
En ro l lmen t Un i v e r s i t y  o f  Ro ch e s t e r  M ed i c a l  C en t e r  
20  e v a lu ab l e  p a t i en t s 
S tud y  R a t ion a le Smo ld e r in g  mu l t ip l e  m y e lom a  ( SMM )  i s  a  p r em a l i gn an t  cond i t ion  con v e y in g  a  
v a r i ab l e  r i s k  o f  p ro g r e s s ion  to  mu l t ip l e  m y e lom a ,  bu t  w i th  a  m ed i an  t im e  to  
p ro g r e s s ion  o f  2  y e a r s  fo r  h i gh  r i s k  p a t i en t s  [1 ] .  Wh i l e  th e  e x a c t  m e ch an i sm s  o f  
t r an s fo rm a t ion  f rom  SMM  to  mu l t ip l e  m y e lom a  (MM )  a r e  no t  known ,  
a l t e r a t ion s  in  bon e  m e t abo l i sm  a r e  s e en  in  bo th  p a t i en t s  w i th  SMM  and  MM  
and  a r e  in  p a r t  m ed i a t ed  th rou gh  a l t e r ed  bon e  m e t abo l i sm  l e ad in g  to  in c r e a s ed  
bon e  d e s t ru c t ion  [2 ] .  R e c en t l y ,  ch an g e s  in  m a r k e r s  fo r  bon e - tu rno v e r  h a v e  b e en  
a s so c i a t ed  w i th  d i s e a s e  p ro g r e s s ion  f rom  mono c lon a l  g ammop a th y  o f  
und e t e rm in ed  s i gn i f i c an c e  (MGU S )  to  MM  [3 ] .  A s  MM  r em a in s  an  in cu r ab l e  
d i s e a s e ,  th e r ap i e s  a im ed  to  p r e v en t  d i s e a s e  p ro g r e s s ion  o f  SMM  a r e  n e ed ed . 
D eno sum ab  i s  a  mono c lon a l  an t ibod y  t a r g e t in g  r e c ep to r  a c t i v a to r  o f  nu c l e a r  
f a c to r  k app a -B  l i g and  (RANK L )  th a t  co r r e l a t e s  to  imp ro v ed  bon e  
m i c ro a r ch i t e c tu r e  and  s t r en g th  [ 4 ] ,  bu t  who s e  b io lo g i c  e f f e c t s  a l so  m a k e  
d eno sum ab  o f  p a r t i cu l a r  in t e r e s t  in  SMM  and  MM .  In  p a t i en t s  w i th  MM ,  RANK L  
i s  up  r e gu l a t ed  wh i l e  OPG  i s  supp r e s s ed .  Th i s  d y s r e gu l a t ion  co r r e l a t e s  w i th  
c l in i c a l  d i s e a s e  a c t i v i t y ,  s e v e r i t y  o f  bon e  d i s e a s e ,  and  d e c r e a s ed  su r v i v a l  [5 ] .  In  
p a t i en t s  w i th  MGU S  and  SMM ,  RANK L ,  and  th e  RANK L /OPG  r a t io  a r e  in c r e a s ed  
comp a r ed  to  h e a l th y  con t ro l s ,  bu t  to  a  l e s s e r  e x t en t  th an  in  p a t i en t s  w i th  f r an k  
MM  [5 ] .  Th rou gh  a c t ion s  v i a  RANK L ,  d eno sum ab  a l so  c au s e s  a  r edu c t ion  in  DKK1  
l e v e l s  wh i ch  i s  imp l i c a t ed  in  d i s e a s e  p ro g r e s s ion  and  s k e l e t a l  d y s r e gu l a t ion  and  
p ro v id e s  fu r th e r  r a t ion a l e  fo r  th e  u s e  o f  d eno sum ab  in  p a t i en t s  w i th  SMM  who  
a r e  bo th  a t  r i s k  fo r  s k e l e t a l  e v en t s  and  d i s e a s e  p ro g r e s s ion  [6 ] .  W e  th e r e fo r e  
p ropo s e  to  s tud y  th e  imp a c t  o f  d eno sum ab  on  bon e  a r ch i t e c tu r e  and  m a r k e r s  
o f  bon e  m e t abo l i sm  in  p a t i en t s  w i th  SMM . 
6  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 S tud y  Ob je c t i ve s P r im a r y  ob je c t i ve : 
To  d e t e rm in e  th e  ch an g e  in  r i s k  fo r  p ro g r e s s ion  to  MM  in  p a t i en t s  w i th  
SMM  t r e a t ed  w i th  d eno sum ab  fo r  on e  y e a r . 
Se cond a r y  ob je c t i ve s : 
To  m e a su r e  th e  ch an g e  in  mono c lon a l  (M )  s e rum  p ro t e in  o r  f r e e  l i gh t  ch a in  
( F LC s )  a s  app rop r i a t e  to  a s s e s s  r e spon s e  p e r  IMWG  c r i t e r i a  l i s t ed  in  
App end i x  A . 
D e t e rm in e  th e  r a t e  o f  s k e l e t a l  r e l a t ed  e v en t s  ( SR E s ) 
To  a s s e s s  th e  r a t e  o f  d i s e a s e  p ro g r e s s ion  to  MM 
D e t e rm in e  th e  p ro g r e s s ion  f r e e  su r v i v a l  (P F S ) 
D e f in e  th e  r a t e  o f  ad v e r s e  e v en t s  (A E s ) 
D e t e rm in e  th e  ch an g e  in  bon e  m in e r a l  d en s i t y 
E xp lo r a to r y  ob je c t i ve s : 
To  d e t e rm in e  th e  imp a c t  o f  d eno sum ab  on  so lub l e  f a c to r s  o f  bon e  a c t i v i t y  
in c lud in g  M IP -1α ,  DKK1 ,  No t ch  s i gn a l in g ,  s c l e ro s t in ,  RANK L ,  and  OPG . 
To  d e s c r ib e  th e  ch an g e s  in  m e s en ch ym a l  and  o s t eo l in e a g e  popu l a t ion s  and  
o s t eop ro g en i to r  fun c t ion 
To  d e t e rm in e  th e  imp a c t  o f  d eno sum ab  d i s con t inu a t ion  on  m a r k e r s  o f  bon e  
tu rno v e r  and  bon e  fo rm a t ion  in c lud in g  s e rum  bon e  a l k a l in e  pho sph a t a s e ,  
to t a l  o s t eo c a l c in ,  p ro co l l a g en  t yp e  1  N - t e rm in a l  p rop ep t id e ,  s e rum  C -  
t e rm in a l  c ro s s - l in k ed  t e lop ep t id e s ,  and  u r in a r y  N  and  C - t e rm in a l  c ro s s -  
l in k ed  t e lop ep t id e s . 
In c lu s ion  C r i te r i a P a t i en t s  mu s t  m e e t  a l l  o f  th e  fo l low in g  in c lu s ion  c r i t e r i a  to  b e  e l i g ib l e  fo r  
p a r t i c ip a t ion  in  th i s  s tud y : 
1 .P a t i en t  h a s  con f i rm ed  SMM  a c co rd in g  to  th e  d e f in i t ion  o f  th e  In t e rn a t ion a l  
M y e lom a  Wo r k in g  G roup  ( IMWG )  d e f in i t ion :  s e rum  M -p ro t e in  ≥3  g /d L  o r  
BMPC  >10%  bu t  l e s s  th an  60% ,  o r  bo th ,  a lon g  w i th  no  p l a sm a - c e l l  r e l a t ed  
abno rm a l  o r g an  and  m a r row  fun c t ion  (CRAB  r e l a t ed  to  a  p l a sm a  c e l l  
d i so rd e r )  w i th in  24  w e e k s  p r io r  to  b a s e l in e ,  w i thou t  n ew  e v id en c e  o f  
d i s e a s e  p ro g r e s s ion  to  mu l t ip l e  m y e lom a . 
C :  Ab s en c e  o f  h yp e r c a l c em i a ,  e v id en c ed  b y  a  c a l c ium  ≤11  m g /d L ,  
R :  Ab s en c e  o f  r en a l  f a i lu r e ,  e v id en c ed  b y  a  c r e a t in in e  ≤ 2 .0m g /d L ,  
A :  Ab s en c e  o f  an em i a ,  e v id en c ed  b y  a  h emo g lob in  ≥10  g /d L 
B :  Ab s en c e  o f  l y t i c  bon e  l e s ion s  p e r  IMWG  r e comm end a t ion s : 
On e  o f  e i th e r  P E T -C T ,  low -do s e  who l e -bod y  C T  ( LDWBC T )  o r  MR I  o f  th e  
who l e  bod y  o r  sp in e .  In c r e a s ed  up t a k e  on  P E T -C T  a lon e  i s  no t  ad equ a t e  
fo r  th e  d i a gno s i s  o f  mu l t ip l e  m y e lom a ;  e v id en c e  o f  und e r l y in g  
7  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 o s t eo l y t i c  bon e  d e s t ru c t ion  i s  n e ed ed  on  th e  C T  po r t ion  o f  th e 
e x am in a t ion . 
8  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 2 . On e  o f  th e  r i s k  f a c to r s  b e low  th a t  po r t end s  fo r  an  in c r e a s ed  r i s k  o f  
p ro g r e s s ion  to  MM : 
An  abno rm a l  f r e e  l i gh t  ch a in  r a t io 
M - sp i k e  ≥ 2  g /d L 
≥ 20%  bon e  m a r row  p l a sm a  c e l l s 
Immunop a r e s i s  ≥ 20%  l e s s  th an  th e  in s t i tu t ion a l  no rm a l  s t and a rd  o f  
th e  un in vo l v ed  immuno g lobu l in s 
3 .S e rum  c a l c ium  o r  a lbum in - ad ju s t ed  s e rum  c a l c ium  ≥ 2 .1  mmo l / L  (8 .4  
m g /d L )  and  ≤ 2 .9mmo l / L  (11 .5  m g /d L )  (R e f e r en c e  r an g e  8 .5 -10 .8  m g /d L ) 
4 .  Ab l e  to  to l e r a t e  d a i l y  supp l em en t a t ion  o f  c a l c ium  and  v i t am in  D 
5 . Mu s t  h a v e  a  v i t am in  D  l e v e l  ≥ 30  n g /m L  o r  h a v e  a  l e v e l  12n g /m L  to  30n g /m L  
and  b e  on  a c t i v e  r ep l e t ion  w i th  cho l e c a l c i f e ro l  50 ,000  IU  po  w e e k l y  o r  
equ i v a l en t . 
6 .P a r t i c ip an t s  mu s t  h a v e  no rm a l  o r g an  a s  d e f in ed  b e low : 
To t a l  b i l i rub in  ≤ 2 .0  x  in s t i tu t ion a l  upp e r  l im i t  o f  no rm a l  (U LN ) ;  
p a t i en t s  d i a gno s ed  w i th  G i lb e r t ’ s  s ynd rom e  c an  en ro l l  w i th  a  to t a l  
b i l i rub in  >  2  a f t e r  r e v i ew  o f  th e  p r in c ip a l  in v e s t i g a to r 
A S T ( SGO T )  ≤2 .5  ×  in s t i tu t ion a l  U LN 
A L T ( SGP T )  ≤2 .5  ×  in s t i tu t ion a l  U LN 
7 .  A g e  ≥ 18  y e a r s . 
8 .  ECOG  P S  ≤1 
9 .L i f e  e xp e c t an c y  g r e a t e r  th an  12  mon th s 
10 .Sub j e c t s  w i th  r ep rodu c t i v e  po t en t i a l  mu s t  b e  w i l l in g  to  u s e ,  in  comb in a t ion  
w i th  h i s /h e r  p a r tn e r ,  2  h i gh l y  e f f e c t i v e  m e thod s  o f  e f f e c t i v e  con t r a c ep t ion  
o r  p r a c t i c e  s e xu a l  ab s t in en c e  th rou ghou t  th e  s tud y  and  con t inu e  fo r  5  
mon th s  a f t e r  th e  s tud y  du r a t ion .  Sub j e c t s  who  a r e  su r g i c a l l y  s t e r i l e  ( e . g .  
h i s to r y  o f  b i l a t e r a l  tub a l  l i g a t ion ,  h y s t e r e c tom y )  o r  who s e  s e xu a l  p a r tn e r  i s  
s t e r i l e  ( e . g .  h i s to r y  o f  v a s e c tom y )  a r e  no t  r equ i r ed  to  u s e  add i t ion a l  
con t r a c ep t i v e  m e a su r e s . 
11 .Ab i l i t y  to  und e r s t and  and  th e  w i l l in gn e s s  to  s i gn  a  w r i t t en  in fo rm ed  
con s en t  do cum en t . 
1 .  P a t i en t  i s  w i l l in g  and  ab l e  to  comp l y  w i th  th e  p ro to co l  fo r  th e  du r a t ion  o f  
th e  s tud y  in c lud in g  und e r go in g  t r e a tm en t  and  s ch edu l ed  v i s i t s  and  
e x am in a t ion s  in c lud in g  fo l low  up . 
12 .S t a t em en t  on  In c lu s ion  o f  Wom en  and  M ino r i t i e s 
M en  and  wom en  o f  a l l  e thn i c i t i e s  and  r a c i a l  b a c k g round s  a r e  
e l i g ib l e  fo r  th i s  s tud y . 
9  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 E x c lu s ion  C r i te r i a P a t i en t s  who  m e e t  an y  o f  th e  fo l low in g  e x c lu s ion  c r i t e r i a  a r e  no t  to  b e  en ro l l ed  
to  th i s  s tud y : 
1 .P r io r  adm in i s t r a t ion  o f  d eno sum ab . 
2 .An y  h i s to r y  o f  IV  b i spho sphon a t e  u s e  p r io r  to  o r  du r in g  th e  s tud y 
3 .P r e s c r ip t ion  o r a l  f luo r id e s  o r  b i spho sphon a t e  u s a g e  >  3  mon th s  w i th in  
th e  p a s t  2  y e a r s 
4 .S y s t em i c  co r t i co s t e ro id s  >  10m g  p r edn i son e  p e r  d a y 
5 .P a t i en t  h a s  s ymp tom a t i c  MM ,  a s  d e f in ed  b y  an y  o f  th e  fo l low in g  r e l a t ed  
to  th e  p l a sm a  c e l l  d i so rd e r : 
L y t i c  l e s ion s  o r  p a tho lo g i c  f r a c tu r e s . 
An em i a  (h emo g lob in  <10  g /d L ) 
H yp e r c a l c em i a  ( co r r e c t ed  s e rum  c a l c ium  >  11 .0  m g /d L ) 
R en a l  in su f f i c i en c y  ( c r e a t in in e  >  2 .0  m g /d L ) . 
C lon a l  bon e  m a r row  p l a sm a  c e l l s  >  60% 
An  in vo l v ed  s e rum  f r e e  l i gh t  ch a in  ( k app a  o r  L ambd a )  >  
100m g / L  w i th  th e  r a t io  o f  th e  in vo l v ed /un in vo l v ed  f r e e  l i gh t  
ch a in s  a l so  >  100  m g / L 
On e  o r  mo r e  o s t eo l y t i c  l e s ion s  on  r ad io g r aph y ,  bu t  mo r e  th an  
on e  l e s ion  i s  r equ i r ed  i f  <  10%  m a r row  p l a sm a  c e l l s .  F rom  MR I  
im a g in g ,  th e r e  mu s t  b e  mo r e  th an  on e  l e s ion  o f  >  5mm  in  s i z e . 
6 . O th e r :  s ymp tom a t i c  h yp e r v i s co s i t y ,  am y lo ido s i s ,  p l a sm a  c e l l  l eu k em i a ,  
PO EM S  s ynd rom e  (po l yn eu rop a th y ,  o r g anom e g a l y ,  endo c r inop a th y ,  
mono c lon a l  p ro t e in ) 
7 .P r io r  h i s to r y  o r  cu r r en t  e v id en c e  o f  o s t eon e c ro s i s /o s t eom y e l i t i s  o f  th e  
j aw . 
8 .A c t i v e  d en t a l  o r  j aw  cond i t ion  th a t  r equ i r e s  o r a l  su r g e r y ,  in c lud in g  too th  
e x t r a c t ion . 
9 . Non -h e a l ed  d en t a l /o r a l  su r g e r y ,  in c lud in g  too th  e x t r a c t ion . 
10 .P l ann ed  in v a s i v e  d en t a l  p ro c edu r e s  du r in g  th e  cou r s e  o f  s tud y . 
11 .E v id en c e  o f  an y  o f  th e  fo l low in g  cond i t ion s  p e r  sub j e c t  s e l f - r epo r t  o r  
m ed i c a l  ch a r t  r e v i ew : 
An y  p r io r  in v a s i v e  m a l i gn an c y  w i th in  3  y e a r s  o f  en ro l lm en t  th a t  
m a y  a f f e c t  ou t com e  o f  s tud y 
An y  non - in v a s i v e  m a l i gn an c y  no t  t r e a t ed  w i th  cu r a t i v e  in t en t  o r  
w i th  known  a c t i v e  d i s e a s e  w i th in  3  y e a r s  b e fo r e  en ro l lm en t  
th a t  m a y  a f f e c t  ou t com e  o f  s tud y 
M a jo r  su r g e r y  o r  s i gn i f i c an t  t r aum a t i c  in ju r y  o c cu r r in g  w i th in  4  
w e e k s  b e fo r e  en ro l lm en t 
A c t i v e  in f e c t ion  w i th  H ep a t i t i s  B  v i ru s  o r  H ep a t i t i s  C  v i ru s 
10  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 Known  in f e c t ion  w i th  hum an  immunod e f i c i en c y  v i ru s  (H IV )  
r equ i r in g  IV  an t i - in f e c t i v e  th e r ap y 
13 .Sub j e c t  i s  p r e gn an t  o r  b r e a s t  f e ed in g ,  o r  p l ann in g  to  b e com e  p r e gn an t  
w i th in  5  mon th s  a f t e r  th e  end  o f  t r e a tm en t . 
14 .F em a l e  sub j e c t  o f  ch i ld -b e a r in g  po t en t i a l  i s  no t  w i l l in g  to  u s e ,  in  
comb in a t ion  w i th  h e r  p a r tn e r ,  2  m e thod s  o f  h i gh l y  e f f e c t i v e  
con t r a c ep t ion  du r in g  t r e a tm en t  and  fo r  5  mon th s  a f t e r  th e  end  o f  
t r e a tm en t . 
15 .C l in i c a l l y  s i gn i f i c an t  h yp e r s en s i t i v i t y  to  d eno sum ab  o r  an y  compon en t s  
o f  d eno sum ab  120m g . 
16 .Known  s en s i t i v i t y  to  an y  o f  th e  p rodu c t s  to  b e  adm in i s t e r ed  du r in g  th e  
s tud y  ( e . g . ,  c a l c ium ,  o r  v i t am in  D ) . 
17 .Sub j e c t  i s  r e c e i v in g  o r  i s  l e s s  th an  14  d a y s  s in c e  end in g  o th e r  
e xp e r im en t a l  d ru g  (no  m a r k e t in g  au tho r i z a t ion  fo r  an y  ind i c a t ion ) . 
18 .An y  m a jo r  m ed i c a l  o r  p s y ch i a t r i c  d i so rd e r  th a t ,  in  th e  op in ion  o f  th e  
in v e s t i g a to r ,  m i gh t  p r e v en t  th e  sub j e c t  f rom  comp l e t in g  th e  s tud y  o r  
in t e r f e r e  w i th  th e  in t e rp r e t a t ion  o f  th e  s tud y  r e su l t s . 
E f f i c a c y  Endpo in t s 
Th e  p r im a r y  ob j e c t i v e  o f  th e  s tud y  i s  to  d e t e rm in e  th e  r a t e  o f  down g r ad ed  r i s k  
fo r  th e  p ro g r e s s ion  to  mu l t ip l e  m y e lom a  a s  d e f in ed  b y  a  r edu c t ion  in  th e  r i s k  
c a t e go r y  fo r  p ro g r e s s ion .  Th e  r i s k  c a t e go r i e s  w i l l  b e  id en t i f i ed  a s  in  s e c t ion  7 .1 .6  
u s in g  th e  M a yo  c l in i c  and  P E TH EMA  c r i t e r i a  [7 ,  8 ] . 
S tud y  De s i gn S in g l e  c en t e r ,  op en  l ab e l ,  Ph a s e  I I  s in g l e - a rm  t r i a l  o f  d eno sum ab  in  p a t i en t s  w i th  
smo ld e r in g  mu l t ip l e  m y e lom a .  Th e  t r i a l  w i l l  a im  to  en ro l l  10  p a t i en t s  p e r  y e a r  
w i th  2  y e a r s  o f  fo l low  up  a f t e r  comp l e t ion  o f  th e r ap y  fo r  a  to t a l  s tud y  du r a t ion  
o f  5  y e a r s . 
Do s in g 
Re g imen  & A l l  c y c l e s  w i l l  b e  28  d a y s . 
D eno sum ab :  120m g  w i l l  b e  adm in i s t e r ed  sub cu t an eou s l y  on c e  e v e r y  4  w e e k s , 
T re a tmen t + / -  on e  w e e k . 
S tud y  V i s i t s SCH EMA 
12  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 1.  BACKG  ROUND 
1 .1SMM 
P l a sm a  c e l l  d y s c r a s i a s  e x i s t  a s  a  sp e c t rum  o f  d i s e a s e s ,  f rom  th e  a s ymp tom a t i c  p r e cu r so r s  mono c lon a l  
g ammop a th y  o f  und e t e rm in ed  s i gn i f i c an c e  (MGU S )  and  smo ld e r in g  mu l t ip l e  m y e lom a  ( SMM )  to  th e  
m a l i gn an c y  mu l t ip l e  m y e lom a  (MM ) .  MM  i s  r e l a t i v e l y  r a r e  w i th  30 ,000  n ew  c a s e s  e s t im a t ed  in  2018  
[9 ] , and  w i th  14%  o f  tho s e  p a t i en t s  e xp e c t ed  to  h a v e  SMM  [10 ] .  MGU S  i s  a  r e l a t i v e l y  common  f ind in g  w i th  
in c r e a s in g  in c id en c e  w i th  a g e ,  s e en  in  up  to  3%  o f  p a t i en t s  o v e r  a g e  50  and  5%  o f  p a t i en t s  o v e r  a g e  70  
[11 ] .  MM  i s  an  in cu r ab l e  c an c e r  c au s in g  s i gn i f i c an t  mo rb id i t y  and  mo r t a l i t y  ch a r a c t e r i z ed  b y  
h yp e r c a l c em i a ,  r en a l  in su f f i c i en c y ,  an em i a ,  and  l y t i c  bon e  l e s ion s  (CRAB  c r i t e r i a ) ,  and  i s  f e l t  to  b e  
p r e c ed ed  b y  p r e cu r so r  p l a sm a  c e l l  d y s c r a s i a s  in  th e  fo rm  o f  MGU S  o r  SMM  [12 ] .  Mo s t  p a t i en t s  w i th  MGU S  
o r  SMM  do  no t  d e v e lop  MM ,  p ro v id in g  an  oppo r tun i t y  to  bo th  s tud y  and  und e r s t and  who  i s  a t  r i s k  to  
p ro g r e s s  and  to  in v e s t i g a t e  s t r a t e g i e s  a im ed  a t  p r e v en t in g  th e  d e v a s t a t in g  con s equ en c e s  fo r  th e  p a t i en t s  
d e s t in ed  to  g e t  MM . 
SMM  r equ i r e s  th e  ab s en c e  o f  m y e lom a  d e f in in g  e v en t s  r e l a t ed  to  th e  p l a sm a  c e l l  d i so rd e r ;  CRAB  c r i t e r i a  
(h yp e r c a l c em i a ,  an em i a ,  r en a l  in su f f i c i en c y ,  bon e  l e s ion s ,  and  an  in vo l v ed  s e rum  l i gh t  ch a in s <  100m g / L  and  a  
l i gh t  ch a in  r a t io  <  100 ) ,  and  th e  p r e s en c e  o f  b e tw e en  10% -60%  c lon a l  p l a sm a  c e l l s  in  th e  bon e  m a r row ,  and /  o r  
a  s e rum  M  p ro t e in  l e v e l  ≥3  g /d L ,  and  /o r  a  u r in e  mono c lon a l  p ro t e in  l e v e l  ≥500  m g /24  hou r s  [13 ] .  Wh i l e  
p a t i en t s  w i th  SMM  a r e  b y  d e f in i t ion ,  a s ymp tom a t i c ,  th e y  c a r r y  a  l i f e lon g  r i s k  o f  p ro g r e s s in g  to  th e  in cu r ab l e  
m a l i gn an c y ,  mu l t ip l e  m y e lom a  (MM ) .  Th e  a v e r a g e  r i s k  o f  p ro g r e s s ion  to  MM  f rom  SMM  i s  10%  p e r  y e a r  fo r  
th e  f i r s t  f i v e  y e a r s ,  and  th e  r i s k  d e c r e a s e s  w i th  th e  p a s s a g e  o f  t im e  to  a  m a in t a in ed  r i s k  o f  1%  p e r  y e a r  [14 ] .  
Amon g s t  p a t i en t s  w i th  SMM ,  r i s k  f a c to r s  th a t  p r ed i spo s e  a  h i gh e r  th an  a v e r a g e  r i s k  o f  p ro g r e s s ion  h a v e  b e en  
id en t i f i ed  and  in c lud e  a  s e rum  mono c lon a l  p ro t e in  l e v e l  ≥ 4 g /d L ,  a  bon e  m a r row  p l a sm a  c e l l  p e r c en t a g e  >  50%  
o r  b e tw e en  20 -50% ,  immunop a r e s i s ,  and  an  abno rm a l  f r e e  l i gh t  ch a in  r a t io  o f  in vo l v ed  to  un in vo l v ed  ch a in s  o f  
>8  o r  e l e v a t ed  f rom  no rm a l  [1 ,  7 ] .  A  mo r e  r e c en t  r i s k  s t r a t i f i c a t ion  s y s t em  w a s  p r e s en t ed  a t  A SCO ,  2019  and  
p r ed i c t s  a  h i gh e r  r i s k  o f  d i s e a s e  p ro g r e s s ion  to  MM  fo r  p a t i en t s  w i th  a  p a r ap ro t e in  o f  a t  l e a s t  2 g /  d L  and  a t  
l e a s t  20%  bon e  m a r row  p l a sm a  c e l l s  [60 ] .   S t r a t i f i c a t ion  o f  SMM  u s in g  r i s k  f a c to r s  fo r  p ro g r e s s ion  h a s  a l low ed  
g r e a t e r  p r e c i s ion  in  id en t i f y in g  p a t i en t s  mo r e  l i k e l y  to  g e t  MM .     Th i s  i s  an  e xp lo r a to r y  s tud y  and  w i l l  
in c lud e  an y  p a t i en t  w i th  SMM  w i th  an  in c r e a s ed  r i s k  o f  p ro g r e s s ion  to       MM . .  SMM  i s  d i f f e r en t i a t ed  f rom  
MGU S  b y  a  h i gh e r  p l a sm a  c e l l  bu rd en  and  in c r e a s ed  r i s k  o f  p ro g r e s s ion  to  MM  [11 ] .  P a t i en t s  w i th  MGU S  h a v e  
c lon a l  bon e  m a r row  p l a sm a  c e l l s  <  10% ,  an  M -p ro t e in  <  3 g /d L ,  u r in e  mono c lon a l  p ro t e in s  <  500  m g /24  hou r s ,  
and  th e  ab s en c e  o f  m y e lom a  d e f in in g  e v en t s  o r  CRAB  c r i t e r i a  and  an  a v e r a g e  r i s k  o f  p ro g r e s s ion  to  MGU S  o f  
1%  p e r  y e a r  [15 ] . 
13  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 *R i s k  f a c to r s  in c lud ed  in  th e  mod e l  in c lud e  mono c lon a l  p ro t e in  l e v e l s  ≥3 g /d L ,  Bon e  m a r row  p l a sm a  c e l l s  ≥10% ,  and  h a v in g  an  
abno rm a l  f r e e  l i gh t  ch a in  r a t io 
Th e  cu r r en t  s t and a rd  o f  c a r e  fo r  p a t i en t s  w i th  SMM  o r  MGU S  i s  ob s e r v a t ion  w i thou t  a c t i v e  t r e a tm en t  
b e c au s e  e a r l y  t r i a l s  fo r  th e  t r e a tm en t  o f  SMM  d id  no t  d emon s t r a t e  a  su r v i v a l  ad v an t a g e  and  
d emon s t r a t ed  to x i c i t y  [16 ,  17 ] .  In i t i a l  r e su l t s  w i th  th a l idom id e  d emon s t r a t ed  r e spon s e  r a t e s ,  bu t  
w id e sp r e ad  ad ap t a t ion  o f  e a r l y  t r e a tm en t  w a s  l im i t ed  b y  th e  r i s k s  in vo l v ed  w i th  t r e a t in g  p a t i en t s  who  
m a y  n e v e r  d e v e lop  an  a c t i v e  d i s e a s e [18 ,  19 ] .  A  r andom i z ed  t r i a l  o f  th a l idom id e  +  zo l ed ron i c  a c id  v e r su s  
zo l ed ron i c  a c id  a lon e  show ed  imp ro v ed  P F S ,  bu t  no  d i f f e r en c e  in  th e  r a t e  o f  P F S  a s  d e f in ed  b y  CRAB  
c r i t e r i a  o r  O S  [20 ] .  Mo r e  r e c en t l y ,  th e  P E TH EMA  g roup  r epo r t ed  r e su l t s  on  th e  t r e a tm en t  o f  p a t i en t s  w i th  
SMM  a t  h i gh  r i s k  fo r  d i s e a s e  p ro g r e s s ion  who  w e r e  r andom i z ed  to  t r e a tm en t  w i th  l en a l idom id e  and  
d e x am e th a son e  v e r su s  ob s e r v a t ion  a lon e .  P a t i en t s  on  th e  t r e a tm en t  a rm  h ad  imp ro v em en t s  in  th e  3 -  
y e a r  o v e r a l l  su r v i v a l  and  low e r  r a t e s  o f  d i s e a s e  p ro g r e s s ion  [21 ] .  How e v e r ,  g en e r a l i z ab i l i t y  o f  th e  
P E TH EMA  s tud y  h a s  b e en  qu e s t ion ed  b a s ed  on  th e  u s e  o f  f low  m a r k e r s  fo r  r i s k  s t r a t i f i c a t ion ,  and  on  th e  
cho i c e  o f  s a l v a g e  th e r ap y  in  th e  ob s e r v a t ion  a rm  th a t  d id  no t  in c lud e  l en a l idom id e ,  and  th e  w a y  th e  t r i a l  
d e a l t  w i th  b io ch em i c a l  p ro g r e s s ion .  D e sp i t e  th i s ,  th e  P E TH EMA  s tud y  h a s  r e g en e r a t ed  in t e r e s t  in  th e  
op t im a l  m an a g em en t  o f  p a t i en t s  w i th  SMM  and  h a s  l e ad  th e  w a y  fo r  mu l t ip l e  on go in g  c l in i c a l  t r i a l s ,  
in c lud in g  th i s  p ropo s ed  s tud y  suppo r t ed  b y  Am g en . 
1 .2BONE  D ISEA SE 
Wh i l e  th e  e x a c t  m e ch an i sm s  o f  t r an s fo rm a t ion  f rom  MGU S  to  MM  a r e  no t  known ,  a l t e r a t ion s  in  bon e  
m e t abo l i sm  a r e  s e en  in  p a t i en t s  w i th  MGU S  and  MM  and  a r e  in  p a r t  m ed i a t ed  th rou gh  a l t e r ed  bon e  
m e t abo l i sm  l e ad in g  to  in c r e a s ed  bon e  d e s t ru c t ion  [ 2 ] .  Th rou ghou t  l i f e ,  bon e  r emod e l in g  i s  an  on go in g  
b a l an c e  b e tw e en  c e l l s  th a t  m a k e  and  b r e a kdown  bon e ,  n am e l y  o s t eob l a s t s ,  o s t eo c l a s t s ,  and  o s t eo c y t e s .  
In  p a t i en t s  w i th  MM ,  th e  b a l an c ed  coup l in g  o f  bon e  mod e l in g  c e l l s  i s  d i s rup t ed  and  l e ad s  to  in c r e a s ed  
o s t eo c l a s t  a c t i v i t y  and  sub s equ en t  bon e  d e s t ru c t ion  [22 ] .  Th e  in c r e a s ed  bon e  tu rno v e r  s e en  in  m y e lom a  
i s  a l so  thou gh t  to  con t r ibu t e  to  d i s e a s e  p a tho g en e s i s  and  c an  b e  co r r e l a t ed  w i th  ad v an c ed  d i s e a s e  s t a g e 
14  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 and  an  in c r e a s ed  r i s k  o f  d e a th  [23 ] .  R e c en t l y ,  ch an g e s  in  m a r k e r s  fo r  bon e - tu rno v e r  h a v e  b e en  a s so c i a t ed  
w i th  d i s e a s e  p ro g r e s s ion  f rom  MGU S  to  MM  [3 ] .  A  m e t a - an a l y s i s  h a s  a l so  d emon s t r a t ed  an  in c r e a s ed  r i s k  
o f  f r a c tu r e  and  low e r  bon e  m in e r a l  d en s i t y  in  p a t i en t s  w i th  MGU S ,  d emon s t r a t in g  th a t  a l t e r a t ion s  in  bon e  
m e t abo l i sm  p r e c ed e  th e  m a l i gn an t  d i s e a s e  ph a s e  and  fu r th e r  suppo r t s  a  con t r ibu to r y  ro l e  [24 ] . 
Th e  p e r tu rb a t ion s  o f  bon e  m e t abo l i sm  s e en  amon g s t  p a t i en t s  w i th  p l a sm a  c e l l  d y s c r a s i a s  a r e  m ed i a t ed  in  
p a r t  th rou gh  th e  R e c ep to r  A c t i v a to r  o f  Nu c l e a r  F a c to r -  κB  (RANK )  and  RANK  L i g and  (RANK L )  p a thw a y .  
RANK L  i s  a  m emb r an e  bound  p ro t e in  e xp r e s s ed  on  c e l l s  o f  o s t eob l a s t  l in e a g e  th a t  b ind s  th e  RANK  r e c ep to r  
on  o s t eo c l a s t  p r e cu r so r s  to  indu c e  o s t eob l a s t i c  r e so rp t ion  and  in c r e a s e  o s t eo c l a s t  su r v i v a l  [2 ] .  
O s t eop ro t e g r in  (OPG ) ,  i s  a  d e co y  r e c ep to r  fo r  RANK  and  l im i t s  o s t eo c l a s to g en e s i s .  In  p a t i en t s  w i th  MM ,  
RANK L  i s  up  r e gu l a t ed  wh i l e  OPG  i s  supp r e s s ed .  Th i s  d y s r e gu l a t ion  co r r e l a t e s  w i th  c l in i c a l  d i s e a s e  a c t i v i t y ,  
s e v e r i t y  o f  bon e  d i s e a s e ,  and  d e c r e a s ed  su r v i v a l  [5 ] .  In  p a t i en t s  w i th  MGU S ,  RANK L ,  and  th e  RANK L /OPG  
r a t io  a r e  in c r e a s ed  comp a r ed  to  h e a l th y  con t ro l s ,  bu t  to  a  l e s s e r  e x t en t  th an  in  p a t i en t s  w i th  f r an k  MM  
[5 ] .  MM  c e l l s  a r e  f e l t  to  d i r e c t l y  p a r t i c ip a t e  in  th e  bon e  d y s r e gu l a t ion  a s  MM  c e l l s  c an  d i r e c t l y  p rodu c e  
bo th  RANK L  and  d e g r ad e  OPG  [25 -27 ] . 
C l in i c a l l y ,  th e  RANK /RANK L /OPG  p a thw a y  h a s  b e en  e xp lo i t ed  to  a l t e r  bon e  mod e l in g  and  d e c r e a s e  tumo r  
bu rd en .  In  th e  SC ID -hu -MM  mou s e  mod e l  o f  hum an  MM ,  a  RANK L  an t a gon i s t  l im i t ed  bon e  d e s t ru c t ion  
and  r edu c ed  tumo r  bu rd en  [28 ] .  Ano th e r  s tud y  d emon s t r a t ed  th e  ab i l i t y  o f  OPG  to  d e c r e a s e  s e rum  
p a r ap ro t e in  l e v e l s  and  inh ib i t  bon e  d e s t ru c t ion  in  mou s e  mod e l s  u s in g  th e  5 T2MM  c e l l  l in e  [29 ] .  In  
hum an s ,  t a r g e t in g  bon e  r emod e l in g  w i th  b i spho sphon a t e s  d e c r e a s e s  s k e l e t a l  r e l a t ed  e v en t s  [30 ,  31 ] .  In  
v i t ro ,  b i spho sphon a t e s  h a v e  a  d i r e c t  c y to to x i c  e f f e c t  [32 ,  33 ] .  I t  h a s  b e en  su g g e s t ed  a s  w e l l  th a t  mo r e  
po t en t  b i spho sphon a t e s  c an  imp ro v e  o v e r a l l  su r v i v a l  r a t e s  [34 ,  35 ] .  O v e r a l l ,  th e  an im a l  and  hum an  
e xp e r i en c e  d emon s t r a t e s  th e  th e r ap eu t i c  po t en t i a l  in  t a r g e t in g  bon e  r emod e l in g  to  modu l a t e  m y e lom a  
d i s e a s e  a c t i v i t y . 
G i v en  th e  e a r l y  p e r tu rb a t ion s  in  bon e  mod e l in g  s e en  in  p a t i en t s  w i th  MGU S  and  SMM ,  b i spho sphon a t e s  
h a v e  b e en  s tud i ed .  B i spho sphon a t e s  a r e  p y ropho sph a t e  an a lo g s  th a t  b ind  bon e  h yd ro x y ap a t i t e  and  
inh ib i t  o s t eo c l a s t  fun c t ion  and  bon e  r e so rp t ion  du r in g  r emod e l in g  [36 ] .  In  p am id ron a t e  and  zo l ed ron i c  
a c id ,  th e  mo s t  common l y  u s ed  b i spho sphon a t e s  fo r  p l a sm a  c e l l  d i so rd e r s ,  th e  m e ch an i sm  o f  a c t ion  i s  
th rou gh  inh ib i t ion  o f  th e  en z ym e  f a rn e s y l  p y ropho sph a t e  s yn th a s e ,  c au s in g  c y to s k e l e ton  abno rm a l i t i e s  in  
o s t eo c l a s t s  [37 ] .  Th e  a c t ion  o f  b i spho sphon a t e s  t r an s l a t e s  to  imp ro v em en t  in  bon e  m in e r a l  d en s i t y  in  
p a t i en t s  w i th  MGU S  wh en  g i v en  zo l ed ron i c  a c id  [38 ] .  How e v e r ,  r andom i z ed  s tud i e s  h a v e  e v a lu a t ed  th e  
imp a c t  o f  b i spho sphon a t e s  on  SMM  and  found  th a t  wh i l e  b i spho sphon a t e s  d e c r e a s e  th e  r i s k  o f  s k e l e t a l  
e v en t s ,  th e  p ro g r e s s ion  f r e e  su r v i v a l  w a s  no t  imp ro v ed  w i th  th e  u s e  o f  a  b i spho sphon a t e  [39 ,  40 ] . 
1 .3EXP LORATORY  ENDPO INTS 
In  p a t i en t s  w i th  MGU S ,  a l t e r ed  bon e  a r ch i t e c tu r e  h a s  a l so  b e en  l in k ed  to  e l e v a t ed  DKK1 ,  s c l e ro s t in ,  and  
M IP -1 a  l e v e l s  [41 ] .  DKK1  i s  a  k e y  r e gu l a to r  o f  o s t eob l a s t  a c t i v i t y  thou gh t  to  p l a y  a  ro l e  in  m y e lom a  bon e  
d i s e a s e  th rou gh  a c t ion  v i a  th e  Wn t  p a thw a y  on  RANK L  and  OPG  [42 ] .  DKK1  i s  a l so  thou gh t  to  p l a y  a  ro l e  
in  d i s e a s e  p ro g r e s s ion  and  r e l ap s e  in  MM .  Th e r ap i e s  t a r g e t in g  DKK1  (BHQ880 )  a r e  in  d e v e lopm en t  fo r  th e  
t r e a tm en t  o f  MM  and  SMM  [43 ,  44 ] .  D eno sum ab  c au s e s  a  r edu c t ion  in  DKK1  l e v e l s  and  fu r th e r  s tud y 
15  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 in to  co r r e l a t ion  o f  th e  c l in i c a l  imp a c t  o f  d eno sum ab  w i th  DKK1  l e v e l s  and  o s t eop ro g en i to r s  e v a lu a t ion  a r e  
n e ed ed  [6 ] .  No t ch  s i gn a l in g  i s  a l so  imp l i c a t ed  in  th e  p ro g r e s s ion  o f  MM  f rom  p r e cu r so r  s t a t e s  th rou gh  
up r e gu l a t ion  o f  RANK L  and  a l t e r a t ion s  in  th e  bon e  m a r row  s t rom a l  en v i ronm en t  [ 45 ] .  Th e  imp a c t  o f  
d eno sum ab  on  bon e  s i gn a l in g  p a thw a y s  r equ i r e s  fu r th e r  s tud y  g i v en  th e  impo r t an c e  o f  th e s e  s i gn a l in g  
p a thw a y s  a t  th e  in t e r f a c e  b e tw e en  bon e  RANK L  e xp r e s s ion ,  bon e  h e a l th ,  and  MM  d i s e a s e  p a tho g en e s i s . 
In  add i t ion  to  a l t e r ed  bon e  mod e l in g ,  MM  in vo l v ed  a l t e r a t ion s  in  bon e  c e l l  fun c t ion .  P a t i en t s  w i th  MM  
h a v e  d e c r e a s ed  o s t eo c y t e s  and  imp a i r ed  ab i l i t y  o f  bon e  m a r row  s t rom a l  c e l l s  to  d i f f e r en t i a t e  in to  
o s t eob l a s t s  [ 46 ,  47 ] .  C e l l  to  c e l l  in t e r a c t ion s  w i th in  th e  bon e  m a r row  s t rom a l  comp a r tm en t  a r e  impo r t an t  
fo r  MM  c e l l  hom in g  and  th e s e  a l t e r ed  s t rom a l  comp a r tm en t s  in  m y e lom a  a r e  impo r t an t  fo r  d i s e a s e  
p a tho g en e s i s  [48 ] .  Th e  imp a c t  o f  d eno sum ab  on  th e  p r e cu r so r  s t rom a l  en v i ronm en t  i s  no t  known ,  bu t  th e  
impo r t an c e  o f  o s t eop ro g en i to r s  and  th e  s t rom a l  comp a r tm en t  in  MM  p a tho g en e s i s  m a k e  fu r th e r  s tud y  
o f  po t en t i a l  d eno sum ab  imp a c t s  o f  p a r t i cu l a r  impo r t an c e .  W e  th e r e fo r e  p ropo s e  to  s tud y  th e  imp a c t  o f  
d eno sum ab  on  bon e  a r ch i t e c tu r e  and  m a r k e r s  o f  bon e  m e t abo l i sm  in  p a t i en t s  w i th  MGU S  and  SMM . 
1 .4STUDY  DRUG 
D eno sum ab  i s  a  fu l l y  hum an  mono c lon a l  I gG2  an t ibod y  t a r g e t in g  RANK L  in  so lub l e  and  m emb r an e  bound  
fo rm s .  D eno sum ab  b ind s  w i th  h i gh  a f f in i t y  and  sp e c i f i c i t y  w i thou t  b ind in g  to  o th e r  r e l a t ed  p ro t e in s  o f  th e  
TN F  f am i l y  [52 ] .  A  k e y  d i f f e r en c e  b e tw e en  d eno sum ab  and  b i spho sphon a t e s  i s  th a t  d eno sum ab  c an  e x e r t  
e f f e c t  w i th in  th e  e x t r a c e l lu l a r  m i l i eu  v e r su s  r equ i r in g  in t e rn a l i z a t ion ,  a l low in g  a  mo r e  b ro ad  imp a c t  fo r  
d eno sum ab  on  th e  d e v e lopm en t  and  su r v i v a l  o f  o s t eo c l a s t s  [53 ] .  Fu r th e rmo r e ,  th e  a c t i v i t y  o f  c i r cu l a t in g  
d eno sum ab  a l low s  fo r  b ro ad e r  imp a c t  on  bon e  v e r su s  a t  th e  bon e  m in e r a l  su r f a c e  [54 ,  55 ] .  C l in i c a l l y ,  th e  
d i f f e r en c e s  b e tw e en  b i spho sphon a t e s  and  d eno sum ab  h a v e  b e en  ob s e r v ed .  In  wom en  w i th  low  bon e  
m in e r a l  d en s i t y ,  d eno sum ab  in c r e a s ed  bon e  m in e r a l  d en s i t y  comp a r ed  to  a  b i spho sphon a t e  [56 ]  .  
Ano th e r  s tud y  d emon s t r a t ed  th e  ab i l i t y  o f  d eno sum ab  to  in c r e a s e  bon e  m in e r a l  d en s i t y  in  p a t i en t s  
a l r e ad y  t r e a t ed  w i th  a  b i spho sphon a t e  [57 ] .  In  m a l i gn an c y ,  a  r andom i z ed  ph a s e  3  s tud y  d emon s t r a t ed  
non - in f e r io r i t y  o f  d eno sum ab  comp a r ed  to  zo l ed ron i c  a c id  in  d e l a y in g  t im e  to  f i r s t  s k e l e t a l  r e l a t ed  e v en t ,  
bu t  show ed  d eno sum ab  h ad  g r e a t e r  ab i l i t y  to  supp r e s s  bon e  tu rno v e r  [58 ] .  A  ph a s e  3  t r i a l  in  MM  a l so  
show ed  non - in f e r io r i t y  o f  d eno sum ab  comp a r ed  to  zo l ed ron i c  a c id ,  bu t  d emon s t r a t ed  an  imp ro v em en t  
in  p ro g r e s s ion  f r e e  su r v i v a l  fo r  p a t i en t s  t r e a t ed  on  th e  d eno sum ab  a rm  [50 ] .  O v e r a l l ,  th e  p r e c l in i c a l  and  
c l in i c a l  d a t a  su g g e s t s  th a t  d eno sum ab  e x e r t s  a  fund am en t a l l y  d i f f e r en t  imp a c t  on  bon e  r emod e l in g  v i a  a  
d i f f e r en t  m e ch an i sm  o f  a c t ion  f rom  b i spho sphon a t e s  and  o f f e r s  a  no v e l  oppo r tun i t y  to  fu r th e r  e xp lo r e  
th e  imp a c t  o f  RANK L  inh ib i t ion  in  p a t i en t s  w i th  p l a sm a  c e l l  d y s c r a s i a s . 
C a s e  r epo r t s  h a v e  su g g e s t ed  a  r a r e  r i s k  o f  mu l t ip l e  v e r t eb r a l  f r a c tu r e s  in  wom en  who  d i s con t inu e  
d eno sum ab [49 ] .  Th e  d e s c r ib ed  c a s e  r epo r t s  d emon s t r a t e  th e  r i s k  o f  mu l t ip l e  v e r t eb r a l  f r a c tu r e s  in  wom en  
und e r go in g  t r e a tm en t  fo r  b r e a s t  c an c e r  o r  w i th  a  h i s to r y  o f  o s t eopo ro s i s ,  w i th  lon g e r  du r a t ion  o f  u s e  
s e em in g  to  co r r e l a t e  w i th  th e  in c r e a s ed  r i s k .  Th e r e  a r e  no  r epo r t s  o f  mu l t ip l e  v e r t eb r a l  f r a c tu r e s  in  wom en  
t r e a t ed  w i th  d eno sum ab  fo r  mu l t ip l e  m y e lom a  [50 ] .  Th e  e x a c t  m e ch an i sm  o f  th i s  in c r e a s ed  r i s k  i s  no t  
known ,  bu t  a  r ebound  in c r e a s e  in  bon e  r e so rp t ion  and  r e su l t an t  d e c r e a s e  in  bon e  m in e r a l  d en s i t y  i s  
thou gh t  to  b e  th e  l i k e l y  cu lp r i t  [51 ] .  In  th i s  s tud y ,  w e  p ropo s e  to  fo l low  m a r k e r s  o f  bon e  r e so rp t ion 
16  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 and  DXA  s c an s  fo r  2  y e a r s  a f t e r  th e  d i s con t inu a t ion  o f  d eno sum ab  to  d e t e rm in e  th e  lon g - t e rm  e f f e c t s  o f  
d eno sum ab  w i thd r aw a l  in  p a t i en t s  w i th  SMM . 
D eno sum ab  i s  cu r r en t l y  FDA  app ro v ed  fo r  th e  p r e v en t ion  o f  s k e l e t a l - r e l a t ed  e v en t s  in  p a t i en t s  w i th  
mu l t ip l e  m y e lom a .  Add i t ion a l  and  upd a t ed  in fo rm a t ion  c an  b e  found  in  th e  In v e s t i g a to r ’ s  B ro chu r e  fo r  
add i t ion a l  and  upd a t ed  in fo rm a t ion  on  s a f e t y ,  b a c k g round ,  and  c l in i c a l  e xp e r i en c e . 
1 .4 .1 PHARMACOK IN E T IC S 
D eno sum ab  d i sp l a y s  do s e -d ep end en t ,  non l in e a r  ph a rm a co k in e t i c s  a t  do s e s  b e low  60m g  in  h e a l th y  
p a t i en t s  and  p a t i en t  popu l a t ion s  e v a lu a t ed .  How e v e r ,  do s e -p ropo r t ion a l  in c r e a s e s  in  e xpo su r e  (b a s ed  on  
a r e a  und e r  th e  s e rum  con c en t r a t ion - t im e  cu r v e  and  m a x imum  s e rum  d eno sum ab  con c en t r a t ion )  a r e  s e en  
a t  h i gh e r  do s e s .  B io a v a i l ab i l i t y  i s  62% .  In  p a t i en t s  w i th  n ew l y  d i a gno s ed  MM ,  120  m g  d eno sum ab  
sub cu t an eou s l y  e v e r y  4  w e e k s  (Q4W ) ,  up  to  2 .8 - fo ld  a c cumu l a t ion  in  s e rum  d eno sum ab  con c en t r a t ion s  
w a s  ob s e r v ed  a t  s t e ad y - s t a t e  ( a t  6  mon th s )  and  th e s e  s t e ad y - s t a t e  e xpo su r e s  w e r e  m a in t a in ed  w i th  
con t inu ed  do s in g .  Th e s e  r e su l t s  a r e  con s i s t en t  w i th  a  l a c k  o f  ch an g e  in  ph a rm a co k in e t i c s  w i th  t im e  upon  
mu l t ip l e  do s in g .  Th e  m e an  e l im in a t ion  h a l f - l i f e  w a s  28  d a y s .  M ed i an  r edu c t ion s  in  uN T x /C r  o f  
app ro x im a t e l y  75%  w e r e  ob s e r v ed  b y  w e e k  5 .  R edu c t ion s  in  bon e  tu rno v e r  m a r k e r s  w e r e  m a in t a in ed ,  
w i th  m ed i an  r edu c t ion s  o f  74%  to  79%  fo r  uN T x /C r  f rom  w e e k s  9  to  49  o f  con t inu ed  120m g  q4w  do s in g . 
1 .4 .2D ENO SUMAB  DO S E  S E L EC T ION 
A s  m en t ion ed  abo v e ,  mu l t ip l e  ph a s e  3  s tud i e s  h a v e  d emon s t r a t ed  th e  e f f i c a c y  and  s a f e t y  o f  th e  120  m g  
SC  Q4W  do s e  r e g im en ,  w i th  non - in f e r io r i t y  in  th e  r i s k  o f  SR E s  comp a r ed  w i th  zo l ed ron i c  a c id  ob s e r v ed  in  
sub j e c t s  w i th  ad v an c ed  m a l i gn an c i e s  in vo l v in g  bon e .  In  add i t ion ,  th i s  do s e  r e g im en  l ed  to  s i gn i f i c an t l y  
g r e a t e r  (p  <  0 .0001 )  supp r e s s ion  o f  uN T x /C r  wh en  comp a r ed  to  zo l ed ron i c  a c id ;  th i s  r e su l t  and  th e  robu s t  
SR E  d a t a  fo r  d eno sum ab  su g g e s t  th a t  t a r g e t in g  m a x im a l  supp r e s s ion  o f  uN T x /C r  i s  an  app rop r i a t e  s t r a t e g y  
fo r  do s e  s e l e c t ion . 
D eno sum ab  adm in i s t e r ed  a t  a  do s e  o f  120  m g  SC  Q4W  h a s  b e en  w e l l  to l e r a t ed  in  th e  p i vo t a l  ph a s e  3  
s tud i e s .  Th e r e fo r e ,  120  m g  SC  Q4W  h a s  b e en  s e l e c t ed  a s  th e  do s e  in  sub j e c t s  w i th  SMM  in  th i s  s tud y 
1 .5  H YPO TH E S I S 
Cu r r en t  s t and a rd  o f  c a r e  fo r  p a t i en t s  w i th  SMM  i s  c lo s e  ob s e r v a t ion  d e sp i t e  th e  r i s k  o f  d e v e lop in g  an  
in cu r ab l e  m a l i gn an c y .  Wh i l e  th e  e x a c t  m e ch an i sm s  fo r  d i s e a s e  p ro g r e s s ion  f rom  SMM  to  MM  a r e  no t  
known ,  p e r tu rb a t ion s  in  bon e  mod e l in g  a r e  l in k ed  to  d i s e a s e  p ro g r e s s ion  b io lo g i c a l l y  and  c l in i c a l l y .  
Sp e c i f i c a l l y ,  th e  RANK L  p a thw a y  i s  po s tu l a t ed  to  p l a y  a  ro l e  in  th e  d e v e lopm en t  o f  MM  and  inh ib i t ion  o f  
th i s  p a thw a y  h a s  l ed  to  tumo r  r edu c t ion  in  an im a l  mod e l s .  D eno sum ab  i s  an  FDA  app ro v ed  a g en t  th a t  h a s  
p ro v en  s a f e  and  e f f e c t i v e  in  modu l a t in g  bon e  mod e l in g  and  p r e v en t in g  s k e l e t a l  r e l a t ed  e v en t s  in 
17  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 p a t i en t s  w i th  MM .  Th e  un iqu e  m e ch an i sm  o f  a c t ion  and  s t ron g  s a f e t y  p ro f i l e  m a k e  d eno sum ab  an  id e a l  
d ru g  to  t a r g e t  d i s e a s e  p ro g r e s s ion  in  SMM .  W e  th e r e fo r e  h ypo th e s i z e  th a t  d eno sum ab  w i l l  r e su l t  in  
r edu c ed  d i s e a s e  a c t i v i t y  and  a  d e c r e a s ed  r i s k  o f  p ro g r e s s ion  to  MM .  W e  fu r th e r  h ypo th e s i z e  th a t  th e  
a l t e r a t ion s  in  bon e  r emod e l in g  w i l l  l e ad  to  in c r e a s ed  bon e  m in e r a l  d en s i t y ,  and  low e r  th an  e xp e c t ed  r a t e s  
o f  d i s e a s e  p ro g r e s s ion  and  p ro lon g ed  p ro g r e s s ion  f r e e  su r v i v a l  wh en  comp a r ed  to  h i s to r i c a l  a v e r a g e s .  
Add i t ion a l l y ,  th e  u l t im a t e  e f f e c t s  o f  d eno sum ab  on  o s t eop ro g en i to r  numb e r s ,  fun c t ion  and  th e  imp a c t  on  
modu l a to r s  o f  MM  d i s e a s e  a c t i v i t y  a s  i t  in t e r a c t s  w i th  th e  bon e  m a r row  s t rom a l  comp a r tm en t  a r e  no t  
known  bu t  b e a r  fu r th e r  in v e s t i g a t ion . 
2OB JECT  IVES  AND  E  ND  P  O  INTS 
2 .1PR IMARY  OB JECT IVE 
To  d e t e rm in e  th e  ch an g e  in  r i s k  fo r  p ro g r e s s ion  to  MM  in  p a t i en t s  w i th  SMM  t r e a t ed  w i th  d eno sum ab  
fo r  on e  y e a r . 
2 .2SECONDARY  OB JECT IVES 
To  m e a su r e  th e  ch an g e  in  mono c lon a l  (M )  s e rum  p ro t e in  o r  f r e e  l i gh t  ch a in  ( F LC s )  a s  app rop r i a t e  to  
a s s e s s  fo r  d i s e a s e  r e spon s e  p e r  th e  IMWG  c r i t e r i a  in  App end i x  A . 
D e t e rm in e  th e  r a t e  o f  s k e l e t a l  r e l a t ed  e v en t s  ( SR E s ) 
To  a s s e s s  th e  r a t e  o f  d i s e a s e  p ro g r e s s ion  to  MM 
D e t e rm in e  th e  p ro g r e s s ion  f r e e  su r v i v a l  (P F S ) 
D e f in e  th e  r a t e  o f  ad v e r s e  e v en t s  (A E s ) 
D e t e rm in e  th e  ch an g e  in  bon e  m in e r a l  d en s i t y  a s  m e a su r ed  b y  bon e  d en s i tom e t r y  (DXA  s c ann in g ) 
E xp lo r a to r y  ob je c t i ve s : 
To  d e t e rm in e  th e  imp a c t  o f  d eno sum ab  on  so lub l e  f a c to r s  o f  bon e  a c t i v i t y  in c lud in g  M IP -1α ,  No t ch  
s i gn a l in g ,  DKK1 ,  s c l e ro s t in ,  RANK L ,  and  OPG . 
To  d e s c r ib e  th e  ch an g e s  in  m e s en ch ym a l  and  o s t eo l in e a g e  popu l a t ion s  and  o s t eop ro g en i to r  fun c t ion 
To  d e t e rm in e  th e  imp a c t  o f  d eno sum ab  d i s con t inu a t ion  on  m a r k e r s  o f  bon e  tu rno v e r  and  bon e  
fo rm a t ion  in c lud in g  s e rum  bon e  a l k a l in e  pho sph a t a s e ,  to t a l  o s t eo c a l c in ,  p ro co l l a g en  t yp e  1  N -  
t e rm in a l  p rop ep t id e ,  s e rum  C - t e rm in a l  c ro s s - l in k ed  t e lop ep t id e s ,  and  u r in a r y  N  and  C - t e rm in a l  c ro s s -  
l in k ed  t e lop ep t id e s . 
3E L  IG IB  I L  IT  Y  CR  ITER I  A 
P a t i en t s  mu s t  m e e t  a l l  o f  th e  fo l low in g  in c lu s ion  c r i t e r i a  and  non e  o f  th e  e x c lu s ion  c r i t e r i a  to  b e  e l i g ib l e  
fo r  p a r t i c ip a t ion  in  th i s  s tud y . 
18  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 3 .1INC LUS ION  CR ITER IA 
P a t i en t s  mu s t  m e e t  a l l  o f  th e  fo l low in g  in c lu s ion  c r i t e r i a  to  b e  e l i g ib l e  fo r  p a r t i c ip a t ion  in  th i s  s tud y : 
1 .P a t i en t  h a s  con f i rm ed  SMM  a c co rd in g  to  th e  d e f in i t ion  o f  th e  In t e rn a t ion a l  M y e lom a  Wo r k in g  
G roup  ( IMWG )  d e f in i t ion :  s e rum  M -p ro t e in  ≥3  g /d L  o r  BMPC  >10%  bu t  l e s s  th an  60% ,  o r  bo th ,  
a lon g  w i th  no  p l a sm a - c e l l  r e l a t ed  abno rm a l  o r g an  and  m a r row  fun c t ion  (CRAB  r e l a t ed  to  a  p l a sm a  
c e l l  d i so rd e r )  w i th in  24  w e e k s  p r io r  to  b a s e l in e ,  w i thou t  n ew  e v id en c e  o f  d i s e a s e  p ro g r e s s ion  to  
mu l t ip l e  m y e lom a . 
C :  Ab s en c e  o f  h yp e r c a l c em i a ,  e v id en c ed  b y  a  c a l c ium  ≤11  m g /d L .  
R :  Ab s en c e  o f  r en a l  f a i lu r e ,  e v id en c ed  b y  a  c r e a t in in e  ≤ 2 .0m g /d L  
A :  Ab s en c e  o f  an em i a ,  e v id en c ed  b y  a  h emo g lob in  ≥10  g /d L . 
B :  Ab s en c e  o f  l y t i c  bon e  l e s ion s  p e r  IMWG  r e comm end a t ion s : 
On e  o f  e i th e r  P E T -C T ,  low -do s e  who l e -bod y  C T  ( LDWBC T )  o r  MR I  o f  th e  who l e  bod y  o r  sp in e .  
In c r e a s ed  up t a k e  on  P E T -C T  a lon e  i s  no t  ad equ a t e  fo r  th e  d i a gno s i s  o f  mu l t ip l e  m y e lom a ;  e v id en c e  
o f  und e r l y in g  o s t eo l y t i c  bon e  d e s t ru c t ion  i s  n e ed ed  on  th e  C T  po r t ion  o f  th e  e x am in a t ion . 
2 . On e  o f  th e  r i s k  f a c to r s  b e low  th a t  po r t end s  fo r  an  in c r e a s ed  r i s k  o f  p ro g r e s s ion  to  MM : 
•  An  abno rm a l  f r e e  l i gh t  ch a in  r a t io 
• M - sp i k e  ≥ 2  g /d L 
•≥ 20%  bon e  m a r row  p l a sm a  c e l l s 
•  Immunop a r e s i s  ≥ 20%  l e s s  th an  th e  in s t i tu t ion a l  no rm a l  s t and a rd  o f  th e  un in vo l v ed  
immuno g lobu l in s 
3 .S e rum  c a l c ium  o r  a lbum in - ad ju s t ed  s e rum  c a l c ium  ≥ 2 .1  mmo l / L  (8 .4  m g /d L )  and  ≤ 2 .9mmo l / L  
(11 .5  m g /d L )  (R e f e r en c e  r an g e  8 .5 -10 .8  m g /d L ) 
4 .Ab l e  to  to l e r a t e  d a i l y  supp l em en t a t ion  o f  c a l c ium  and  v i t am in  D 
5 . Mu s t  h a v e  a  v i t am in  D  l e v e l  ≥ 30  n g /m L  o r  h a v e  a  l e v e l  12n g /m L  to  30n g /m L  and  b e  on  a c t i v e  r ep l e t ion  w i th  
cho l e c a l c i f e ro l  50 ,000  IU  po  w e e k l y  o r  equ i v a l en t . 
6 .P a r t i c ip an t s  mu s t  h a v e  no rm a l  o r g an  a s  d e f in ed  b e low : 
To t a l  b i l i rub in  ≤ 2 .0  x  in s t i tu t ion a l  upp e r  l im i t  o f  no rm a l  (U LN ) ;  p a t i en t s  d i a gno s ed  w i th  
G i lb e r t ’ s  s ynd rom e  c an  en ro l l  w i th  a  to t a l  b i l i rub in  >  2  a f t e r  r e v i ew  o f  th e  p r in c ip a l  in v e s t i g a to r 
A S T  ( SGO T )  ≤2 .5  ×  in s t i tu t ion a l  U LN  
A L T  ( SGP T )  ≤2 .5  ×  in s t i tu t ion a l  U LN 
7 .A g e  ≥ 18  y e a r s . 
8 .ECOG  P S  ≤1 
9 .L i f e  e xp e c t an c y  g r e a t e r  th an  12  mon th s 
10 .Sub j e c t s  w i th  r ep rodu c t i v e  po t en t i a l  mu s t  b e  w i l l in g  to  u s e ,  in  comb in a t ion  w i th  h i s /h e r  p a r tn e r ,  
2  h i gh l y  e f f e c t i v e  m e thod s  o f  e f f e c t i v e  con t r a c ep t ion  o r  p r a c t i c e  s e xu a l  ab s t in en c e  th rou ghou t  
th e  s tud y  and  con t inu e  fo r  5  mon th s  a f t e r  th e  s tud y  du r a t ion .  Sub j e c t s  who  a r e  su r g i c a l l y  s t e r i l e  
19  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 ( e . g .  h i s to r y  o f  b i l a t e r a l  tub a l  l i g a t ion ,  h y s t e r e c tom y )  o r  who s e  s e xu a l  p a r tn e r  i s  s t e r i l e  ( e . g .  h i s to r y  
o f  v a s e c tom y )  a r e  no t  r equ i r ed  to  u s e  add i t ion a l  con t r a c ep t i v e  m e a su r e s . 
11 .Ab i l i t y  to  und e r s t and  and  th e  w i l l in gn e s s  to  s i gn  a  w r i t t en  in fo rm ed  con s en t  do cum en t . 
12 .P a t i en t  mu s t  b e  w i l l in g  and  ab l e  to  comp l y  w i th  th e  p ro to co l  fo r  th e  du r a t ion  o f  th e  s tud y  
in c lud in g  und e r go in g  t r e a tm en t  and  s ch edu l ed  v i s i t s  and  e x am in a t ion s  in c lud in g  fo l low  up . 
13 .M en  and  wom en  o f  a l l  r a c i a l  and  e thn i c  o r i g in s  a r e  e l i g ib l e  fo r  th i s  s tud y . 
3 .2EXC LUS ION  CR ITER IA 
P a t i en t s  who  m e e t  an y  o f  th e  fo l low in g  e x c lu s ion  c r i t e r i a  a r e  no t  to  b e  en ro l l ed  to  th i s  s tud y : 
20  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 1 .P r io r  adm in i s t r a t ion  o f  d eno sum ab . 
2 .An y  h i s to r y  o f  IV  b i spho sphon a t e  u s e  p r io r  to  o r  du r in g  th e  s tud y 
3 .P r e s c r ip t ion  o r a l  f luo r id e s  o r  b i spho sphon a t e  u s a g e  >  3  mon th s  w i th in  th e  p a s t  2  y e a r s 
4 .S y s t em i c  co r t i co s t e ro id s  >  10m g  p r edn i son e  p e r  d a y 
5 .Known  s e cond a r y  c au s e  fo r  o s t eop en i a  o r  o s t eopo ro s i s 
6 .P a t i en t  h a s  s ymp tom a t i c  MM ,  a s  d e f in ed  b y  an y  o f  th e  fo l low in g  r e l a t ed  to  th e  p l a sm a  c e l l  d i so rd e r : 
L y t i c  l e s ion s  o r  p a tho lo g i c  f r a c tu r e s . 
An em i a  (h emo g lob in  <10  g /d L ) 
H yp e r c a l c em i a  ( co r r e c t ed  s e rum  c a l c ium  >  11 .0  m g /d L ) 
R en a l  in su f f i c i en c y  ( c r e a t in in e  >  2 .0  m g /d L ) . 
C lon a l  bon e  m a r row  p l a sm a  c e l l s  >  60% 
An  in vo l v ed  s e rum  f r e e  l i gh t  ch a in  ( k app a  o r  L ambd a )  >  100m g / L  w i th  th e  r a t io  o f  th e  
in vo l v ed /un in vo l v ed  f r e e  l i gh t  ch a in s  a l so  >  100  m g / L 
On e  o r  mo r e  o s t eo l y t i c  l e s ion s  on  r ad io g r aph y ,  bu t  mo r e  th an  on e  l e s ion  i s  r equ i r ed  i f  <  10%  
m a r row  p l a sm a  c e l l s .  F rom  MR I  im a g in g ,  th e r e  mu s t  b e  mo r e  th an  on e  l e s ion  o f  >  5mm  in  
s i z e . 
7 . O th e r :  s ymp tom a t i c  h yp e r v i s co s i t y ,  am y lo ido s i s ,  p l a sm a  c e l l  l eu k em i a ,  PO EM S  s ynd rom e  
(po l yn eu rop a th y ,  o r g anom e g a l y ,  endo c r inop a th y ,  mono c lon a l  p ro t e in ) 
8 .  P r io r  h i s to r y  o r  cu r r en t  e v id en c e  o f  o s t eon e c ro s i s /o s t eom y e l i t i s  o f  th e  j aw . 
9 .A c t i v e  d en t a l  o r  j aw  cond i t ion  th a t  r equ i r e s  o r a l  su r g e r y ,  in c lud in g  too th  e x t r a c t ion . 
10 .Non -h e a l ed  d en t a l /o r a l  su r g e r y ,  in c lud in g  too th  e x t r a c t ion . 
11 .P l ann ed  in v a s i v e  d en t a l  p ro c edu r e s  du r in g  th e  cou r s e  o f  s tud y . 
12 .E v id en c e  o f  an y  o f  th e  fo l low in g  cond i t ion s  p e r  sub j e c t  s e l f - r epo r t  o r  m ed i c a l  ch a r t  r e v i ew : 
An y  p r io r  in v a s i v e  m a l i gn an c y  w i th in  3  y e a r s  o f  en ro l lm en t  th a t  m a y  a f f e c t  ou t com e  o f  s tud y 
An y  non - in v a s i v e  m a l i gn an c y  no t  t r e a t ed  w i th  cu r a t i v e  in t en t  o r  w i th  known  a c t i v e  d i s e a s e  
w i th in  3  y e a r s  b e fo r e  en ro l lm en t  th a t  m a y  a f f e c t  ou t com e  o f  s tud y 
M a jo r  su r g e r y  o r  s i gn i f i c an t  t r aum a t i c  in ju r y  o c cu r r in g  w i th in  4  w e e k s  b e fo r e  en ro l lm en t 
A c t i v e  in f e c t ion  w i th  H ep a t i t i s  B  v i ru s  o r  H ep a t i t i s  C  v i ru s 
Hum an  immunod e f i c i en c y  v i ru s  (H IV )  r equ i r in g  IV  an t i - in f e c t i v e  th e r ap y 
13 .Sub j e c t  i s  p r e gn an t  o r  b r e a s t  f e ed in g ,  o r  p l ann in g  to  b e com e  p r e gn an t  w i th in  5  mon th s  a f t e r  th e  end  
o f  t r e a tm en t . 
14 .F em a l e  sub j e c t  o f  ch i ld -b e a r in g  po t en t i a l  i s  no t  w i l l in g  to  u s e ,  in  comb in a t ion  w i th  h e r  p a r tn e r ,  2  
m e thod s  o f  h i gh l y  e f f e c t i v e  con t r a c ep t ion  du r in g  t r e a tm en t  and  fo r  5  mon th s  a f t e r  th e  end  o f  
t r e a tm en t . 
15 .C l in i c a l l y  s i gn i f i c an t  h yp e r s en s i t i v i t y  to  d eno sum ab  o r  an y  compon en t s  o f  d eno sum ab  120m g . 
16 .Known  s en s i t i v i t y  to  an y  o f  th e  p rodu c t s  to  b e  adm in i s t e r ed  du r in g  th e  s tud y  ( e . g . ,  c a l c ium ,  o r  v i t am in  
D ) . 
17 .Sub j e c t  i s  r e c e i v in g  o r  i s  l e s s  th an  14  d a y s  s in c e  end in g  o th e r  e xp e r im en t a l  d ru g  (no  m a r k e t in g  
au tho r i z a t ion  fo r  an y  ind i c a t ion ) . 
21  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 18 .An y  m a jo r  m ed i c a l  o r  p s y ch i a t r i c  d i so rd e r  th a t ,  in  th e  op in ion  o f  th e  in v e s t i g a to r ,  m i gh t  p r e v en t  th e  
sub j e c t  f rom  comp l e t in g  th e  s tud y  o r  in t e r f e r e  w i th  th e  in t e rp r e t a t ion  o f  th e  s tud y  r e su l t s . 
22  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 4STUD  Y  D  ES IG  N 
4 .1OVERV IEW  O F  STUDY  DE  S IGN 
Th i s  i s  an  op en  l ab e l ,  Ph a s e  I I  t r i a l  o f  d eno sum ab  120m g  sub cu t an eou s  ( SC )  fo r  p a t i en t s  w i th  smo ld e r in g  
mu l t ip l e  m y e lom a  ( SMM ) .  Sub j e c t s  w i l l  b e  r e c ru i t ed  f rom  th e  J am e s  P .  W i lmo t  C an c e r  C en t e r ,  Un i v e r s i t y  
o f  Ro ch e s t e r  in  Ro ch e s t e r ,  N ew  Yo r k .  P a t i en t s  s e en  in  th e  inp a t i en t  o r  ou tp a t i en t  s e t t in g  w i th  h i s to lo g i c a l l y  
con f i rm ed  SMM  w i l l  b e  e v a lu a t ed  fo r  th i s  s tud y . 
20  p a t i en t s  w i l l  b e  t r e a t ed  a s  fo l low s : 
D eno sum ab :  d a y  1  =  120m g  SC  e v e r y  4  w e e k s  fo r  12  c y c l e s .  C y c l e s  w i l l  b e  28  d a y s  in  l en g th .  P a t i en t s  w i l l  
b e  fo l low ed  a f t e r  comp l e t ion  o f  th e  s tud y  p e r  s t and a rd  o f  c a r e  fo r  p ro g r e s s ion  f r e e  su r v i v a l  fo r  an  
add i t ion a l  2  y e a r s  a f t e r  th e  l a s t  do s e  o f  d eno sum ab .  A l l  p a t i en t s  w i l l  t a k e  d a i l y  v i t am in  D  and  c a l c ium  
supp l em en t s  o f  a t  l e a s t  1200m g  e l em en t a l  c a l c ium  and  800 IU  o f  v i t am in  D  un l e s s  do cum en t ed  
h yp e r c a l c em i a  d e v e lop s  on  s tud y .  P r e - e x i s t in g  h ypo c a l c em i a  mu s t  b e  co r r e c t ed  p r io r  to  in i t i a t in g  th e r ap y  
w i th  d eno sum ab . 
S e rum  v i t am in  D  l e v e l s  w i l l  b e  ch e c k ed  du r in g  s c r e en in g  and  p a t i en t s  w i th  h yd ro x y v i t am in  D  l e v e l  <  
30n g /m L  p r io r  to  d eno sum ab  adm in i s t r a t ion  mu s t  t a k e  a t  l e a s t  50 ,000  IU  cho l e c a l c i f e ro l  w e e k l y  du r in g  
t r e a tm en t  o r  equ i v a l en t  un t i l  h yd ro x y v i t am in  D  l e v e l  ≥ 30n g /m L  a t  wh i ch  t im e  p a t i en t s  c an  con t inu e  800 IU  
v i t am in  d  d a i l y .  H yd ro x y v i t am in  D  l e v e l s  <  30n g /m L  w i l l  b e  r ep e a t ed  a t  l e a s t  e v e r y  12  w e e k s  o r  mo r e  
f r equ en t l y  a t  in v e s t i g a to r ’ s  d i s c r e t ion . 
Co r re l a te s : 
C l in i c a l  l ab s  in c lud in g  CBC ,  CMP ,  and  SP EP  w i th  I F E ,  F LC ,  qu an t i t a t i v e  immuno g lobu l in s ,  and  pho spho rou s  
l e v e l s  w i l l  b e  co l l e c t ed  a t  b a s e l in e ,  mon th l y  du r in g  t r e a tm en t ,  and  a t  13  mon th s .  A  UP EP  w i th  I F E  w i l l  b e  
co l l e c t ed  a t  b a s e l in e  and  a t  13  mon th s  and  add i t ion a l l y  a s  p e r  c l in i c a l l y  ind i c a t ed .  O th e r  c l in i c a l  l ab s  w i l l  
b e  co l l e c t ed  du r in g  th e  s tud y  p e r  s t and a rd  o f  c a r e  o f  th e  in v e s t i g a to r . 
In v e s t i g a t ion a l  L ab s  (p e r iph e r a l  b lood  and  u r in e )  to  b e  co l l e c t ed  a t  b a s e l in e ,  13  mon th s ,  24  mon th s ,  and  
36  mon th s  w i l l  b e  an a l y z ed  in  th e  l abo r a to r y  o f  B r e a  L ip e 
DXA  s c an s  w i l l  b e  condu c t ed  a t  b a s e l in e ,  13  mon th s ,  24  mon th s ,  and  36  mon th s 
Bon e  m a r row  and  a sp i r a t e  s amp l e s  w i l l  b e  an a l y z ed  fo r  b a s e l in e  d i s e a s e  a s s e s sm en t  and  d i s e a s e  r e spon s e  
in  th e  c l in i c a l  p a tho lo g y  l abo r a to r y  a t  th e  Un i v e r s i t y  o f  Ro ch e s t e r  M ed i c a l  C en t e r  w i th  add i t ion a l  a sp i r a t e  
s amp l e s  to  b e  an a l y z ed  in  th e  L ip e  l abo r a to r y . 
P a t i en t s  m a y  d i s con t inu e  th e r ap y  e a r l y  fo r  un a c c ep t ab l e  to x i c i t y  o r  w i thd r aw a l  f rom  th e  s tud y  du e  to  
in v e s t i g a to r  d e c i s ion  o r  o th e r  r e a son s . 
23  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 4 .2REG ISTRAT ION 
4 .3 PAT IENTS  MU ST  NOT  START  ANY  PROTOCO L  INTERVENT ION  PR IOR  TO  
REG ISTRAT ION  THROUGH  THE  W I LMOT  CANCER  INST ITUTE .  REG ISTRAT I  ON S  ARE  
CAPTURED  IN  THE  W I LMOT  CANCER  IN ST ITUTE  REDCAP  DATABA SE  AT  THE  UN IVER S ITY  
O F  ROCHESTER .  S ITE  PERSONNE L  W I L L  BE  RESPONS IB LE  FOR  ENTER ING  THE  PAT IENT  
DATA  INTO  REDCAP  W ITH IN  24  HOUR S  O F  THE  S IGN ING  O F  IN FORMED  CON SENT .  
D ISCONT INUAT ION  FROM  STUDY  TREATMENT 
P a t i en t s  w i l l  b e  d i s con t inu ed  f rom  s tud y  t r e a tm en t  fo r  an y  o f  th e  fo l low in g  r e a son s : 
P a r t i a l  w i thd r aw a l  o f  con s en t  m e an in g  th a t  a  p a t i en t  d e c l in e s  fu r th e r  d eno sum ab ,  bu t  con s en t s  
to  con t inu ed  d a t a  and  s amp l e  co l l e c t ion . 
Fu l l  w i thd r aw a l  o f  con s en t  m e an in g  a  p a t i en t  do e s  no t  w i sh  to  r e c e i v e  fu r th e r  d eno sum ab  and  
do e s  no t  w i sh  to  con t inu e  an y  fu r th e r  s tud y  p a r t i c ip a t ion . 
P r e gn an c y  in  a  f em a l e  p a t i en t 
In ab i l i t y  o f  th e  p a t i en t  to  comp l y  w i th  s tud y  r equ i r em en t s 
U s e  o f  b i spho sphon a t e s  o r  comm e r c i a l  u s e  o f  d eno sum ab 
Non - comp l i an c e / lo s t  to  fo l low -up 
In v e s t i g a to r  d i s c r e t ion 
S tud y  t e rm in a t ion 
P a t i en t s  who  d i s con t inu e  f rom  s tud y  t r e a tm en t  w i l l  con t inu e  to  b e  fo l low ed  fo r  p ro g r e s s ion  and  l a t e  
to x i c i t i e s  fo r  on e  y e a r .  A f t e r  w i thd r aw a l  f rom  p ro to co l  t r e a tm en t ,  p a t i en t s  w i l l  b e  fo l low ed  fo r  A E s  fo r  30  
c a l end a r  d a y s  a f t e r  th e i r  l a s t  do s e  o f  s tud y  d ru g .  A l l  n ew  A E s  o c cu r r in g  du r in g  th i s  p e r iod  w i l l  b e  r epo r t ed  
and  fo l low ed  un t i l  r e so lu t ion ,  un l e s s ,  in  th e  op in ion  o f  th e  in v e s t i g a to r ,  th e s e  v a lu e s  a r e  no t  l i k e l y  to  
imp ro v e  b e c au s e  o f  th e  und e r l y in g  d i s e a s e .  In  th i s  c a s e  th e  in v e s t i g a to r  mu s t  r e co rd  h i s  o r  h e r  r e a son in g  
fo r  th i s  d e c i s ion  in  th e  p a t i en t ’ s  m ed i c a l  r e co rd s .  A l l  p a t i en t s  who  h a v e  C TCA E  G r ad e  3  o r  4  l abo r a to r y  
abno rm a l i t i e s  a t  th e  t im e  o f  w i thd r aw a l  shou ld  b e  fo l low ed  un t i l  th e  l abo r a to r y  v a lu e s  h a v e  r e tu rn ed  to  
G r ad e  1  o r  2 ,  un l e s s  in  th e  op in ion  o f  th e  in v e s t i g a to r ,  i t  i s  no t  l i k e l y  th a t  th e s e  v a lu e s  a r e  to  imp ro v e  
b e c au s e  o f  th e  und e r l y in g  d i s e a s e .  In  th i s  c a s e ,  th e  in v e s t i g a to r  mu s t  r e co rd  h i s  o r  h e r  r e a son in g  fo r  
m a k in g  th i s  d e c i s ion  in  th e  p a t i en t ’ s  m ed i c a l  r e co rd s . 
4 .4CR ITER IA  FOR   STUDY  T  ERM INAT ION 
Th i s  s tud y  w i l l  b e  con s id e r ed  t e rm in a t ed  wh en  1  o f  th e  fo l low in g  cond i t ion s  a r e  m e t : 
A l l  sub j e c t s  h a v e  comp l e t ed  a l l  r equ i r ed  s tud y  v i s i t s ; 
A l l  sub j e c t s  h a v e  d i s con t inu ed  f rom  th e  s tud y ; 
24  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 Th e  Un i v e r s i t y  o f  Ro ch e s t e r  D a t a  S a f e t y  Mon i to r in g  Comm i t t e e  o r  In s t i tu t ion a l  R e v i ew  Bo a rd  ( IRB )  
d i s con t inu e s  th e  s tud y  b e c au s e  o f  s a f e t y  con s id e r a t ion s . 
5STUD  Y  A S  SES  SM  ENTS  AN  D  TREATM  E  NT  SC  HE  D  U L  E 
T ab l e  5 .1  b e low  l i s t s  a l l  o f  th e  r equ i r ed  a s s e s sm en t s  th a t  shou ld  b e  p e r fo rm ed  a t  th e  co r r e spond in g  s tud y  
v i s i t . 
TAB L E  5 .1 :  S TUD Y  A S S E S SM EN T S  AND  TR EA TM EN T  SCH EDU L E 
25  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 P ro cedu re P r e - 
s tud y 1S tud y 
D a y  1 2W e e k s 
2 -4 C2 -C12 O f f 
T r e a tm en t 16 24  mon th s 36 
mon th s 
In fo rm ed  Con s en t X
In c lu s ion / E x c lu s ion 
C r i t e r i a XX
M ed i c a l  and  T r e a tm en t 
H i s to r y X
Ph y s i c a l  E x am 3XX XX
O r a l  E x am in a t ion 4XX XX
ECOG  P e r fo rm an c e 
S t a tu s XX XX
CBC  w i th  d i f f 3X XX
S e rum  Ch em i s t r i e s 3 ,5 
X XX
S e rum  C a l c ium 6X XXX
7sC TX ,  M IP -1α ,  DKK1 , 
s c l e ro s t in ,  NO TCH  
RANK L ,  and  OPG 7X X
7M a r k e r s  o f  bon e  
r e so rp t ion  and  tu rno v e r X XXX
uN TX 8X XXX
SP EP  w i th  I F E X XX
UP EP  w i th  I F E 9X X
F r e e  l i gh t  ch a in  t e s t in g X XX
V i t am in  D  l e v e l X x
P r e gn an c y  T e s t 10 X
Bon e  m a r row  b iop s y / 
a sp i r a t e  11 X X
P E T -C T ,  low -do s e  who l e - 
bod y  C T  o r  MR I  o f  th e  
who l e  bod y  o r  sp in e X
D eno sum ab  ( SC ) 12 X X
DXA X XXX
Ad v e r s e  E v en t 
E v a lu a t ion 13 X XX
S k e l e t a l  E v en t 
R e co rd in g 14 X XX
Con com i t an t 
M ed s / T r e a tm en t 15 XX XX
1S c reen in g :  A l l  s c r e en in g  a s s e s sm en t s  mu s t  b e  comp l e t ed  and  r e su l t s  ob t a in ed  ( e . g . ,  ch em i s t r y ,  
h em a to lo g y )  b e fo r e  en t r y  in to  th e  s tud y .  A s s e s sm en t s  condu c t ed  a s  s t and a rd  o f  c a r e  do  no t  r equ i r e  
in fo rm ed  con s en t  and  m a y  b e  p ro v id ed  a s  s c r e en in g  d a t a .  Im a g in g  t e s t s  don e  a s  s t and a rd  o f  c a r e  w i th in  
th e  12  mon th s  p r io r  to  en ro l lm en t  w i l l  b e  con s id e r ed  w i th in  th e  s c r e en in g  w indow .   O th e r  s c r e en in g  
a s s e s sm en t s  w i l l  h a v e  a  30  d a y  w indow . 
26  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 2S tud y  D a y  1 :  Th e  f i r s t  d a y  th a t  d i s e a s e - r e l a t ed  t r e a tm en t  i s  adm in i s t e r ed  w i l l  b e  s tud y  d a y  1 . 
3Ph y s i c a l  E x am ,  V i t a l  S i gn s ,  Hem a to lo g y  and  Chem :  v i s i t  d a y s  h a v e  -  8  d a y  w indow 
27  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 4O r a l  E x am in a t ion :  A  v i su a l  e x am in a t ion  o f  th e  o r a l  c a v i t y ,  in c lud in g  t e e th ,  mu co s a  to  e s t ab l i sh  b a s e l in e  
o r a l  h e a l th  cond i t ion s  and  to  id en t i f y  an y  n ew  abno rm a l i t i e s  o r  ch an g e s  in  p r e - e x i s t in g  cond i t ion s . 
5Se rum  Chem i s t r ie s :  To  in c lud e  N a ,  K ,  C L ,  CO2 ,  M g ,  Pho spho ru s ,  BUN ,  c r e a t in in e ,  g lu co s e ,  a lbum in ,  to t a l  
p ro t e in ,  a l k a l in e  pho sph a t a s e ,  to t a l  b i l i rub in ,  A S T ,  A L T 
6Se rum  C a l c ium :  Mon i to r ed  w e e k l y  fo r  f i r s t  4  w e e k s  th en  e v e r y  c y c l e  th e r e a f t e r  w i th  a  + / -3  d a y  w indow .  
C a l c ium  l e v e l  w i l lb e  a s s e s s ed  p r io r  to  th e  adm in i s t r a t ion  o f  d eno sum ab . 
7So lub le  m a r ke r s  o f  bone  tu rno ve r :  to  b e  d r awn  a f t e r  f a s t in g  to  b e  an a l y z ed  in  th e  l abo r a to r y  o f  B r e a  
L ip e ,  MD 
8U r in a r y  m a r ke r s :  to  b e  co l l e c t ed  f rom  s e cond  mo rn in g  vo id  and  to  b e  an a l y z ed  in  th e  l abo r a to r y  o f  B r e a  
L ip e ,  MD 
9UP EP :  Tw en t y - fou r  hou r  u r in e  s amp l e s  fo r  qu an t i t a t ion  o f  M -p ro t e in  and  a s s e s sm en t  o f  M -p ro t e in  b y  
immuno f i x a t ion  a r e  to  b e  r equ e s t ed  f rom  a l l  p a t i en t s  du r in g  s c r e en in g  and  w i l l  b e  an a l y z ed  in  th e  lo c a l  
l abo r a to r y .  P a t i en t s  m a y  r e fu s e  to  p ro v id e  u r in e  s amp l e s . 
10 Se rum  p re gn an c y  te s t :  p r io r  to  C y c l e  1  /  D a y  1  fo r  f em a l e s  o f  ch i ldb e a r in g  po t en t i a l .  I f  p a t i en t  h a s  
e xp e r i en c ed  m enop au s e  o r  no  lon g e r  h a s  u t e ru s  /  o v a r i e s  th i s  c an  b e  om i t t ed . 
11 Bone  m a r row  b iop s y  and  a sp i r a te :  rou t in e  p ro c e s s in g  p e r  p a tho lo g y  w i th  a sp i r a t e  and  m a r row  s amp l e s  
s en t  to  th e  l abo r a to r y  o f  B r e a  L ip e ,  MD .  B a s e l in e  bon e  m a r row  b iop s y / a sp i r a t e  no t  n e ed ed  i f  r e c en t  
s amp l e  w i th in  3  mon th s . 
12 T re a tmen t  adm in i s t r a t ion :  + / -  8  d a y  w indow ,  bu t  mu s t  h a v e  a  m in imum  o f  3 -w e e k  in t e r v a l s  fo r  
adm in i s t r a t ion  o f  d eno sum ab . 
13 Ad ve r se  e ven t  repo r t in g :  Ad v e r s e  e v en t s  mu s t  b e  a s s e s s ed  and  do cum en t ed  a t  e a ch  s ch edu l ed  c l in i c  
v i s i t .  Sub j e c t s  mu s t  b e  fo l low ed  fo r  ad v e r s e  e v en t s  fo r  30  d a y s  a f t e r  th e  l a s t  do s e  o f  d eno sum ab ,  o r  un t i l  
a l l  d eno sum ab - r e l a t ed  to x i c i t i e s  and  on go in g  s e r iou s  ad v e r s e  e v en t s  h a v e  r e so l v ed  o r  a r e  con s id e r ed  
s t ab l e ,  wh i ch e v e r  i s  l a t e r . 
14 S ke le t a l  e ven t  ( S E )  re co rd in g :  S E s  w i l l  in c lud e  a l l  p a tho lo g i c  f r a c tu r e s ,  r ad i a t ion  to  bon e ,  su r g e r y  to  bon e  
fo r  f r a c tu r e  o r  s t ab i l i z a t ion .  S E s  w i l l  b e  con f i rm ed  b y  im a g in g . 
15 Con com i t t an t  med i c a t ion s :  T yp e  and  t im in g  o f  con com i t an t  m ed i c a t ion s  w i l l  b e  co l l e c t ed .  C a l c ium  and  
v i t am in  D  supp l em en t a t ion  w i l l  b e  r e co rd ed . 
16 O f f  t re a tmen t :  4  w e e k s  +  30  d a y s  fo l low in g  comp l e t ion  o f  c y c l e  12  o r  upon  d i s con t inu a t ion  o f  th e r ap y .  
Fo l low  A E s  fo r  30  d a y s  a f t e r  d i s con t inu a t ion  o f  p ro to co l  t r e a tm en t ;  a f t e r  30  d a y s  on l y  A E s  r e l a t ed  to  
p ro to co l  mu s t  b e  fo l low ed .  Fo l low -up  su r v i v a l  and  s a f e t y  d a t a  w i l l  b e  co l l e c t ed  p e r  rou t in e  o f  c a r e  c l in i c  
v i s i t s  fo r  2  y e a r s  a f t e r  th e  l a s t  do s e  o f  d eno sum ab . 
6AGENT  AD  M  IN I  STRAT  I  ON 
6 .1DENOSUMAB 
28  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 D eno sum ab  i s  a  hum an  I gG2  mono c lon a l  an t ibod y  th a t  b ind s  to  hum an  RANK L .  D eno sum ab  h a s  an  
app ro x im a t e  mo l e cu l a r  w e i gh t  o f  147  kD a  and  i s  p rodu c ed  in  g en e t i c a l l y  en g in e e r ed  m amm a l i an  
(Ch in e s e  h am s t e r  o v a r y )  c e l l s . 
On s e t  o f  a c t ion :  D e c r e a s e s  m a r k e r s  o f  bon e  r e so rp t ion  b y  ~85%  w i th in  3  d a y s ;  m a x im a l  r edu c t ion s  
ob s e r v ed  w i th in  1  mon th 
Du r a t ion :  M a r k e r s  o f  bon e  r e so rp t ion  r e tu rn  to  b a s e l in e  w i th in  12  mon th s  o f  d i s con t inu in g  th e r ap y 
B io a v a i l ab i l i t y :  SC :  62% 
H a l f - l i f e  e l im in a t ion :  ~25 -28  d a y s 
T im e  to  p e a k ,  s e rum :  10  d a y s  ( r an g e :  3 -21  d a y s 
6 .1 .1FORM 
D eno sum ab  w i l l  b e  p ro v id ed  a s  a  s t e r i l e ,  c l e a r ,  co lo r l e s s  to  s l i gh t l y  y e l low ,  p r e s e r v a t i v e  f r e e  l iqu id ,  in  
s in g l e -u s e  3 .0  m L  g l a s s  v i a l s  con t a in in g  a  d e l i v e r ab l e  do s e  o f  1 .7m L 
D eno sum ab  w i l l  b e  p a c k a g ed  in  bo x e s  con t a in in g  s in g l e -u s e  v i a l s  o f  d eno sum ab  o f  120m g /  1 .7m L  
(70m g /m L ) . 
6 .1 .2S TORAG E  AND  S TAB I L I T Y 
S to r e  d eno sum ab  in  a  r e f r i g e r a to r  a t  2 °C  to  8 °C  (36 ° F  to  46 ° F )  in  th e  o r i g in a l  c a r ton .  Do  no t  f r e e z e .  
On c e  r emo v ed  f rom  th e  r e f r i g e r a to r ,  d eno sum ab  mu s t  no t  b e  e xpo s ed  to  t emp e r a tu r e s  abo v e  
25 °C /77 ° F  o r  d i r e c t  l i gh t  and  on c e  r emo v ed  f rom  th e  r e f r i g e r a to r  mu s t  b e  u s ed  w i th in  24  hou r s .  
D i s c a rd  d eno sum ab  i f  no t  u s ed  w i th in  24  hou r s .  Do  no t  u s e  d eno sum ab  a f t e r  th e  e xp i r y  d a t e  p r in t ed  
on  th e  l ab e l .  A vo id  v i go rou s  sh a k in g . 
6 .1 .3PR EPARA T ION 
E a ch  bo x  o f  d eno sum ab  w i l l  con t a in  on e  1 .7  m L  v i a l .  A  s in g l e  u s e  s y r in g e  shou ld  b e  u s ed  to  p r ep a r e  
th e  do s e .  Th e r e  a r e  no  o th e r  sp e c i a l  p r ep a r a t ion s  r equ i r ed  p r io r  to  d eno sum ab  adm in i s t r a t ion . 
6 .1 .4ADM IN I S TRA T ION 
Sub cu t an eou s  in j e c t ion s  a r e  to  b e  g i v en  a t  d i f f e r en t  lo c a t ion s .  Th e r e  a r e  no  o th e r  sp e c i a l  p r ep a r a t ion s  
r equ i r ed  p r io r  to  d eno sum ab  adm in i s t r a t ion . 
6 .1 .5ORD ER ING 
29  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 D eno sum ab  w i l l  b e  sh ipp ed  to  th e  r e spon s ib l e  in v e s t i g a t ion a l  ph a rm a c i s t  a t  th e  Un i v e r s i t y  o f  
Ro ch e s t e r ,  who  w i l l  ch e c k  th e  amoun t  and  cond i t ion  o f  th e  d ru g  and  en t e r  th e s e  d a t a  in to  th e  P roo f  
o f  R e c e ip t  Fo rm .  I f  an y  abno rm a l i t y  on  th e  bo t t l e s  i s  ob s e r v ed ,  th e  Ph a rm a c i s t  o r  th e  app rop r i a t e  
p e r son  mu s t  do cum en t  th a t  on  th e  a c know l ed g em en t  o f  r e c e ip t  and  con t a c t  th a t  Spon so r  and /o r  
Spon so r  d e s i gn e e .  Th e  P roo f  o f  R e c e ip t  Fo rm  shou ld  th en  b e  r e tu rn ed  to  Am g en  In c . ,  and  th e  o r i g in a l  
r e t a in ed  a t  th e  s i t e . 
6 .1 .6SA F E T Y 
A  comp l e t e  l i s t  o f  th e  ad v e r s e  e v en t s  and  po t en t i a l  r i s k s  a s so c i a t ed  w i th  th e  d eno sum ab  adm in i s t e r ed  in  
th i s  s tud y  c an  b e  found  a t  h t tp : / /p i . am g en . com /un i t eds t a t e s / x g e v a / x g e v ap i .pd f 
H ypo c a l cem i a :  D eno sum ab  c an  c au s e  s e v e r e  s ymp tom a t i c  h ypo c a l c em i a ,  and  f a t a l  c a s e s  h a v e  b e en  
r epo r t ed .  H ypo c a l c em i a  n e ed s  to  b e  co r r e c t ed  p r io r  to  in i t i a t in g  d eno sum ab .  Mon i to r  c a l c ium  l e v e l s  
and  adm in i s t e r  c a l c ium ,  m a gn e s ium ,  and  v i t am in  D  a s  n e c e s s a r y .  C a l c ium  l e v e l s  h a v e  to  b e  mon i to r ed  
w e e k l y  fo r  th e  f i r s t  4  w e e k s  o f  t r e a tm en t  th en  e v e r y  c y c l e  th e r e a f t e r .  A l l  sub j e c t s  n e ed  to  b e  
ad equ a t e l y  supp l em en t ed  w i th  c a l c ium  and  v i t am in  D  ( s e e  S e c t ion  5 .1 ) .  I f  h ypo c a l c em i a  o c cu r s ,  
add i t ion a l  sho r t - t e rm  c a l c ium  supp l em en t a t ion  m a y  b e  n e c e s s a r y . 
O s teone c ro s i s  o f  the  j aw  (ON J ) :  c an  o c cu r  in  p a t i en t s  r e c e i v in g  d eno sum ab ,  m an i f e s t in g  a s  j aw  p a in ,  
o s t eom y e l i t i s ,  o s t e i t i s ,  bon e  e ro s ion ,  too th  o r  p e r iodon t a l  in f e c t ion ,  too th a ch e ,  g in g i v a l  u l c e r a t ion ,  o r  
g in g i v a l  e ro s ion .  Th e  r i s k  o f  ON J  i s  a s so c i a t ed  w i th  th e  l en g th  o f  th e  e xpo su r e  and  r i s k  f a c to r s  fo r  ON J .  
Sub j e c t s  shou ld  b e  mon i to r ed  fo r  ON J  a s  p a r t  o f  rou t in e  c l in i c a l  p r a c t i c e .  Sub j e c t s  shou ld  b e  in s t ru c t ed  
to  m a in t a in  good  o r a l  h y g i en e  wh i l e  on  t r e a tm en t  w i th  d eno sum ab . 
A  d en t a l  e x am in a t ion  w i th  app rop r i a t e  p r e v en t i v e  d en t i s t r y  shou ld  b e  con s id e r ed  p r io r  to  t r e a tm en t  
w i th  d eno sum ab  in  sub j e c t s  w i th  r i s k  f a c to r s  fo r  ON J .  Sub j e c t s  who  a r e  su sp e c t ed  o f  h a v in g  o r  who  
d e v e lop  ON J  wh i l e  on  d eno sum ab  shou ld  r e c e i v e  c a r e  b y  a  d en t i s t  o r  an  o r a l  su r g eon .  E xp e r t  
e v a lu a t ion  o f  p a t i en t s  w i th  po t en t i a l  ON J  c a s e s  shou ld  b e  b a s ed  on  th e  Am e r i c an  A s so c i a t ion  o f  O r a l  
and  M a x i l lo f a c i a l  Su r g eon s  (AAOM S )  gu id e l in e s  fo r  ON J .  In  sub j e c t s  who  d e v e lop  ON J  du r in g  t r e a tm en t  
w i th  d eno sum ab  120  m g ,  a  t empo r a r y  in t e r rup t ion  o f  t r e a tm en t  shou ld  b e  con s id e r ed  b a s ed  on  
ind i v idu a l  r i s k /b en e f i t  a s s e s sm en t  un t i l  th e  cond i t ion  r e so l v e s .  Wh i l e  on  t r e a tm en t  w i th  d eno sum ab ,  
sub j e c t s  shou ld  b e  in s t ru c t ed  to  a vo id  in v a s i v e  d en t a l  p ro c edu r e s ,  i f  po s s ib l e .  Fo r  sub j e c t s  in  whom  
in v a s i v e  d en t a l  p ro c edu r e s  c anno t  b e  a vo id ed ,  th e  c l in i c a l  jud gm en t  o f  th e  t r e a t in g  ph y s i c i an  shou ld  
gu id e  th e  m an a g em en t  p l an  o f  e a ch  p a t i en t  b a s ed  on  ind i v idu a l  b en e f i t / r i s k  a s s e s sm en t . 
In  th r e e  ph a s e  I I I  a c t i v e - con t ro l l ed  c l in i c a l  t r i a l s  in  sub j e c t s  w i th  ad v an c ed  m a l i gn an c i e s  in vo l v in g  
bon e ,  ON J  w a s  con fo rm ed  in  1 .8%  o f  p a t i en t s  in  th e  d eno sum ab  g roup  t r e a t ed  w i th  120  m g  
sub cu t an eou s l y  e v e r y  4  w e e k s .  Th e  t r i a l s  in  p a t i en t s  w i th  b r e a s t  and  p ro s t a t e  c an c e r  in c lud ed  
d eno sum ab  e x t en s ion  t r e a tm en t  ph a s e  (m ed i an  o v e r a l l  e xpo su r e  o f  14 .9  mon th s ;  r an g e 
30  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 0 .1  –  67 .2 ) .  Th e  p a t i en t - y e a r  ad ju s t ed  in c id en c e  o f  con f i rm ed  ON J  w a s  1 .1%  du r in g  th e  f i r s t  y e a r  o f  
t r e a tm en t  and  4 .1%  th e r e a f t e r .  Th e  m ed i an  t im e  to  ON J  w a s  20 .6  mon th s  ( r an g e :  4 -53 ) . 
A t yp i c a l  femo r a l  f r a c tu re  (A F F ) :  h a s  b e en  r epo r t ed  w i th  d eno sum ab .  Th e s e  f r a c tu r e s  c an  o c cu r  
an ywh e r e  in  th e  f emo r a l  sh a f t  f rom  ju s t  b e low  th e  l e s s e r  t ro ch an t e r  to  abo v e  th e  sup r a cond y l a r  f l a r e  
and  a r e  t r an s v e r s e  o r  sho r t  ob l iqu e  in  o r i en t a t ion  w i thou t  e v id en c e  o f  comm inu t ion .  A F F  mo s t  
common l y  o c cu r  w i th  m in im a l  o r  no  t r aum a  to  th e  a f f e c t ed  a r e a .  Th e y  m a y  b e  b i l a t e r a l  and  m an y  
p a t i en t s  r epo r t  p rod rom a l  p a in  in  th e  a f f e c t ed  a r e a ,  u su a l l y  p r e s en t in g  a s  du l l ,  a ch in g  th i gh  p a in ,  
w e e k s  to  mon th s  b e fo r e  a  comp l e t e  f r a c tu r e  o c cu r s .  Du r in g  d eno sum ab  t r e a tm en t ,  sub j e c t s  shou ld  
b e  ad v i s ed  to  r epo r t  n ew  o r  unu su a l  th i gh ,  h ip ,  o r  g ro in  p a in .  Sub j e c t s  p r e s en t in g  w i th  su ch  s ymp tom s  
shou ld  b e  e v a lu a t ed  fo r  an  in comp l e t e  f emo r a l  f r a c tu r e ,  and  th e  con t r a l a t e r a l  f emu r  shou ld  a l so  b e  
e x am in ed .  E xp e r t  e v a lu a t ion  o f  p a t i en t s  w i th  po t en t i a l  A F F  c a s e s  shou ld  b e  b a s ed  on  th e  Am e r i c an  
So c i e t y  fo r  Bon e  and  M in e r a l  R e s e a r ch  (A SBMR )  gu id e l in e s  fo r  A  F F . 
H ype r sen s i t i v i t y :  C l in i c a l l y  s i gn i f i c an t  h yp e r s en s i t i v i t y  in c lud in g  an aph y l a x i s  h a s  b e en  r epo r t ed  w i th  
u s e  o f  d eno sum ab .  R e a c t ion s  m a y  in c lud e  h ypo t en s ion ,  d y spn e a ,  upp e r  a i rw a y  ed em a ,  l ip  sw e l l in g ,  
r a sh ,  p ru r i tu s ,  and  u r t i c a r i a .  C l in i c a l l y  s i gn i f i c an t  h yp e r s en s i t i v i t y  h a s  b e en  id en t i f i ed  a s  a  
con t r a ind i c a t ion  fo r  t r e a tm en t  w i th  d eno sum ab .  I f  an  an aph y l a c t i c  o r  o th e r  c l in i c a l l y  s i gn i f i c an t  
a l l e r g i c  r e a c t ion  o c cu r s ,  in i t i a t e  app rop r i a t e  th e r ap y  and  d i s con t inu e  d eno sum ab  th e r ap y  
p e rm an en t l y 
Mu l t ip le  ve r teb r a l  f r a c tu re s :  Th e r e  i s  a  r i s k  o f  mu l t ip l e  v e r t eb r a l  f r a c tu r e s  (MV F )  fo l low in g  
d eno sum ab  d i s con t inu a t ion .  Wh en  d eno sum ab  i s  d i s con t inu ed ,  e v a lu a t e  th e  ind i v idu a l  p a t i en t ’ s  r i s k  
fo r  v e r t eb r a l  f r a c tu r e s . 
Mu s cu lo s ke le t a l  p a in :  In c lud in g  s e v e r e  c a s e s ,  h a s  b e en  id en t i f i ed  a s  an  ad v e r s e  d ru g  r e a c t ion  b a s ed  
on  d a t a  f rom  th e  po s t -m a r k e t in g  s e t t in g . 
6 .1 .7D E S TRUC T ION  AND  R E TURN 
A  D eno sum ab  A c coun t ab i l i t y  R e co rd  fo r  th e  d eno sum ab  m and a t ed  b y  th e  p ro to co l  mu s t  b e  k ep t  cu r r en t  
and  shou ld  con t a in : 
D a t e s  and  qu an t i t i e s  o f  d eno sum ab  r e c e i v ed  f rom  Am g en  In c . 
M anu f a c tu r in g  lo t  numb e r  AND  bo x  numb e r s  fo r  p rodu c t  r e c e i v ed 
Sub j e c t ’ s  id en t i f i c a t ion  ( sub j e c t  numb e r  and  in i t i a l s ) 
D a t e  and  bo x  numb e r  o f  d eno sum ab  d i sp en s ed 
In i t i a l s  o f  th e  d i sp en s e r 
31  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 U s ed  v i a l s  w i l l  no t  b e  r e tu rn ed  to  Am g en .  An y  p a r t i a l  o r  r em a in in g  d ru g  a t  th e  t im e  o f  u s e  w i l l  b e  d i s c a rd ed  
p e r  in s t i tu t ion a l  s a f e  h and l in g  p ro c edu r e .  D ru g  a c coun t ab i l i t y  w i l l  b e  m a in t a in ed  w i th in  th e  in s t i tu t ion a l  
s y s t em . 
A t  th e  end  o f  th e  s tud y ,  o r  a s  d i r e c t ed ,  a l l  d eno sum ab  supp l i e s  w i l l  b e  d i s c a rd ed  p e r  in s t i tu t ion a l  
s t and a rd s .  Fo r  e a ch  m ed i c a t ion  d e s t ro y ed ,  do cum en t a t ion  w i l l  b e  f i l ed  and  k ep t  in  th e  app rop r i a t e  
p ro to co l  f i l e .  Do cum en t a t ion  w i l l  in c lud e ,  m ed i c a t ion  d e s t ro y ed ,  qu an t i t y ,  p ro to co l  numb e r ,  and  d a t e  
d ru g  i s  p l a c ed  in  B ioh a z a rd  con t a in e r . 
6 .1 .8DO SAG E  AD JU S TM EN T S  AND  D I SCON T INUA T ION  O F  D ENO SUMAB 
Th e r e  w i l l  b e  no  do s e  ad ju s tm en t s  fo r  th e  SC  d eno sum ab . 
Adm in i s t r a t ion  o f  SC  d eno sum ab  w i l l  b e  w i thh e ld  fo r  an y  sub j e c t  who  e xp e r i en c e s  a  g r ad e  3  o r  4  
ad v e r s e  e v en t  ( r e f e r  to  Common  T e rm ino lo g y  C r i t e r i a  fo r  Ad v e r s e  E v en t s  [C TCA E ]  V e r s ion  5 .0 )  
r epo r t ed  b y  th e  in v e s t i g a to r  a s  r e l a t ed  to  d eno sum ab ,  o r  o s t eon e c ro s i s  o f  th e  j aw  (ON J )  a s  
d e t e rm in ed  b y  th e  in v e s t i g a to r  o r  b y  an  ind ep end en t  e xp e r t  p an e l .  D eno sum ab  w i l l  b e  h e ld  fo r  
a lbum in - ad ju s t ed  s e rum  c a l c ium  l e v e l s  l e s s  th an  8 .4  m g /d L .  R e - e xpo su r e  to  d eno sum ab  m a y  o c cu r  
on l y  wh en  th e  e v en t  r e so l v e s  to  g r ad e  1  o r  l e s s  o r  to  th e  sub j e c t ’ s  b a s e l in e  and  i f  th e  in v e s t i g a to r  and  
spon so r  a g r e e  sub j e c t  s a f e t y  w i l l  no t  b e  comp rom i s ed . 
I f  an y  s ch edu l ed  do s e  a f t e r  s tud y  d a y  1  i s  d e l a y ed  fo r  mo r e  th an  8  c a l end a r  d a y s  f rom  th e  s ch edu l ed  
v i s i t  d a t e ,  th i s  w i l l  b e  con s id e r ed  a  m i s s ed  do s e  and  r e co rd ed  a s  su ch  on  th e  c a s e  r epo r t  fo rm  (CR F ) .  
Th e  n e x t  do s e  i s  to  b e  g i v en  on  th e  n e x t  s ch edu l ed  v i s i t  d a t e  (b a s ed  on  s tud y  d a y  1 ) .  Th e r e  mu s t  b e  a  
m in imum  o f  a  3 -w e e k  in t e r v a l  b e tw e en  adm in i s t r a t ion s  o f  d eno sum ab .  I f  sub j e c t s  a r e  d e l a y ed  fo r  
mo r e  th an  5  w e e k s ,  th en  sub j e c t s  w i l l  b e  r emo v ed  f rom  s tud y  a t  th e  t r e a t in g  ph y s i c i an ’ s  d i s c r e t ion . 
Adm in i s t r a t ion  o f  th e  d eno sum ab  i s  r e comm end ed  to  b e  w i thh e ld  30  d a y s  p r io r  to  an y  e l e c t i v e  
in v a s i v e  o r a l /  d en t a l  p ro c edu r e .  D eno sum ab  adm in i s t r a t ion  i s  r e comm end ed  to  b e  w i thh e ld  un t i l  
do cum en t ed  e v id en c e  o f  comp l e t e  mu co s a l  h e a l in g  fo l low in g  an y  in v a s i v e  o r a l /d en t a l  p ro c edu r e . 
In v a s i v e  d en t a l  p ro c edu r e s  shou ld  b e  a vo id ed ,  i f  po s s ib l e .  I f  a  sub j e c t  und e r go e s  an  in v a s i v e  d en t a l  
p ro c edu r e  wh i l e  on  s tud y ,  a  c l in i c a l  d e c i s ion  to  con t inu e  th e  sub j e c t  on  th e  d eno sum ab  mu s t  b e  
do cum en t ed  in  th e  m ed i c a l  ch a r t . 
6 .2  CONCOM I TAN T /  EXC LUD ED  M ED ICA T ION S 
C a l c ium  and  v i t am in  D  supp l em en t s  w i l l  no t  b e  p ro v id ed  a s  p a r t  o f  th e  t r i a l ,  bu t  w i l l  b e  p r e s c r ib ed  b y  
th e  in v e s t i g a to r  a s  a  con com i t an t  m ed i c a t ion  p e r  s t and a rd  o f  c a r e  a s  d e s c r ib ed  p r e v iou s l y . 
No  fo rm a l  d ru g  –d ru g  in t e r a c t ion  t r i a l s  h a v e  b e en  condu c t ed  w i th  d eno sum ab . 
32  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 B i spho sphon a t e s  (o r a l  o r  IV )  a r e  no t  p e rm i t t ed  du r in g  th e  s tud y  p e r iod  o r  un t i l  th e  end  o f  s tud y  
a s s e s sm en t s  a r e  comp l e t ed . 
7M  EASUREM  ENT  O  F  E F  F  EC  T 
7 .1METHOD  O F  ASSESSMENT 
In  add i t ion  to  c l in i c a l  e x am in a t ion ,  l abo r a to r y -b a s ed  e v a lu a t ion  w i l l  b e  u s ed  in  th i s  s tud y  fo r  a l l  p a t i en t s  
en ro l l ed . 
7 .1 .1S ERUM 
B lood  s amp l e s  fo r  qu an t i t a t ion  o f  I g  ( I gA ,  I gG ,  and  I gM  a r e  r equ i r ed ;  I gD  and  I g E  a r e  op t ion a l ) 
and  M -p ro t e in  and  a s s e s sm en t  o f  M -p ro t e in  b y  immuno f i x a t ion  in  s e rum  a r e  to  b e  co l l e c t ed  f rom  
a l l  p a t i en t s  du r in g  S c r e en in g .  Su ch  s amp l e s  a l so  a r e  to  b e  co l l e c t ed  a t  th e  t im e  po in t s  d e s i gn ed  in  
T ab l e  5 .1 .
A l l  s amp l e s  w i l l  b e  an a l y z ed  b y  th e  lo c a l  l abo r a to r y . 
7 .1 .2FR E E  L IGH T  CHA IN  T E S T ING 
S e rum  s amp l e s  fo r  F LC  t e s t in g  a r e  to  b e  co l l e c t ed  f rom  a l l  p a t i en t s  du r in g  s c r e en in g  and  a t  th e  
t im e  po in t s  d e s i gn ed  in  T ab l e  5 .1 .  Th e  f r e e  k app a / l ambd a  r a t io  i s  to  b e  r e co rd ed  in  th e  eCR F .  
A  s e rum  s amp l e  fo r  F LC  t e s t in g  a l so  i s  to  b e  co l l e c t ed  in  o rd e r  to  con f i rm  s t r in g en t  comp l e t e  
r e spon s e  ( sCR ) . 
A l l  s amp l e s  w i l l  b e  an a l y z ed  b y  th e  lo c a l  l abo r a to r y . 
7 .1 .3UR IN E 
Tw en t y - fou r  hou r  u r in e  s amp l e s  fo r  qu an t i t a t ion  o f  M -p ro t e in  and  a s s e s sm en t  o f  M -p ro t e in  b y  
immuno f i x a t ion  a r e  to  b e  r equ e s t ed  f rom  a l l  p a t i en t s  du r in g  s c r e en in g .  P a t i en t s  m a y  r e fu s e  to  p ro v id e  
u r in e  s amp l e s . 
A l l  s amp l e s  w i l l  b e  an a l y z ed  b y  th e  lo c a l  l abo r a to r y . 
7 .1 .4BON E  MARROW  EXAM INA T ION 
Bon e  m a r row  a sp i r a t ion  and  t r eph in e  b iop s y  p e r  in s t i tu t ion  s t and a rd  a r e  to  b e  p e r fo rm ed  fo r  a l l  p a t i en t s  
du r in g  s c r e en in g  p r io r  to  s tud y  t r e a tm en t  adm in i s t r a t ion  and  th e  end  o f  s tud y .  I f  a  bon e  m a r row  b iop s y  
h a s  b e en  don e  w i th in  3  mon th s  b e fo r e  s c r e en in g ,  th i s  do e s  no t  n e ed  to  b e  r ep e a t ed .  Bon e 
m a r row  a sp i r a t ion  and  b iop s y  a r e  to  b e  r ep e a t ed  du r in g  t r e a tm en t  a s  c l in i c a l l y  ind i c a t ed ,  a t  th e 
33  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 In v e s t i g a to r ’ s  d i s c r e t ion ,  in  o rd e r  to  con f i rm  comp l e t e  r e spon s e  (CR ) . 
A  po r t ion  o f  th e  p r e - t r e a tm en t  s amp l e  and  th e  end  o f  t r e a tm en t  s amp l e  w i l l  b e  u s ed  fo r  co r r e l a t i v e  
s tud i e s . 
34  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 7 .1 .5DXA  SCAN S 
DXA  s c an s  a r e  to  b e  p e r fo rm ed  du r in g  s c r e en in g  and  a t  th e  end  o f  s tud y .  A l l  s c an s  w i l l  b e  p e r fo rm ed  a t  
th e  lo c a l  r ad io lo g y  f a c i l i t y .  Bon e  d en s i t y  w i l l  b e  m e a su r ed  a t  th e  lumb a r  sp in e ,  f emo r a l  n e c k ,  to t a l  h ip ,  and  
d i s t a l  1 /3  o f  th e  r ad iu s . 
7 .1 .6A S S E S SM EN T  O F  R E SPON S E 
P a t i en t s  w i l l  b e  a s s i gn ed  a  b a s e l in e  c a t e go r y  o f  SMM  r i s k  fo r  p ro g r e s s ion  a s  b e low  in  T ab l e  7 .1 .6 .  P a t i en t s  
w i l l  b e  d e t e rm in ed  to  h a v e  a  down g r ad ed  r i s k  o f  p ro g r e s s ion  i f  th e  r i s k  c a t e go r y  d e c r e a s e s .  P a t i en t s  w i th  
low  r i s k  SMM  w i l l  h a v e  a  down g r ad ed  r i s k  i f  th e y  no  lon g e r  m e e t  th e  c r i t e r i a  fo r  SMM ,  bu t  h a v e  MGU S  
in s t e ad .  MGU S  w i l l  b e  d e f in ed  p e r  IWMG  c r i t e r i a  a s  an  M -p ro t e in  <  3 g /d L  and  c lon a l  bon e  m a r row  p l a sm a  
c e l l s  <  10%  and  u r in e  mono c lon a l  p ro t e in  <  500m g /24  hou r s  [14 ] . 
T ab le  7 .1 .6 
R i s k  F a c to r s Low  r i s k Low - 
in te rmed i a te  r i s k H i gh - 
in te rmed i a te  r i s k H i gh  r i s k 
BM  p l a sm a  c e l l  % 
≥50 
M -p ro t e in  ≥ 3 g /d L 
In vo l v ed /un in vo l v ed 
f r e e  l i gh t  ch a in s  ≥ 8 P a t i en t  h a s  SMM ,  
bu t  non e  o f  th e  
l i s t ed  r i s k  f a c to r s 1  r i s k  f a c to r  i s  
p r e s en t 2  r i s k  f a c to r s  a r e  
p r e s en t 3  r i s k  f a c to r s  a r e  
p r e s en t 
Immunopa r e s i s No t  p r e s en t P r e s en t w i thou t 
o th e r  r i s k  f a c to r s 
D i s e a s e  p ro g r e s s ion  and  th e  r e spon s e  r a t e  w i l l  b e  d e t e rm in ed  b y  th e  In t e rn a t ion a l  M y e lom a  Wo r k in g  
G roup  C r i t e r i a  ( IMWG )  [13 ]  (App end i x  A ) .  In v e s t i g a to r s  w i l l  a s s e s s  r e spon s e  and  p ro g r e s s ion  on  th e  b a s i s  
o f  an a l y s e s  o f  M -p ro t e in  in  s e rum  o r  u r in e  th a t  w i l l  b e  p e r fo rm ed  lo c a l l y  and  a c co rd in g  to  m e thod s  and  
f r equ en c i e s  con s i s t en t  w i th  lo c a l  s t and a rd  o f  c a r e .  I t  i s  r e comm end ed  to  mon i to r  s e rum  (o r  u r in e )  M -  
p ro t e in  e v e r y  4  w e e k s  un t i l  f i r s t  p ro g r e s s ion . 
D i s e a s e  p ro g r e s s ion  in  bon e  and  ou t s id e  o f  th e  bon e  ( e x t r a  o s s eou s )  w i l l  b e  d e t e rm in ed  b y  th e  
in v e s t i g a to r  b a s ed  on  lo c a l  r e v i ew  o f  im a g e s  and /o r  c l in i c a l  ob s e r v a t ion s  a c co rd in g  to  m e thod s  and  
f r equ en c i e s  con s i s t en t  w i th  lo c a l  s t and a rd  o f  c a r e .  Th e  c r i t e r i a  fo r  d i s e a s e  p ro g r e s s ion  a r e  d e s c r ib ed  
h e r e in .  D i s e a s e  p ro g r e s s ion  w i l l  b e  do cum en t ed  on  th e  CR F . 
Ch an g e s  in  bon e  m in e r a l  d en s i t y  w i l l  b e  d e t e rm in ed  b y  bon e  d en s i tom e t r y  (DXA ) .  
8  S TA T I  S T IC  A L  CON  S ID  E  R  A T ION  S 
35  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 8 .1DES IGN 
Th i s  i s  a  s in g l e  c en t e r ,  s in g l e - a rm  p ro sp e c t i v e  op en - l ab e l  t r i a l  o f  d eno sum ab  in  p a t i en t s  w i th  smo ld e r in g  
mu l t ip l e  m y e lom a  ( SMM ) .  W e  a im  to  e s t ab l i sh  p r e l im in a r y  e s t im a t e s  o f  down g r ad e  r a t e  a f t e r  d eno sum ab  
t r e a tm en t  in  th i s  popu l a t ion .  Th e  down g r ad e  r a t e  w i l l  b e  e s t im a t ed  f rom  tw en t y  en ro l l ed  sub j e c t s .  E x a c t  
b inom i a l  m e thod s  w i l l  b e  u s ed  to  c a l cu l a t e  an  a s so c i a t ed  90%  two - s id ed  con f id en c e  in t e r v a l .  Th e  
m a x imum  po s s ib l e  w id th  o f  a  90%  two - s id ed  con f id en c e  in t e r v a l  u s in g  20  sub j e c t s  i s  0 .396 ,  wh en  th e  r a t e  
i s  0 .50 .  W e  an t i c ip a t e  a  down g r ad e  r a t e  mu ch  low e r  th an  0 .50 .  I f  th e  down g r ad e  r a t e  w e r e  0 .10 ,  th e  
r e su l t in g  90%  two - s id ed  con f id en c e  in t e r v a l  wou ld  h a v e  a  w id th  o f  0 .265  ( f rom  0 .018  to  0 .283 ) .  T ab l e  8 .1  
h i gh l i gh t s  90%  con f id en c e  in t e r v a l  l im i t s  b a s ed  on  th e  numb e r  o f  down g r ad e s  s e en  in  tw en t y  en ro l l ed  
p a t i en t s .  D e sp i t e  th e  w id e  con f id en c e  in t e r v a l s  p rodu c ed  du e  to  l im i t ed  s amp l e  s i z e ,  th i s  in fo rm a t ion  i s  
s t i l l  c r i t i c a l  to  ob t a in  p r io r  to  in v e s t i g a t in g  th i s  r e g im en  in  a  l a r g e r  d e f in i t i v e  t r i a l .  Th i s  s tud y  w i l l  p rodu c e  
p i lo t  d a t a  th a t  w i l l  b e  u s ed  to  p l an  fu tu r e  l a r g e r  d e f in i t i v e  s tud i e s .  2  o r  mo r e  down g r ad e  e v en t s  w i l l  b e  
con s id e r ed  su f f i c i en t  r a t ion a l e  fo r  mo v in g  fo rw a rd  w i th  a  l a r g e r  t r i a l . 
T ab le  8 .1 :  90%  Con f iden ce  In te r v a l s  fo r  a  r an ge  o f  po s s ib le  e ven t  coun t s 
Numbe r  o f  down g r ade  e ven t s 90%  con f iden ce  in te r v a l  l im i t s 
1 (0 .003 ,  0 .216 ) 
2 (0 .018 ,  0 .283 ) 
3 (0 .042 ,  0 .344 ) 
4 (0 .071 ,  0 .401 ) 
5 (0 .104 ,  0 .456 ) 
8 .2EAR LY  STOPP ING  RU LE  FOR  SAFETY 
Th i s  s tud y  w i l l  b e  con t inuou s l y  mon i to r ed  fo r  g r ad e  4  o r  h i gh e r  ad v e r s e  e v en t s  (A E s )  r e l a t ed  (po s s ib l y ,  
p rob ab l y  o r  d e f in i t e l y )  to  d eno sum ab  u s in g  a  Po co c k - s t y l e  bound a r y  fo r  r ep e a t ed  t e s t in g .  { I v ano v a ,  2005 
#1764 }U s in g  th e  t ab l e  b e low ,  th e  t r i a l  w i l l  b e  s topp ed  and  d a t a  r e v i ew ed  i f  th e  bound a r y  numb e r  o f  
r e l a t ed  g r ad e  4  o r  h i gh e r  A E  e v en t s  i s  r e a ch ed  o r  e x c e ed ed .  On l y  po in t s  wh e r e  s topp in g  i s  po s s ib l e  a r e  
l i s t ed .  I f  th e  t ru e  r a t e  o f  su ch  e v en t s  i s  5%  (m a x imum - to l e r a t ed  r a t e ) ,  th e r e  i s  a  7%  ch an c e  o f  e a r l y  
t e rm in a t ion  ( t yp e  I  e r ro r ) .  I f  th e  t ru e  r a t e  i s  a s  h i gh  a s  25% ,  th e r e  i s  an  86%  ch an c e  o f  s topp in g  th e  t r i a l  
e a r l y . 
T ab le  8 .2 :  E a r l y  S topp in g  Bound a r y 
#  P a t ien t s 2345678910 11 12 13 14 15 16 17 18 19 20 
#  E ven t s 2222223333333334444
36  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 8 .3PAT IENT  D ISPOS IT ION 
Th e  d i spo s i t ion  o f  p a t i en t s  in c lud e s  th e  numb e r  and  p e r c en t a g e  o f  p a t i en t s  fo r  th e  fo l low in g  c a t e go r i e s :  
p a t i en t s  en ro l l ed ,  p a t i en t s  t r e a t ed  ( s a f e t y  popu l a t ion ) ,  p a t i en t s  in  th e  in t en t  to  t r e a t  popu l a t ion ,  and  
p a t i en t s  d i s con t inu ed  f rom  th e  s tud y .  Th e  r e a son s  fo r  s tud y  d i s con t inu a t ion  w i l l  a l so  b e  summ a r i z ed  in  
th i s  t ab l e .  On l y  on e  p r im a r y  r e a son  fo r  s tud y  d i s con t inu a t ion  w i l l  b e  r epo r t ed  in  th e  summ a r y .  How e v e r ,  
a l l  r e a son s  w i l l  b e  p r e s en t ed  in  th e  l i s t in g .  A  l i s t in g  w i l l  p r e s en t  d a t a  con c e rn in g  p a t i en t  d i spo s i t ion . 
8 .4PAT IENT  DEMOGRAPH ICS  AND  BASE L INE  CHARACTER IST ICS 
B a s e l in e  d emo g r aph i c  and  c l in i c a l  ch a r a c t e r i s t i c s  w i l l  b e  summ a r i z ed  a s  m ed i an s  and  in t e rqu a r t i l e  r an g e s  
( IQR )  fo r  con t inuou s  v a r i ab l e s ,  and  a s  coun t s  and  p ropo r t ion s  fo r  c a t e go r i c a l  v a r i ab l e s . 
8 .5EXTENT  O F  EXPOSURE 
Th e  do s e  (m g )  o f  s tud y  d ru g  adm in i s t e r ed ,  th e  to t a l  numb e r  o f  do s e s  o f  s tud y  d ru g ,  and  th e  du r a t ion  o f  
t r e a tm en t  (numb e r  o f  s tud y  c y c l e s )  w i l l  b e  summ a r i z ed  w i th  d e s c r ip t i v e  s t a t i s t i c s .  Th e  numb e r  and  
p e r c en t a g e  o f  p a t i en t s  who s e  do s e  i s  mod i f i ed  a t  an y  t im e  w i l l  b e  summ a r i z ed  b y  e a ch  t yp e  o f  
mod i f i c a t ion  b y  c y c l e  and  o v e r a l l .  Th e  p ropo r t ion  o f  p a t i en t s  comp l e t in g  e a ch  c y c l e  o f  t r e a tm en t  w i l l  b e  
summ a r i z ed . 
8 .6STAT IST ICA L  ANA LYSES 
Th e  t r e a t ed  popu l a t ion  i s  d e f in ed  a s  a l l  en ro l l ed  sub j e c t s  who  r e c e i v ed  a t  l e a s t  1  do s e  o f  d eno sum ab .  
E f f i c a c y  and  s a f e t y  an a l y s i s  w i l l  b e  b a s ed  on  th i s  popu l a t ion .  Th e  down g r ad e  r a t e  (DR )  i s  d e f in ed  a s  th e  
p ropo r t ion  o f  p a t i en t s  fo r  whom  r i s k  o f  p ro g r e s s ion  f rom  SMM  to  MM  i s  low e r  a f t e r  d eno sum ab  
t r e a tm en t .  Th e  c r i t e r i a  d e f in in g  r i s k  a r e  d e f in ed  in  T ab l e  7 .1 .6 .  P a t i en t s  who  c anno t  b e  a s s e s s ed  fo r  an y  
r e a son  w i l l  b e  con s id e r ed  no t  down g r ad ed  and  w i l l  b e  in c lud ed  in  th e  d enom in a to r  wh en  c a l cu l a t in g  th e  
DR . 
S e cond a r y  endpo in t s  w i l l  b e  an a l y z ed  a s  fo l low s .  M ed i an s  and  in t e rqu a r t i l e  r an g e s  ( IQR )  w i l l  b e  r epo r t ed  
fo r  con t inuou s  v a r i ab l e s  and  coun t s  and  p ropo r t ion s  w i l l  b e  r epo r t ed  fo r  c a t e go r i c a l  v a r i ab l e s .  Th e  non -  
p a r am e t r i c  W i l co xon  s i gn ed  r an k  t e s t  w i l l  b e  u s ed  to  comp a r e  p r e -  and  mon th l y  m e a su r e s  o f  mono c lon a l 
(M )  s e rum  p ro t e in  l e v e l s ,  f r e e  l i gh t  ch a in  ( F LC )  l e v e l s ,  and  bon e  m in e r a l  d en s i t y  (b a s e l in e  and  e a ch  po s t -  
t r e a tm en t  po in t ) .  I f  th e  no rm a l i t y  a s sump t ion  i s  v a l id  o r  c an  b e  m e t  w i th  t r an s fo rm a t ion ,  l in e a r  m i x ed  
mod e l s  w i l l  b e  u s ed  comp a r e  ch an g e s  in  e a ch  m e a su r e  a c ro s s  a l l  t im e  po in t s  s imu l t an eou s l y ,  and  w i l l  
in c lud e  a  sub j e c t - sp e c i f i c  in t e r c ep t  to  a c coun t  fo r  co r r e l a t ion s  in  d a t a  com in g  f rom  th e  s am e  sub j e c t .  T im e  
w i l l  b e  t r e a t ed  a s  a  c a t e go r i c a l  f i x ed  e f f e c t .  A  s ep a r a t e  mod e l  w i l l  b e  f i t  fo r  e a ch  ou t com e :  M  s e rum  p ro t e in  
l e v e l s ,  F LC  l e v e l s  and  bon e  m in e r a l  d en s i t y .  R a t e s  o f  s k e l e t a l  r e l a t ed  e v en t s  w i l l  b e  c a l cu l a t ed  and 
37  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 p r e s en t ed  w i th  a s so c i a t ed  95%  two - s id ed  e x a c t  b inom i a l  con f id en c e  in t e r v a l s .  Cumu l a t i v e  in c id en c e  fo r  
p ro g r e s s ion  to  MM  f rom  t r e a tm en t  in i t i a t ion  ( S tud y  D a y  1  in  T ab l e  5 .1 )  th rou gh  1  y e a r  w i l l  b e  c a l cu l a t ed ,  
t r e a t in g  d e a th  a s  a  comp e t in g  r i s k .  P F S  i s  d e f in ed  a s  th e  t im e  to  p ro g r e s s ion  o r  d e a th  f rom  an y  c au s e ,  
wh i ch e v e r  o c cu r s  f i r s t .  P F S  f rom  t r e a tm en t  in i t i a t ion  ( S tud y  D a y  1  in  T ab l e  5 .1 )  th rou gh  3  y e a r s  w i l l  b e  
summ a r i z ed  u s in g  th e  K ap l an -M e i e r  m e thod .  S a f e t y  and  to x i c i t y  d a t a  w i l l  b e  summ a r i z ed  a t  th e  e v en t  
l e v e l  and  a t  th e  sub j e c t  l e v e l .  Ad v e r s e  e v en t  l e v e l  d a t a  w i l l  b e  t abu l a t ed  and  summ a r i z ed  a s  f r equ en c y ,  
t yp e  and  s e v e r i t y  o f  e a ch  ad v e r s e  e v en t .  Sub j e c t  l e v e l  d a t a  w i l l  b e  t abu l a t ed  and  summ a r i z ed  a s  sub j e c t  
in c id en c e  o f  e a ch  ad v e r s e  e v en t .  Th e  s a f e t y  popu l a t ion  in c lud e s  a l l  sub j e c t s  who  r e c e i v ed  a t  l e a s t  1  do s e  
o f  d eno sum ab . 
9SAFETY  REP  ORT IN  G 
S tud y  In v e s t i g a to r s  w i l l  condu c t  con t inuou s  r e v i ew  o f  d a t a  and  p a t i en t  s a f e t y .  Th e  In v e s t i g a to r  w i l l  subm i t  
s em i - annu a l  p ro g r e s s  r epo r t s  o f  th e s e  d a t a  to  th e  D a t a  S a f e t y  Mon i to r in g  Comm i t t e e  fo r  r e v i ew .  Th e  
r e v i ew  w i l l  in c lud e :  th e  numb e r  o f  p a t i en t s  en ro l l ed ,  w i thd r aw a l s ,  s i gn i f i c an t  to x i c i t i e s  a s  d e s c r ib ed  in  th e  
p ro to co l ,  s e r iou s  ad v e r s e  e v en t s  bo th  e xp e c t ed  and  un e xp e c t ed ,  do s e  ad ju s tm en t s ,  and  r e spon s e s  
ob s e r v ed .  Th e  P I  m a in t a in s  a  d a t ab a s e  o f  a l l  ad v e r s e  e v en t s  w i th  to x i c i t y  g r ad e  and  in fo rm a t ion  r e g a rd in g  
t r e a tm en t  r equ i r ed ,  comp l i c a t ion s ,  o r  s equ e l a e .  Th e  In v e s t i g a to r  w i l l  subm i t  a  cop y  o f  th e  A E  sp r e ad sh e e t  
a lon g  w i th  a  P ro g r e s s  R epo r t  to  th e  D a t a  S a f e t y  Mon i to r in g  Comm i t t e e  (D SMC )  fo r  r e v i ew .  A c tu a l  r e v i ew  
d a t e s  w i l l  b e  a s s i gn ed  wh en  th e  1 s t  p a t i en t  i s  a c c ru ed . 
Th e  D SMC  a t  th e  W i lmo t  C an c e r  In s t i tu t e ,  Un i v e r s i t y  o f  Ro ch e s t e r  p ro v id e s  o v e r s i gh t  o f  s tud y  p ro g r e s s  
and  s a f e t y  b y  r e v i ew  o f  a c c ru a l  and  ad v e r s e  e v en t s  a t  s em i - annu a l  m e e t in g s  o r  mo r e  o f t en  i f  con c e rn s  
a r i s e .  An y  ad v e r s e  e v en t  r equ i r in g  e xp ed i t ed  r e v i ew  p e r  p ro to co l ,  w i l l  b e  subm i t t ed  to  th e  S a f e t y  
Coo rd in a to r  o f  th e  D SMC  a t  th e  Un i v e r s i t y  o f  Ro ch e s t e r  fo r  d e t e rm in a t ion  a s  to  wh e th e r  fu r th e r  a c t ion  i s  
r equ i r ed .  Wh en  p a t i en t  s a f e t y  i s  o f  con c e rn ,  an  in t e r im  m e e t in g  m a y  b e  c a l l ed 
An y  s e r iou s  ad v e r s e  e v en t  th a t  i s  s e r iou s ,  r e l a t ed  AND  un e xp e c t ed  mu s t  b e  r epo r t ed  w i th in  5  
c a l end a r  d a y s  to  bo th  th e  D SMC  S a f e t y  Coo rd in a to r  and  th e  R SRB  ( s e e  R SRB  gu id e l in e s ) .  Th e  
D SMC  Ch a i r  w i l l  d e t e rm in e  wh e th e r  fu r th e r  a c t ion  i s  r equ i r ed ,  and  wh en  p a t i en t  s a f e t y  i s  o f  
con c e rn ,  an  in t e r im  m e e t in g  m a y  b e  c a l l ed . 
S e r iou s  ad v e r s e  e v en t s  th a t  a r e  r e l a t ed  AND  e xp e c t ed  o r  un r e l a t ed  AND  un e xp e c t ed  w i l l  b e  
r epo r t ed  to  th e  D SMC  fo r  r e v i ew .  SA E  r epo r t s  a r e  e xp e c t ed  to  in c lud e  su f f i c i en t  d e t a i l  so  th a t  th e  
D SMC  c an  d e t e rm in e  th e  s e v e r i t y ,  to x i c i t y  g r ad e ,  e xp e c t edn e s s ,  t r e a tm en t  r equ i r ed ,  and  a  fo l low  
up  r epo r t  do cum en t in g  r e so lu t ion  o r  i f  th e r e  a r e  s equ e l a e .  S e r iou s  ad v e r s e  e v en t s  th a t  r equ i r e  
d e t a i l ed  r epo r t s  (bu t  no t  n e c e s s a r i l y  e xp ed i t ed )  a r e  e xp e c t ed ,  r e l a t ed ,  non -h em a to lo g i c  to x i c i t i e s  
o f  g r ad e s  3 ,  4  o r  5 . 
S a f e t y  d a t a  and  a g g r e g a t e  r epo r t s  w i l l  b e  r epo r t ed  to  Am g en  a s  in  s e c t ion  9 .7 . 
Th e  S a f e t y  Coo rd in a to r  adm in i s t r a t i v e l y  coo rd in a t e s  r epo r t s  and  d a t a  co l l e c t ion  and  p r ep a r e s  do cum en t s  
fo r  th e  D SMC  Ch a i r  and  comm i t t e e  r e v i ew .  Th e  S a f e t y  Coo rd in a to r  w i l l  adm in i s t r a t i v e l y  mon i to r  ad v e r s e 
38  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 e v en t  r a t e s  u t i l i z in g  th e  r epo r t  f rom  th e  s tud y  d a t ab a s e .  I f  an y  s tud y  h a s  h ad  two  o r  mo r e  o f  th e  s am e  
SA E ’ s  r epo r t ed  in  a  mon th  o r  mo r e  th an  s i x  o f  th e  s am e  SA E ’ s  in  s i x  mon th s ,  th e  D SMC  w i l l  r e v i ew  th e  
summ a r y  o f  SA E s ,  d i s cu s s  e v en t s  w i th  S tud y  Ch a i r ,  and  condu c t  a  mo r e  d e t a i l ed  r e v i ew  w i th  th e  S tud y  
Ch a i r .  Th e  D a t a  S a f e t y  Mon i to r in g  Ch a i r  w i l l  d e t e rm in e  i f  fu r th e r  a c t ion  i s  r equ i r ed . 
9 .1ADVERSE  EVENT  CHARACTER IST ICS 
C TCA E  te rm  (A E  de s c r ip t ion )  and  g r ade :  Th e  d e s c r ip t ion s  and  g r ad in g  s c a l e s  found  in  th e  r e v i s ed  NC I  
Common  T e rm ino lo g y  C r i t e r i a  fo r  Ad v e r s e  E v en t s  (C TCA E )  v e r s ion  5 .0  w i l l  b e  u t i l i z ed  fo r  A E  r epo r t in g .  
A l l  in v e s t i g a to r s  shou ld  h a v e  a c c e s s  to  a  cop y  o f  th e  C TCA E  v e r s ion  5 .0 .  A  cop y  o f  th e  C TCA E  v e r s ion  5 .0  
c an  b e  down lo ad ed  f rom  th e  C T EP  w eb  s i t e :  
h t tp : / / c t ep . c an c e r . go v /p ro to co lD e v e lopm en t / e l e c t ron i capp l i c a t ion s / c t c .h tm . 
‘ E xpe c tedne s s ’ :  A E s  c an  b e  ‘Un e xp e c t ed ’  o r  ‘ E xp e c t ed ’  fo r  e xp ed i t ed  r epo r t in g  pu rpo s e s  on l y .  P l e a s e  r e f e r  
to  th e  d eno sum ab  p r e s c r ib in g  in fo rm a t ion  fo r  a  l i s t in g  o f  e xp e c t ed  A E s . 
9 .2DEF IN IT IONS  O F  ADVER  SE  EVENTS 
An  ad v e r s e  e v en t  (A E )  i s  an y  un tow a rd  m ed i c a l  o c cu r r en c e  in  a  p a t i en t  o r  c l in i c a l  in v e s t i g a t ion  p a t i en t  
adm in i s t e r ed  a  ph a rm a c eu t i c a l  p rodu c t .  An  A E  do e s  no t  n e c e s s a r i l y  h a v e  to  h a v e  a  c au s a l  r e l a t ion sh ip  
w i th  th i s  t r e a tm en t .  An  ad v e r s e  e v en t  (A E )  c an  th e r e fo r e  b e  an y  un f a vo r ab l e  and  un in t end ed  s i gn  
( in c lud in g  an  abno rm a l  l abo r a to r y  f ind in g ,  fo r  e x amp l e ) ,  s ymp tom ,  o r  d i s e a s e  t empo r a r i l y  a s so c i a t ed  w i th  
th e  u s e  o f  a  m ed i c in a l  p rodu c t ,  wh e th e r  o r  no t  con s id e r ed  r e l a t ed  to  th e  m ed i c in a l  p rodu c t .  Th i s  in c lud e s  
an y  o c cu r r en c e  th a t  i s  n ew  in  on s e t  o r  a g g r a v a t ed  in  s e v e r i t y  o r  f r equ en c y  f rom  th e  b a s e l in e  cond i t ion . 
In  c l in i c a l  s tud i e s ,  an  A E  c an  in c lud e  an  und e s i r ab l e  m ed i c a l  cond i t ion  o c cu r r in g  a t  an y  t im e ,  in c lud in g  run -  
in  o r  w a shou t  p e r iod s ,  e v en  i f  no  s tud y  t r e a tm en t  h a s  b e en  adm in i s t e r ed .  Th e  NC I  Common  T e rm ino lo g y  
C r i t e r i a  fo r  Ad v e r s e  E v en t s  (C TCA E )  v5 .0  i s  to  b e  u s ed  fo r  th e  g r ad in g  o f  s e v e r i t y  o f  s ymp tom s  and  
abno rm a l  f ind in g s .  Fo r  ad v e r s e  e v en t s  no t  co v e r ed  b y  th e  NC I -C TCA E  V e r s ion  5 .0  g r ad in g  s y s t em ,  th e  
fo l low in g  d e f in i t ion s  w i l l  b e  u s ed : 
G r ade  1 :  M i ld ;  a s ymp tom a t i c  o r  m i ld  s ymp tom s ;  c l in i c a l  o r  d i a gno s t i c  ob s e r v a t ion s  on l y ;  in t e r v en t ion  
no t  ind i c a t ed . 
G r ade  2 :  Mod e r a t e ;  m in im a l ,  lo c a l  o r  non - in v a s i v e  in t e r v en t ion  ind i c a t ed . 
G r ade  3 :  S e v e r e  o r  m ed i c a l l y  s i gn i f i c an t  bu t  no t  imm ed i a t e l y  l i f e - th r e a t en in g ;  ho sp i t a l i z a t ion  o r  
p ro lon g a t ion  o f  ho sp i t a l i z a t ion  ind i c a t ed . 
G r ade  4 :  L i f e - th r e a t en in g  con s equ en c e s ;  u r g en t  in t e r v en t ion  ind i c a t ed . 
G r ade  5 :  D e a th  r e l a t ed  to  A E . 
39  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 9 .3ADVERSE  EVENTS  (AES )  AND  TREATMENT  EMERGENT  ADVERSE  EVENTS  (  TEAES ) 
A l l  A E s  and  SA E s  o c cu r r in g  on  s tud y  w i l l  b e  l i s t ed  b y  p a t i en t .  Th e  f r equ en c y  and  p e r c en t a g e s  o f  p a t i en t s  
w i th  t r e a tm en t - em e r g en t  ad v e r s e  e v en t s  ( T EA E s )  w i l l  b e  t abu l a t ed  b y  s y s t em  o r g an  c l a s s  ( SOC )  and  
p r e f e r r ed  t e rm  (P T ) ,  wh e r e  t r e a tm en t - em e r g en t  i s  d e f in ed  a s  an y  A E  th a t : 
O c cu r s  a f t e r  f i r s t  do s in g  o f  s tud y  m ed i c a t ion  and  th rou gh  th e  end  o f  th e  s tud y  o r  up  th rou gh  30  
d a y s  a f t e r  th e  l a s t  do s e  o f  s tud y  t r e a tm en t ,  o r 
I s  con s id e r ed  t r e a tm en t - r e l a t ed  r e g a rd l e s s  o f  th e  s t a r t  d a t e  o f  th e  e v en t ,  o r 
I s  p r e s en t  b e fo r e  f i r s t  do s in g  o f  s tud y  m ed i c a t ion  bu t  wo r s en s  in  in t en s i t y  o r  th e  in v e s t i g a to r  
sub s equ en t l y  con s id e r s  t r e a tm en t - r e l a t ed . 
T EA E s  th a t  a r e  con s id e r ed  a t  l e a s t  po s s ib l y  r e l a t ed  to  s tud y  t r e a tm en t  w i l l  b e  t abu l a t ed  a s  w e l l  a s  d e a th s ,  
SA E s ,  and  e v en t s  r e su l t in g  in  t r e a tm en t  d i s con t inu a t ion . 
A t  e a ch  l e v e l  o f  summ a r i z a t ion ,  a  p a t i en t  w i l l  b e  coun t ed  on l y  on c e  fo r  e a ch  A E ,  SOC ,  o r  P T  e xp e r i en c ed  
w i th in  th a t  l e v e l .  In  th e  summ a t ion  fo r  A E  s e v e r i t y ,  w i th in  e a ch  l e v e l  o f  A E ,  SOC ,  o r  P T  e xp e r i en c ed ,  th e  
on e  w i th  th e  h i gh e s t  s e v e r i t y  w i l l  b e  in c lud ed .  In  th e  summ a t ion  fo r  A E ’ s  r e l a t ion sh ip  to  th e  s tud y  d ru g ,  
w i th in  e a ch  l e v e l  o f  A E ,  SOC ,  o r  P T  e xp e r i en c ed ,  th e  on e  w i th  th e  c lo s e s t  r e l a t ion sh ip  to  th e  s tud y  d ru g  
w i l l  b e  in c lud ed . 
9 .4ADVERSE  EVENTS /SER IOUS  ADVERSE  EVENT  CAUSA L ITY  ASSESSMENT 
Th e  In v e s t i g a to r  mu s t  a l so  a s s e s s  th e  r e l a t ion sh ip  o f  an y  ad v e r s e  e v en t  to  th e  u s e  o f  s tud y  d ru g s  b a s ed  
on  a v a i l ab l e  in fo rm a t ion ,  u s in g  th e  fo l low in g  gu id e l in e s : 
No t  Re l a ted :  C l e a r - cu t  t empo r a l  and /o r  m e ch an i s t i c  r e l a t ion  to  a  c au s e  o th e r  th an  th e  s tud y  
d ru g ( s ) . 
Doub t fu l :  Th e r e  i s  no  r e a son ab l e  po s s ib i l i t y  th a t  th e  e v en t  i s  r e l a t ed  to  th e  s tud y  d ru g ( s )  bu t  a  
d e f in i t e  c au s e  c anno t  b e  a s c e r t a in ed . 
Po s s ib le :  Th e r e  i s  s t i l l  a  r e a son ab l e  po s s ib i l i t y  th a t  th e  c au s e  o f  th e  e v en t  w a s  th e  s tud y  d ru g ( s )  
bu t  th e r e  e x i s t s  a  mo r e  l i k e l y  c au s e  o f  th e  e v en t  su ch  a s  comp l i c a t ion s  o f  p ro g r e s s i v e  d i s e a s e . 
P rob ab le :  Th e  mo s t  l i k e l y  c au s e  o f  th e  e v en t  i s  th e  s tud y  d ru g ( s )  bu t  o th e r  c au s e s  c anno t  b e  
comp l e t e l y  e x c lud ed . 
De f in i te :  C l e a r  cu t  t empo r a l  and /o r  m e ch an i s t i c  r e l a t ion  to  th e  s tud y  d ru g ( s ) .  A l l  o th e r  c au s e s  
h a v e  b e en  e l im in a t ed .  E v en t s  c l a s s i f i ed  a s  d e f in i t e  w i l l  o f t en  b e  con f i rm ed  b y  do cum en t in g  
r e so lu t ion  on  d i s con t inu a t ion  o f  th e  s tud y  d ru g  and  r e cu r r en c e  upon  r e sump t ion . 
9 .4 .1  HAND L ING  O F  ADV ER S E  EV EN T S 
A l l  ad v e r s e  e v en t s  r e su l t in g  in  d i s con t inu a t ion  f rom  th e  s tud y  w i l l  b e  fo l low ed  un t i l  r e so lu t ion  o r  
s t ab i l i z a t ion .  P a t i en t s  w i l l  b e  fo l low ed  fo r  A E s  fo r  30  c a l end a r  d a y s  a f t e r  d i s con t inu a t ion  o r  comp l e t ion  o f  
p ro to co l - sp e c i f i c  t r e a tm en t .  A l l  n ew  A E s  o c cu r r in g  du r in g  th i s  p e r iod  w i l l  b e  r epo r t ed  and  fo l low ed  un t i l 
40  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 r e so lu t ion  un l e s s ,  in  th e  op in ion  o f  th e  in v e s t i g a to r ,  th e s e  v a lu e s  a r e  no t  l i k e l y  to  imp ro v e  b e c au s e  o f  th e  
und e r l y in g  d i s e a s e .  In  th i s  c a s e ,  th e  in v e s t i g a to r  w i l l  r e co rd  o r  h e r  r e a son in g  fo r  th i s  d e c i s ion  in  th e  
p a t i en t ’ s  m ed i c a l  r e co rd  and  a s  a  comm en t  on  th e  CR F .  A f t e r  30  d a y s ,  on l y  A E s ,  SA E s ,  o r  d e a th s  a s s e s s ed  
b y  th e  in v e s t i g a to r  a s  t r e a tm en t  r e l a t ed  a r e  to  b e  r epo r t ed . 
9 .5SER IOUS  ADVERSE  EVENTS 
9 .5 .1D E F IN I T ION S  O F  S ER IOU S  ADV ER S E  EV EN T S 
Th e  d e f in i t ion s  o f  s e r iou s  ad v e r s e  e v en t s  ( SA E s )  a r e  g i v en  b e low .  Th e  in v e s t i g a to r  i s  r e spon s ib l e  fo r  
en su r in g  th a t  a l l  s t a f f  in vo l v ed  in  th e  s tud y  a r e  f am i l i a r  w i th  th e  con t en t  o f  th i s  s e c t ion . 
An  SA E  o r  r e a c t ion  i s  d e f in ed  a s  an y  un tow a rd  m ed i c a l  o c cu r r en c e  th a t : 
R e su l t s  in  d e a th ,  i s  imm ed i a t e l y  l i f e - th r e a t en in g , 
R equ i r e s  a t  l e a s t  a  24 -hou r  in -p a t i en t  ho sp i t a l i z a t ion  o r  p ro lon g a t ion  o f  e x i s t in g  ho sp i t a l i z a t ion , 
R e su l t s  in  p e r s i s t en t  o r  s i gn i f i c an t  d i s ab i l i t y / in c ap a c i t y ,  and /o r 
C au s e s  a  con g en i t a l  anom a l y /b i r th  d e f e c t . 
M ed i c a l  and  s c i en t i f i c  jud gm en t  shou ld  b e  e x e r c i s ed  in  d e c id in g  wh e th e r  e xp ed i t ed  r epo r t in g  i s  
app rop r i a t e  in  o th e r  s i tu a t ion s ,  su ch  a s  impo r t an t  m ed i c a l  e v en t s  th a t  m a y  no t  b e  imm ed i a t e l y  l i f e -  
th r e a t en in g  o r  r e su l t  in  d e a th  o r  ho sp i t a l i z a t ion ,  bu t  m a y  j eop a rd i z e  th e  p a t i en t  o r  m a y  r equ i r e  
in t e r v en t ion  to  p r e v en t  on e  o f  th e  o th e r  ou t com e s  l i s t ed  in  th e  p r e v iou s  d e f in i t ion .  Th e s e  shou ld  a l so  
u su a l l y  b e  con s id e r ed  s e r iou s .  E x amp l e s  o f  su ch  e v en t s  a r e  in t en s i v e  t r e a tm en t  in  an  em e r g en c y  room  o r  
a t  hom e  fo r  a l l e r g i c  b ron cho sp a sm ;  b lood  d y s c r a s i a s  o r  con vu l s ion s  th a t  do  no t  r e su l t  in  ho sp i t a l i z a t ion ;  
o r  d e v e lopm en t  o f  d ru g  d ep end en c y  o r  d ru g  abu s e . 
P ro g r e s s ion  o f  m a l i gn an c y  ( in c lud in g  f a t a l  ou t com e s ) ,  i f  do cum en t ed  b y  u s e  o f  app rop r i a t e  m e thod  ( fo r  
e x amp l e ,  a s  p e r  IWC L L  H a l l e k  e t  a l .  2008 ,  shou ld  no t  b e  r epo r t ed  a s  a  s e r iou s  ad v e r s e  e v en t . 
A  su sp e c t ed  un e xp e c t ed  s e r iou s  ad v e r s e  r e a c t ion  ( SU SAR )  i s  d e f in ed  a s  an  SA E  th a t  i s  su sp e c t ed  to  b e  a t  
l e a s t  po s s ib l y  r e l a t ed  to  s tud y  m ed i c a t ion ( s )  and  i s  an  un e xp e c t ed  e v en t . 
T r e a tm en t  w i th in  o r  adm i s s ion  to  th e  fo l low in g  f a c i l i t i e s  do e s  no t  m e e t  th e  c r i t e r i a  o f  “ in -p a t i en t  
ho sp i t a l i z a t ion ”  ( a l thou gh  i f  an y  o th e r  SA E  c r i t e r i a  a r e  m e t ,  th e  e v en t  mu s t  s t i l l  b e  t r e a t ed  a s  an  SA E ) : 
Em e r g en c y  D ep a r tm en t  o r  Em e r g en c y  Room 
Ou tp a t i en t  o r  s am e -d a y  su r g e r y  un i t s 
Ob s e r v a t ion  o r  sho r t - s t a y  un i t 
R eh ab i l i t a t ion  f a c i l i t y 
Ho sp i c e  o r  s k i l l ed  nu r s in g  f a c i l i t y 
Nu r s in g  hom e s ,  Cu s tod i a l  c a r e  o r  R e sp i t e  c a r e  f a c i l i t y 
41  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 Ho sp i t a l i z a t ion  du r in g  th e  s tud y  fo r  a  p r e -p l ann ed  su r g i c a l  o r  a  m ed i c a l  p ro c edu r e  (on e  wh i ch  w a s  p l ann ed  
p r io r  to  en t r y  in  th e  s tud y ) ,  do e s  no t  r equ i r e  r epo r t in g  a s  a  s e r iou s  ad v e r s e  e v en t . 
9 .5 .2S ER IOU S  ADV ER S E  EV EN T  R EPOR T ING  B Y  INV E S T IGA TOR S 
I t  i s  impo r t an t  to  d i s t in gu i sh  b e tw e en  s e r iou s  and  s e v e r e  ad v e r s e  e v en t s ,  a s  th e  t e rm s  a r e  no t  
s ynon ymou s .  S e v e r i t y  i s  a  m e a su r e  o f  in t en s i t y ;  how e v e r ,  an  A E  o f  s e v e r e  in t en s i t y  n e ed  no t  n e c e s s a r i l y  
b e  con s id e r ed  s e r iou s .  Fo r  e x amp l e ,  n au s e a  wh i ch  p e r s i s t s  fo r  s e v e r a l  hou r s  m a y  b e  con s id e r ed  s e v e r e  
n au s e a ,  bu t  m a y  no t  b e  con s id e r ed  an  SA E .  On  th e  o th e r  h and ,  a  s t ro k e  wh i ch  r e su l t s  in  on l y  a  l im i t ed  
d e g r e e  o f  d i s ab i l i t y  m a y  b e  con s id e r ed  on l y  a  m i ld  s t ro k e ,  bu t  wou ld  b e  con s id e r ed  an  SA E .  S e v e r i t y  and  
s e r iou sn e s s  shou ld  b e  ind ep end en t l y  a s s e s s ed  wh en  r e co rd in g  A E s  and  SA E s  on  th e  CR F . 
Ad v e r s e  e v en t s  c l a s s i f i ed  b y  th e  t r e a t in g  in v e s t i g a to r  a s  s e r iou s  r equ i r e  e xp ed i t iou s  h and l in g  and  
r epo r t in g  to  th e  Spon so r  in  o rd e r  to  comp l y  w i th  r e gu l a to r y  r equ i r em en t s .  S e r iou s  ad v e r s e  e v en t s  m a y  
o c cu r  a t  an y  t im e  f rom  th e  s i gn in g  o f  th e  in fo rm ed  con s en t  fo rm  th rou gh  th e  30 -d a y  fo l low -up  p e r iod  
a f t e r  th e  l a s t  s tud y  t r e a tm en t .  Spon so r  o r  d e s i gn e e  shou ld  b e  no t i f i ed  o f  a l l  SA E s ,  r e g a rd l e s s  o f  c au s a l i t y ,  
w i th in  24  hou r s  o f  th e  f i r s t  know l ed g e  o f  th e  e v en t  b y  th e  t r e a t in g  ph y s i c i an  o r  r e s e a r ch  p e r sonn e l . 
A l l  SA E s  ( r e g a rd l e s s  o f  c au s a l i t y  a s s e s sm en t )  o c cu r r in g  on  s tud y  o r  w i th in  30  d a y s  o f  l a s t  s tud y  t r e a tm en t  
shou ld  b e  imm ed i a t e l y  r epo r t ed  to  th e  spon so r  a s  SA E s  w i th in  th e  CR F  and  fo l low ed  un t i l  r e so lu t ion  (w i th  
au top s y  r epo r t  i f  app l i c ab l e ) . 
SMM  p ro g r e s s ion  o r  d e a th  du e  to  SMM  p ro g r e s s ion  shou ld  b e  r epo r t ed  b y  th e  in v e s t i g a to r  a s  a  s e r iou s  
ad v e r s e  e v en t  on l y  i f  i t  i s  a s s e s s ed  th a t  th e  s tud y  d ru g s  c au s ed  o r  con t r ibu t ed  to  th e  SMM  p ro g r e s s ion  
( i . e .  b y  a  m e an s  o th e r  th an  l a c k  o f  e f f e c t ) .  Un r e l a t ed  e v en t s  o f  SMM  p ro g r e s s ion  shou ld  b e  c ap tu r ed  on  
th e  app rop r i a t e  CR F . 
Th e  in v e s t i g a to r  mu s t  r e v i ew  and  s i gn  o f f  on  th e  SA E  d a t a  on  th e  SA E  r epo r t .  Th e  SA E  shou ld  b e  r epo r t ed  
to  th e  Spon so r . 
Wh en  an  SA E  i s  r epo r t ed  to  th e  spon so r  o r  d e s i gn e e ,  th e  s am e  in fo rm a t ion  shou ld  b e  en t e r ed  on  th e  CR F  
w i th in  24  hou r s  (1  bu s in e s s  d a y ) . 
Fo l low -up  in fo rm a t ion  fo r  SA E s  and  in fo rm a t ion  on  non - s e r iou s  A E s  th a t  b e com e  s e r iou s  shou ld  a l so  b e  
r epo r t ed  to  th e  spon so r  o r  d e s i gn e e  a s  soon  a s  i t  i s  a v a i l ab l e ;  th e s e  r epo r t s  shou ld  b e  subm i t t ed  u s in g  th e  
app rop r i a t e  SA E  fo rm ,  M edW a t ch3500A . 
Th e  spon so r  i s  r e spon s ib l e  fo r  r epo r t in g  r e l e v an t  SA E s  to  th e  comp e t en t  au tho r i t y ,  o th e r  app l i c ab l e  
r e gu l a to r y  au tho r i t i e s ,  and  p a r t i c ip a t in g  in v e s t i g a to r s ,  in  a c co rd an c e  w i th  ICH  gu id e l in e s ,  FDA  r e gu l a t ion s ,  
and /o r  lo c a l  r e gu l a to r y  r equ i r em en t s . 
Th e  spon so r  i s  r e spon s ib l e  fo r  r epo r t in g  un e xp e c t ed  f a t a l  o r  l i f e - th r e a t en in g  e v en t s  a s so c i a t ed  w i th  th e  
u s e  o f  th e  s tud y  d ru g s  to  th e  r e gu l a to r y  a g en c i e s  and  comp e t en t  au tho r i t i e s  w i th in  7  c a l end a r  d a y s  a f t e r  
b e in g  no t i f i ed  o f  th e  e v en t .  Th e  Spon so r  w i l l  r epo r t  a l l  r e l a t ed  bu t  un e xp e c t ed  SA E s  in c lud in g  non - 
42  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 d e a th /non - l i f e - th r e a t en in g  r e l a t ed  bu t  un e xp e c t ed  SA E s  ( SU SAR )  a s so c i a t ed  w i th  th e  u s e  o f  th e  s tud y  
m ed i c a t ion s  to  th e  r e gu l a to r y  a g en c i e s  and  comp e t en t  au tho r i t i e s  b y  a  w r i t t en  s a f e t y  r epo r t  w i th in  15  
c a l end a r  d a y s  o f  no t i f i c a t ion .  Fo l low in g  th e  subm i s s ion  to  th e  r e gu l a to r y  a g en c i e s  and  comp e t en t  
au tho r i t i e s ,  In v e s t i g a to r s  and  t r i a l  s i t e s  w i l l  b e  no t i f i ed  o f  th e  SU SAR .  In v e s t i g a to r s  mu s t  r epo r t  SU SAR s  
and  fo l low -up  in fo rm a t ion  to  th e i r  r e spon s ib l e  In s t i tu t ion a l  R e v i ew  Bo a rd  ( IRB s ) / Ind ep end en t  E th i c s  
Comm i t t e e  a c co rd in g  to  th e  po l i c i e s  o f  th e  r e spon s ib l e  IRB  (R e s e a r ch  E th i c s  Comm i t t e e ) . 
SU SAR s  and  p r e gn an c y  o r  l a c t a t ion  w i l l  b e  r epo r t ed  to  Am g en  p e r  s e c t ion  9 .7 . 
9 .6RECORD ING  O F  ADVERSE  EVENTS  AND  SER IOUS  ADVERSE  EVENTS 
In v e s t i g a to r s  shou ld  u s e  co r r e c t  m ed i c a l  t e rm ino lo g y / con c ep t s  wh en  r e co rd in g  A E s  o r  SA E s  on  th e  SA E  
R epo r t  Fo rm s  and  A E  CR F .  A vo id  co l loqu i a l i sm s  and  abb r e v i a t ion s . 
A l l  A E s ,  in c lud in g  tho s e  th a t  m e e t  SA E  r epo r t in g  c r i t e r i a ,  shou ld  b e  r e co rd ed  on  th e  A E  CR F ;  A E s  th a t  m e e t  
th e  d e f in i t ion  o f  an  SA E  shou ld  add i t ion a l l y  b e  r epo r t ed . 
9 .6 .1P ER S I S T EN T  OR  R ECURR EN T  ADV ER S E  EV EN T S 
A  p e r s i s t en t  A E  i s  on e  th a t  e x t end s  con t inuou s l y ,  w i thou t  r e so lu t ion ,  b e tw e en  p a t i en t  e v a lu a t ion  t im e  
po in t s .  Su ch  e v en t s  shou ld  on l y  b e  r e co rd ed  on c e  on  th e  SA E  R epo r t  Fo rm  and /o r  th e  A E  CR F .  I f  a  
p e r s i s t en t  A E  b e com e s  mo r e  s e v e r e  ( ch an g e s  f rom  a  G r ad e  1  o r  2  A E  to  a  G r ad e  3  o r  4  A E )  o r  l e s s en s  in  
s e v e r i t y  ( ch an g e s  f rom  a  G r ad e  3  o r  4  A E  to  a  G r ad e  1  o r  2  A E ) ,  i t  shou ld  b e  r e co rd ed  on  a  s ep a r a t e  SA E  
R epo r t  Fo rm  and /o r  A E  CR F . 
A  r e cu r r en t  A E  i s  on e  th a t  o c cu r s  and  r e so l v e s  b e tw e en  p a t i en t  e v a lu a t ion  t im e  po in t s ,  and  sub s equ en t l y  
r e cu r s .  A l l  r e cu r r en t  A E s  shou ld  b e  r e co rd ed  on  an  SA E  R epo r t  Fo rm  and /o r  A E  eCR F  fo r  e a ch  r e cu r r en c e . 
9 .6 .2D EA TH S 
D e a th s  th a t  o c cu r  du r in g  th e  p ro to co l - sp e c i f i ed  A E  r epo r t in g  p e r iod  th a t  a r e  a t t r ibu t ed  b y  th e  in v e s t i g a to r  
so l e l y  to  p ro g r e s s ion  o f  th e  p a t i en t ’ s  SMM  fo r  up  to  30  d a y s  po s t  th e  l a s t  do s e  o f  s tud y  d ru g  w i l l  b e  
r e co rd ed  on  th e  app rop r i a t e  s tud y  CR F  and  r epo r t ed  on  th e  Ad v e r s e  E v en t  p a g e  o f  th e  CR F ,  i . e .  a r e  
e x emp t ed  f rom  e xp ed i t ed  r epo r t in g .  A l l  o th e r  on - s tud y  d e a th s ,  r e g a rd l e s s  o f  a t t r ibu t ion ,  w i l l  b e  r e co rd ed  
on  an  SA E  R epo r t  Fo rm  and  e xp ed i t iou s l y  r epo r t ed  to  th e  Spon so r . 
Wh en  r e co rd in g  a  s e r iou s  ad v e r s e  e v en t  w i th  an  ou t com e  o f  d e a th ,  th e  e v en t  o r  cond i t ion  th a t  c au s ed  o r  
con t r ibu t ed  to  th e  f a t a l  ou t com e  shou ld  b e  r e co rd ed  a s  th e  s in g l e  m ed i c a l  con c ep t  on  th e  Ad v e r s e  E v en t  
p a g e  o f  th e  CR F .  I f  th e  c au s e  o f  d e a th  i s  un known  and  c anno t  b e  a s c e r t a in ed  a t  th e  t im e  o f  r epo r t in g ,  
r e co rd  “D e a th  NO S ”  on  th e  CR F  Ad v e r s e  E v en t  p a g e . 
9 .6 .3HO SP I TA L I ZA T ION ,  PRO LONG ED  HO SP I TA L I ZA T ION ,  OR  SURG ER Y 
43  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 An y  A E  th a t  r e su l t s  in  ho sp i t a l  adm i s s ion  o f  >24  hou r s  o r  p ro lon g s  ho sp i t a l i z a t ion  shou ld  b e  do cum en t ed  
and  r epo r t ed  a s  an  SA E  un l e s s  sp e c i f i c a l l y  in s t ru c t ed  o th e rw i s e  in  th i s  p ro to co l .  Th e r e  a r e  som e  
ho sp i t a l i z a t ion  s c en a r io s  th a t  do  no t  r equ i r e  r epo r t in g  a s  an  SA E  wh en  th e r e  i s  no  o c cu r r en c e  o f  an  A E . 
9 .7SA FETY  REPORT ING  TO  AMGEN 
Th e  Spon so r / In v e s t i g a to r  i s  r e spon s ib l e  fo r  comp l i an c e  w i th  e xp ed i t ed  r epo r t in g  r equ i r em en t s  fo r  
s e r iou s ,  un e xp e c t ed  and  r e l a t ed  ad v e r s e  e v en t s  ( SU SAR s ) ,  fo r  g en e r a t ion  o f  SA E  r epo r t s  in c lud in g  
n a r r a t i v e s ,  and  fo r  p e r iod i c  r epo r t in g  to  Am g en  o f  SA E s  a s  ou t l in ed  in  T ab l e  9 .7 .1  and  T ab l e  9 .7 .2  b e low .  
Ind i v idu a l  s a f e t y  r epo r t s  ( T ab l e  9 .7 .1 )  shou ld  b e  a c comp an i ed  b y  th e  S a f e t y  F a x  Co v e r  Fo rm  and  s en t  to  
Am g en  G lob a l  S a f e t y ,  u t i l i z in g  th e  f a x  o r  em a i l  in fo rm a t ion  p ro v id ed  on  th e  co v e r  p a g e .  A g g r e g a t e  s a f e t y  
r epo r t in g  ( T ab l e  9 .7 .2 )  in c lud in g  l i s t in g s ,  t abu l a t ion s  and  summ a r y  r epo r t s  shou ld  b e  s c ann ed  and  
a c comp an i ed  b y  th e  D a t a  R e con c i l i a t ion  F a x  Co v e r  Fo rm ,  and  s en t  to  Am g en  NA SCR ,  u t i l i z in g  th e  em a i l  
in fo rm a t ion  p ro v id ed  on  th e  co v e r  p a g e . 
T ab le  9 .7 .1 .  E xped i ted  Repo r t in g  Requ i remen t s  fo r  In te r ven t ion a l  S tud ie s 
S a fe t y  D a t a T ime f r ame  fo r  Subm i s s ion  to  Am gen 
Su sp e c t ed  Un e xp e c t ed  S e r iou s  Ad v e r s e  R e a c t ion  
( SU SAR s ) Ind i v idu a l  r epo r t s  s en t  to  Am g en  a t  t im e  o f  
e xp ed i t ed  r epo r t in g  to  IRB  and /o r  FDA . 
P r e gn an c y / L a c t a t ion Ind i v idu a l  r epo r t s  s en t  w i th in  10  c a l end a r  d a y s  o f  
Spon so r / In v e s t i g a to r  aw a r en e s s . 
Ind i v idu a l  r epo r t s  shou ld  b e  f a x ed  to   o r  s c ann ed  and  s en t  v i a  em a i l  to 
T ab le  9 .7 .2 .  A g g re g a te  Repo r t s 
S a fe t y  D a t a T ime f r ame  fo r  subm i s s ion  to  Am gen 
U S  IND  Annu a l  S a f e t y  R epo r t Annu a l l y 
O th e r  A g g r e g a t e  An a l y s e s 
( an y  r epo r t  con t a in in g  s a f e t y  d a t a  g en e r a t ed  
du r in g  th e  cou r s e  o f  a  s tud y ) A t  t im e  o f  I S S  spon so r  subm i s s ion  to  an y  bod y  
go v e rn in g  r e s e a r ch  condu c t  ( e g ,  FDA ,  IRB ,  e t c ) 
44  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 F in a l  ( End  o f  S tud y  R epo r t ) ,  in c lud in g : 
Unb l ind in g  d a t a  fo r  b l ind ed  s tud i e s 
R epo r t s o f un au tho r i z edu s e o fa  
m a r k e t ed  p rodu c t A t  t im e  o f  I S S  spon so r  subm i s s ion  to  an y  bod y  
go v e rn in g  r e s e a r ch  condu c t  ( e g ,  FDA ,  IRB ,  e t c )  bu t  
no t  l a t e r  th an  1  c a l end a r  y e a r  o f  s tud y  comp l e t ion 
A g g r e g a t e  r epo r t s  shou ld  b e  subm i t t ed  v i a  em a i l  to  th e  Am g en  NA SCR  m an a g e r ,  a c comp an i ed  b y  th e  D a t a  
R e con c i l i a t ion  F a x  Co v e r  Fo rm 
10C L  IN I  CA L  D  ATA  CO L  L  E  C  T ION 
10 .1AMENDMENTS  TO  THE  PR  OTOCO L 
Am endm en t s  to  th e  p ro to co l  sh a l l  b e  p l ann ed ,  do cum en t ed ,  and  s i gn a tu r e  au tho r i z ed  p r io r  to  
imp l em en t a t ion . 
A l l  am endm en t s  r equ i r e  r e v i ew  and  app ro v a l  o f  th e  P r in c ip a l  In v e s t i g a to r .  Th e  w r i t t en  am endm en t  mu s t  
b e  subm i t t ed  to  th e  IRB  a t  th e  in v e s t i g a to r ’ s  f a c i l i t y  fo r  th e  bo a rd ’ s  app ro v a l . 
Am endm en t s  sp e c i f i c a l l y  in vo l v in g  ch an g e  to  s tud y  d e s i gn ,  r i s k  to  p a t i en t ,  in c r e a s e  to  do s in g  o r  e xpo su r e ,  
p a t i en t  numb e r  in c r e a s e ,  add i t ion  o r  r emo v a l  o f  n ew  t e s t s  o r  p ro c edu r e s ,  sh a l l  b e  r e v i ew ed  and  app ro v ed  
b y  th e  IRB . 
Th e  am endm en t  w i l l  b e  subm i t t ed  fo rm a l l y  to  th e  FDA  o r  o th e r  r e gu l a to r y  au tho r i t i e s  b y  th e  in v e s t i g a to r  
a s  app l i c ab l e ,  and  sp e c i f i c a l l y  wh en  an  in c r e a s e  to  do s in g  o r  p a t i en t  e xpo su r e  and /o r  p a t i en t  numb e r  h a s  
b e en  p ropo s ed ;  o r ,  wh en  th e  add i t ion  o r  r emo v a l  o f  an  In v e s t i g a to r  i s  n e c e s s i t a t ed . 
10 .2F INANC IA L  D ISC LOSURE  S  AND  ETH ICA L  CONS IDERAT IONS 
Th i s  s tud y  w i l l  b e  condu c t ed  a c co rd in g  to  th e  s t and a rd s  o f  Good  C l in i c a l  P r a c t i c e  ou t l in ed  in  th e  ICH  E6  
T r ip a r t i t e  Gu id e l in e  and  C FR  T i t l e  21  p a r t  312 ,  app l i c ab l e  go v e rnm en t  r e gu l a t ion s ,  in s t i tu t ion a l  r e s e a r ch  
po l i c i e s  and  p ro c edu r e s  and  an y  o th e r  lo c a l  app l i c ab l e  r e gu l a to r y  r equ i r em en t ( s ) . 
10 .3IRB  AND  REGU LATORY  APPROVA L 
Th e  s tud y  p ro to co l ,  IC F ,  IB ,  a v a i l ab l e  s a f e t y  in fo rm a t ion ,  p a t i en t  do cum en t s ,  p a t i en t  r e c ru i tm en t  
p ro c edu r e s ,  in fo rm a t ion  abou t  p a ym en t s  and  comp en s a t ion  a v a i l ab l e  to  th e  p a t i en t s  and  do cum en t a t ion 
45  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 e v id en c in g  th e  P I ’ s  qu a l i f i c a t ion s  mu s t  b e  subm i t t ed  to  th e  IRB  fo r  e th i c a l  r e v i ew  and  app ro v a l  p r io r  to  
th e  s tud y  s t a r t  and  in  a c co rd an c e  w i th  in s t i tu t ion a l  gu id e l in e s . 
Th e  P I / Spon so r  and /o r  d e s i gn e e  w i l l  fo l low  a l l  n e c e s s a r y  r e gu l a t ion s  to  en su r e  in i t i a l  and  on go in g ,  IRB  
s tud y  r e v i ew .  Th e  P I  mu s t  subm i t  and ,  wh en  n e c e s s a r y ,  ob t a in  app ro v a l  f rom  th e  IRB  fo r  a l l  sub s equ en t  
p ro to co l  am endm en t s  and  ch an g e s  to  th e  in fo rm ed  con s en t  do cum en t .  In v e s t i g a to r s  w i l l  b e  ad v i s ed  b y  
th e  spon so r  o r  d e s i gn e e  wh e th e r  an  am endm en t  i s  con s id e r ed  sub s t an t i a l  o r  non - sub s t an t i a l  and  wh e th e r  
i t  r equ i r e s  subm i s s ion  fo r  app ro v a l  o r  no t i f i c a t ion  on l y  to  an  IRB .  S i t e s  mu s t  fo l low  in s t i tu t ion a l  IRB  
gu id e l in e s  fo r  subm i s s ion  r equ i r em en t s . 
I f  app l i c ab l e ,  th e  P I  w i l l  no t i f y  th e  IRB  w i th in  90  d a y s  o f  th e  end  o f  th e  s tud y ,  o r  i f  th e  s tud y  t e rm in a t e s  
e a r l y ,  th e  P I  mu s t  no t i f y  th e  IRB  w i th in  15  d a y s  o f  th e  t e rm in a t ion .  A  r e a son  fo r  th e  e a r l y  t e rm in a t ion  mu s t  
b e  p ro v id ed  ( a s  d e f in ed  in  D i r e c t i v e  2001 /20 / EC ) . 
10 .4INFORMED  CONSENT 
In fo rm ed  con s en t  i s  a  p ro c e s s  b y  wh i ch  a  p a t i en t  vo lun t a r i l y  con f i rm s  h i s  o r  h e r  w i l l in gn e s s  to  p a r t i c ip a t e  
in  a  p a r t i cu l a r  s tud y ,  a f t e r  h a v in g  b e en  in fo rm ed  o f  a l l  a sp e c t s  o f  th e  s tud y  th a t  a r e  r e l e v an t  to  th e  
p a t i en t ' s  d e c i s ion  to  p a r t i c ip a t e .  In fo rm ed  con s en t  i s  do cum en t ed  b y  m e an s  o f  a  w r i t t en ,  s i gn ed ,  and  
d a t ed  in fo rm ed  con s en t  fo rm . 
Th e  IC F  w i l l  b e  subm i t t ed  fo r  app ro v a l  to  th e  IRB  th a t  i s  r e spon s ib l e  fo r  r e v i ew  and  app ro v a l  o f  th e  s tud y .  
E a ch  con s en t  fo rm  mu s t  in c lud e  a l l  o f  th e  r e l e v an t  e l em en t s  cu r r en t l y  r equ i r ed  b y  th e  r e spon s ib l e  
r e gu l a to r y  au tho r i t y ,  a s  w e l l  a s  lo c a l  coun t y  au tho r i t y  o r  s t a t e  r e gu l a t ion s  and  n a t ion a l  r equ i r em en t s . 
B e fo r e  r e c ru i tm en t  and  en ro l lm en t  in to  th e  s tud y ,  e a ch  p ro sp e c t i v e  c and id a t e  w i l l  b e  g i v en  a  fu l l  
e xp l an a t ion  o f  th e  s tud y .  On c e  th e  e s s en t i a l  in fo rm a t ion  h a s  b e en  p ro v id ed  to  th e  p ro sp e c t i v e  c and id a t e ,  
and  th e  in v e s t i g a to r  i s  su r e  th a t  th e  ind i v idu a l  c and id a t e  und e r s t and s  th e  imp l i c a t ion s  o f  p a r t i c ip a t in g  in  
th i s  s tud y ,  th e  c and id a t e  w i l l  b e  a s k ed  to  g i v e  con s en t  to  p a r t i c ip a t e  in  th e  s tud y  b y  s i gn in g  an  in fo rm ed  
con s en t  fo rm .  A  no t a t ion  th a t  w r i t t en  in fo rm ed  con s en t  h a s  b e en  ob t a in ed  w i l l  b e  m ad e  in  th e  p a t i en t ’ s  
m ed i c a l  r e co rd .  A  cop y  o f  th e  in fo rm ed  con s en t  fo rm ,  to  in c lud e  th e  p a t i en t ’ s  s i gn a tu r e ,  w i l l  b e  p ro v id ed  
b y  th e  in v e s t i g a to r  to  th e  p a t i en t . 
I f  an  am endm en t  to  th e  p ro to co l  sub s t an t i a l l y  a l t e r s  th e  s tud y  d e s i gn  o r  th e  po t en t i a l  r i s k s  to  th e  p a t i en t s ,  
th e  p a t i en t ’ s  con s en t  to  con t inu e  p a r t i c ip a t ion  in  th e  s tud y  mu s t  b e  ob t a in ed . 
10 .5CONF IDENT IA L ITY 
Con f id en t i a l i t y  o f  p a t i en t ’ s  p e r son a l  d a t a  w i l l  b e  p ro t e c t ed  in  a c co rd an c e  w i th  th e  H e a l th  In su r an c e  
Po r t ab i l i t y  and  A c coun t ab i l i t y  A c t  o f  1996  (H IPAA ) ,  and  n a t ion a l  d a t a  p ro t e c t ion  l aw s .  H IPAA  r e gu l a t ion s  
r equ i r e  th a t ,  in  o rd e r  to  p a r t i c ip a t e  in  th e  s tud y ,  a  p a t i en t  mu s t  s i gn  an  au tho r i z a t ion  f rom  th e  s tud y  th a t  
h e  o r  sh e  h a s  b e en  in fo rm ed  o f  fo l low in g : 
46  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 Wh a t  p ro t e c t ed  h e a l th  in fo rm a t ion  (PH I )  w i l l  b e  co l l e c t ed  f rom  p a t i en t s  in  th i s  s tud y ; 
Who  w i l l  h a v e  a c c e s s  to  th a t  in fo rm a t ion  and  wh y ; 
Who  w i l l  u s e  o r  d i s c lo s e  th a t  in fo rm a t ion ; 
Th a t  h e a l th  in fo rm a t ion  m a y  b e  fu r th e r  d i s c lo s ed  b y  th e  r e c ip i en t s  o f  th e  in fo rm a t ion ,  and  th a t  i f  
th e  in fo rm a t ion  i s  d i s c lo s ed  th e  in fo rm a t ion  m a y  no  lon g e r  b e  p ro t e c t ed  b y  f ed e r a l  o r  s t a t e  
p r i v a c y  l aw s ; 
Th e  in fo rm a t ion  co l l e c t ed  abou t  th e  r e s e a r ch  s tud y  w i l l  b e  k ep t  s ep a r a t e  f rom  th e  p a t i en t ’ s  
m ed i c a l  r e co rd s ,  bu t  th e  p a t i en t  w i l l  b e  ab l e  to  ob t a in  th e  r e s e a r ch  r e co rd s  a f t e r  th e  con c lu s ion  
o f  th e  s tud y ; 
Wh e th e r  th e  au tho r i z a t ion  con t a in s  an  e xp i r a t ion  d a t e ;  and 
Th e  r i gh t s  o f  a  r e s e a r ch  p a t i en t  to  r e vo k e  h i s  o r  h e r  au tho r i z a t ion .  In  th e  e v en t  th a t  a  p a t i en t  
r e vo k e s  au tho r i z a t ion  to  co l l e c t  o r  u s e  h i s  o r  h e r  PH I ,  th e  in v e s t i g a to r ,  b y  r e gu l a t ion ,  r e t a in s  th e  
ab i l i t y  to  u s e  a l l  in fo rm a t ion  co l l e c t ed  p r io r  to  th e  r e vo c a t ion  o f  p a t i en t  au tho r i z a t ion .  Fo r  p a t i en t s  
th a t  h a v e  r e vo k ed  au tho r i z a t ion  to  co l l e c t  o r  u s e  PH I ,  a t t emp t s  shou ld  b e  m ad e  to  ob t a in  
p e rm i s s ion  to  co l l e c t  a t  l e a s t  v i t a l  s t a tu s  ( i . e . ,  th a t  th e  p a t i en t  i s  a l i v e )  a t  th e  end  o f  th e i r  s ch edu l ed  
s tud y  p e r iod .  In  comp l i an c e  w i th  ICH  GCP  gu id e l in e s  and  app l i c ab l e  p a r t s  o f  21  C FR  i t  i s  a  
r equ i r em en t  th a t  th e  in v e s t i g a to r  and  in s t i tu t ion  p e rm i t  au tho r i z ed  r ep r e s en t a t i v e s  o f  th e  
Spon so r ,  th e  r e gu l a to r y  au tho r i t i e s  and  th e  IRB  d i r e c t  a c c e s s  to  r e v i ew  th e  p a t i en t ’ s  o r i g in a l  
m ed i c a l  r e co rd s  a t  th e  s i t e  fo r  v e r i f i c a t ion  o f  s tud y - r e l a t ed  p ro c edu r e s  and  d a t a . 
M e a su r e s  to  p ro t e c t  con f id en t i a l i t y  in c lud e :  on l y  a  un iqu e  s tud y  numb e r  and  in i t i a l s  w i l l  id en t i f y  p a t i en t s  
on  th e  CR F  o r  o th e r  do cum en t s  subm i t t ed  to  th e  Spon so r .  Th i s  in fo rm a t ion ,  to g e th e r  w i th  th e  p a t i en t ’ s  
d a t e  o f  b i r th ,  w i l l  b e  u s ed  in  th e  d a t ab a s e  fo r  p a t i en t  id en t i f i c a t ion .  P a t i en t  n am e s  o r  add r e s s e s  w i l l  no t  
b e  en t e r ed  in  th e  CR F  o r  d a t ab a s e .  No  m a t e r i a l  b e a r in g  a  p a t i en t ’ s  n am e  w i l l  b e  k ep t  on  f i l e  b y  th e  Spon so r .  
P a t i en t s  w i l l  b e  in fo rm ed  o f  th e i r  r i gh t s  w i th in  th e  IC F . 
10 .6STUDY  DOCUMENTAT ION  AND  STORAGE 
Th e  P I  mu s t  m a in t a in  a  l i s t  o f  app rop r i a t e l y  qu a l i f i ed  p e r son s  to  whom  h e / sh e  h a s  d e l e g a t ed  s tud y  du t i e s  
and  shou ld  en su r e  th a t  a l l  p e r son s  a s s i s t in g  in  th e  condu c t  o f  th e  s tud y  a r e  in fo rm ed  o f  th e i r  ob l i g a t ion s .  
A l l  p e r son s  au tho r i z ed  to  m a k e  en t r i e s  and /o r  co r r e c t ion s  on  th e  CR F s  a r e  to  b e  in c lud ed  on  th i s  
do cum en t .  A l l  en t r i e s  in  th e  p a t i en t ’ s  CR F  a r e  to  b e  suppo r t ed  b y  sou r c e  do cum en t a t ion  wh e r e  
app rop r i a t e .  Sou r c e  do cum en t s  a r e  th e  o r i g in a l  do cum en t s ,  d a t a ,  r e co rd s  and  c e r t i f i ed  cop i e s  o f  o r i g in a l  
r e co rd s  o f  c l in i c a l  f ind in g s ,  ob s e r v a t ion s  and  a c t i v i t i e s  f rom  wh i ch  th e  p a t i en t ’ s  CR F  d a t a  a r e  ob t a in ed .  
Th e s e  c an  in c lud e ,  bu t  a r e  no t  l im i t ed  to ,  ho sp i t a l  r e co rd s ,  c l in i c a l  and  o f f i c e  ch a r t s ,  l abo r a to r y ,  m ed i co -  
t e chn i c a l  d ep a r tm en t  and  ph a rm a c y  r e co rd s ,  d i a r i e s ,  m i c ro f i ch e s ,  EKG  t r a c e s ,  cop i e s  o r  t r an s c r ip t ion s  
c e r t i f i ed  a f t e r  v e r i f i c a t ion  a s  b e in g  a c cu r a t e  and  comp l e t e ,  pho to g r aph i c  n e g a t i v e s ,  m i c ro f i lm  o r  m a gn e t i c  
m ed i a ,  X - r a y s ,  and  co r r e spond en c e . 
Th e  P I  and  s tud y  s t a f f  a r e  r e spon s ib l e  fo r  m a in t a in in g  a  comp r eh en s i v e  and  c en t r a l i z ed  f i l in g  s y s t em  ( S i t e  
S tud y  F i l e / S S F  o r  I S F )  o f  a l l  s tud y - r e l a t ed  ( e s s en t i a l )  do cum en t a t ion ,  su i t ab l e  fo r  in sp e c t ion  a t  an y  t im e  b y 
47  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 r ep r e s en t a t i v e s  f rom  th e  Spon so r  and /o r  app l i c ab l e  r e gu l a to r y  au tho r i t i e s .  Th e  I S F / S S F  mu s t  con s i s t  o f  
tho s e  do cum en t s  th a t  ind i v idu a l l y  o r  co l l e c t i v e l y  p e rm i t  e v a lu a t ion  o f  th e  condu c t  o f  th e  s tud y  and  th e  
qu a l i t y  o f  th e  d a t a  p rodu c ed .  Th e  I S F / S S F  shou ld  con t a in  a s  a  m in imum  a l l  r e l e v an t  do cum en t s  and  
co r r e spond en c e ,  in c lud in g  k e y  do cum en t s  su ch  a s  th e  IB  and  an y  am endm en t s ,  p ro to co l  and  an y  
am endm en t s ,  s i gn ed  IC F s ,  IRB  app ro v a l  do cum en t s ,  F in an c i a l  D i s c lo su r e  fo rm s ,  p a t i en t  id en t i f i c a t ion  l i s t s ,  
en ro l lm en t  lo g s ,  d e l e g a t ion  o f  au tho r i t y  lo g ,  s t a f f  qu a l i f i c a t ion  do cum en t s ,  l abo r a to r y  no rm a l  r an g e s ,  
r e co rd s  r e l a t in g  to  th e  s tud y  d ru g  in c lud in g  a c coun t ab i l i t y  r e co rd s .  D ru g  a c coun t ab i l i t y  r e co rd s  shou ld ,  a t  
a  m in imum ,  con t a in  in fo rm a t ion  r e g a rd in g  r e c e ip t ,  sh ipm en t ,  and  d i spo s i t ion .  E a ch  fo rm  o f  d ru g  
a c coun t ab i l i t y  r e co rd ,  a t  a  m in imum ,  shou ld  con t a in  P I  n am e ,  d a t e  d ru g  sh ipp ed / r e c e i v ed ,  d a t e ,  qu an t i t y  
and  b a t ch / cod e ,  o r  lo t  numb e r  fo r  id en t i t y  o f  e a ch  sh ipm en t .  In  add i t ion ,  a l l  o r i g in a l  sou r c e  do cum en t s  
suppo r t in g  en t r i e s  in  th e  CR F  mu s t  b e  m a in t a in ed  and  b e  r e ad i l y  a v a i l ab l e . 
Th e  IRB  sh a l l  m a in t a in  ad equ a t e  do cum en t a t ion  /  r e co rd s  o f  IRB  a c t i v i t i e s  fo r  a t  l e a s t  3  y e a r s  a f t e r  
comp l e t ion  o f  th e  r e s e a r ch . 
Th e  In v e s t i g a to r  sh a l l  m a in t a in  ad equ a t e  r e co rd s  o f  d ru g  d i spo s i t ion ,  c a s e  h i s to r i e s  and  an y  o th e r  s tud y -  
r e l a t ed  r e co rd s  fo r  no  l e s s  th an  2  y e a r s  a f t e r  th e  l a s t  m a r k e t in g  app l i c a t ion  h a s  b e en  app ro v ed  b y  FDA ;  
o r ,  in  th e  e v en t  th a t  th e  m a r k e t in g  app l i c a t ion  h a s  no t  b e en  app ro v ed  b y  FDA ,  fo r  no  l e s s  th an  2  y e a r s  
a f t e r  th e  l a s t  sh ipm en t  /  d e l i v e r y  o f  th e  d ru g  fo r  in v e s t i g a t ion a l  u s e  i s  d i s con t inu ed  and  FDA  h a s  b e en  
no t i f i ed  o f  th e  d i s con t inu a t ion . 
To  en ab l e  e v a lu a t ion s  and /o r  aud i t s  f rom  r e gu l a to r y  au tho r i t i e s  o r  f rom  th e  Spon so r  o r  i t s  r ep r e s en t a t i v e ,  
th e  in v e s t i g a to r  add i t ion a l l y  a g r e e s  to  k e ep  r e co rd s ,  in c lud in g  th e  id en t i t y  o f  a l l  p a r t i c ip a t in g  p a t i en t s  
( su f f i c i en t  in fo rm a t ion  to  l in k  r e co rd s  e . g . ,  m ed i c a l  r e co rd s ) ,  a l l  o r i g in a l ,  s i gn ed  in fo rm ed  con s en t  fo rm s ,  
and  cop i e s  o f  a l l  CR F s ,  SA E  R epo r t in g  fo rm s ,  sou r c e  do cum en t s ,  d e t a i l ed  r e co rd s  o f  t r e a tm en t  d i spo s i t ion ,  
and  r e l a t ed  e s s en t i a l  r e gu l a to r y  do cum en t s .  Th e  do cum en t s  l i s t ed  abo v e  mu s t  b e  r e t a in ed  b y  th e  
in v e s t i g a to r  fo r  a s  lon g  a s  n e ed ed  to  comp l y  w i th  n a t ion a l  and  in t e rn a t ion a l  r e gu l a t ion s  ( g en e r a l l y  2  y e a r s  
a f t e r  d i s con t inu in g  c l in i c a l  d e v e lopm en t  o r  a f t e r  th e  l a s t  m a r k e t in g  app ro v a l ) .  Th e  Spon so r  o r  i t s  
r ep r e s en t a t i v e  w i l l  no t i f y  th e  in v e s t i g a to r ( s ) / in s t i tu t ion s ( s )  wh en  th e  s tud y - r e l a t ed  r e co rd s  a r e  no  lon g e r  
r equ i r ed . 
10 .7DATA  CO L LECT ION  AND  SAFETY 
Th e  s tud y  CR F  i s  th e  p r im a r y  d a t a  co l l e c t ion  in s t rum en t  fo r  th e  s tud y .  An  e l e c t ron i c  c a s e  r epo r t  fo rm  w i l l  
b e  u t i l i z ed  fo r  th e  co l l e c t ion  o f  a l l  d a t a  and  a l l  d a t a  w i l l  b e  en t e r ed  in to  th e  R edC ap  d a t ab a s e  u s in g  th e  
En g l i sh  l an gu a g e  and  shou ld  b e  k ep t  cu r r en t  to  en ab l e  r e v i ew  o f  th e  p a t i en t s ’  s t a tu s  th rou ghou t  th e  
cou r s e  o f  th e  s tud y . 
In  o rd e r  to  m a in t a in  con f id en t i a l i t y ,  on l y  s tud y  numb e r ,  p a t i en t  numb e r ,  in i t i a l s ,  and  d a t e  o f  b i r th  w i l l  
id en t i f y  th e  p a t i en t  in  th e  CR F .  I f  th e  p a t i en t ’ s  n am e  app e a r s  on  an y  o th e r  do cum en t  ( e . g .  l abo r a to r y  
r epo r t ) ,  i t  mu s t  b e  ob l i t e r a t ed  on  th e  cop y  o f  th e  do cum en t  to  b e  supp l i ed  to  th e  in v e s t i g a to r  s i t e  and  
r ep l a c ed  in s t e ad  w i th  th e  p a t i en t  numb e r  and  p a t i en t ’ s  in i t i a l s .  Th e  in v e s t i g a to r  w i l l  m a in t a in  a  p e r son a l  
p a t i en t  id en t i f i c a t ion  l i s t  (p a t i en t  numb e r s  w i th  co r r e spond in g  p a t i en t  id en t i f i e r s )  to  en ab l e  r e co rd s  to  b e 
48  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 id en t i f i ed  and  v e r i f i ed  a s  au th en t i c .  P a t i en t  d a t a / in fo rm a t ion  w i l l  b e  k ep t  con f id en t i a l ,  and  w i l l  b e  
m an a g ed  a c co rd in g  to  app l i c ab l e  lo c a l ,  s t a t e ,  and  f ed e r a l  r e gu l a t ion s . 
Th e  Un i v e r s i t y  o f  Ro ch e s t e r  D a t a  and  S a f e t y  Mon i to r in g  Comm i t t e e  (D SMC )  w i l l  b e  th e  d a t a  s a f e t y  
mon i to r in g  comm i t t e e  o f  r e co rd  fo r  th e  condu c t ion  o f  th i s  s tud y .  P l e a s e  r e f e r  to  th e  W i lmo t  C an c e r  
In s t i tu t e  (WC I )  Un i v e r s i t y  o f  Ro ch e s t e r  Po l i c y  and  P ro c edu r e s  fo r  D a t a  and  S a f e t y  Mon i to r  do cum en t  fo r  
d e t a i l s . 
10 .8PUB L ICAT ION  PO L ICY 
A l l  in fo rm a t ion  p ro v id ed  r e g a rd in g  th e  s tud y ,  a s  w e l l  a s  a l l  in fo rm a t ion  co l l e c t ed /do cum en t ed  du r in g  th e  
cou r s e  o f  th e  s tud y ,  w i l l  b e  r e g a rd ed  a s  con f id en t i a l . 
A  c l in i c a l  s tud y  r epo r t  w i l l  b e  p r ep a r ed  upon  comp l e t ion  o f  th e  s tud y .  Th e  P I  w i l l  d i s c lo s e  th e  s tud y  r e su l t s ,  
in  th e  fo rm  o f  a  c l in i c a l  s tud y  r epo r t  s ynop s i s ,  to  th e  app l i c ab l e  r e gu l a to r y  au tho r i t i e s  w i th in  on e  y e a r  o f  
th e  end  o f  th e  s tud y . 
11P  L  ANNED  CORRE L  AT IV  E  ANA L  Y  SES 
A t  URMC ,  p e r iph e r a l  b lood  w i l l  b e  co l l e c t ed  f rom  f a s t in g  p a t i en t s  w i th in  30  d a y s  o f  th e  f i r s t  t r e a tm en t  and  
a t  th e  end  o f  t r e a tm en t  a t  th e  t im e s  o f  a  r e gu l a r l y  s ch edu l ed  b lood  d r aw .  Th e  s e cond  mo rn in g  vo id  w i l l  
b e  co l l e c t ed  fo r  a s s e s sm en t  o f  uN T x  m e a su r em en t s  v i a  immuno a s s a y  a t  th e  t im e  o f  a  r e gu l a r l y  s ch edu l ed  
l ab  co l l e c t ion .  Th e s e  a s s a y s  w i l l  in c lud e  m e a su r em en t  o f  sRANK L ,  sC T x ,  NO TCH  s i gn a l s ,  s c l e ro s t in ,  DKK1 ,  
M IP -1α ,  and  OPG  v i a  en z ym e - l in k ed  immuno so rb en t  a s s a y  ( E L I SA ) .  Th e s e  sp e c im en s  w i l l  b e  co l l e c t ed ,  
p ro c e s s ed  and  an a l y z ed  b y  th e  L ip e  l abo r a to r y  a s  b e low . 
P e r iph e r a l  b lood : 
1 .10  m L  o f  Who l e  b lood  w i l l  b e  co l l e c t ed  in  2  g r e en  top  tub e s 
2 .C en t r i fu g e  a t  1800 x g  fo r  30  m inu t e s  in  a  sw in g  bu c k e t  c en t r i fu g e  (no t  a  f i x ed  an g l e )  w i th in  24  
hou r s  o f  co l l e c t ion 
3 .10m L  o f  Who l e  b lood  w i l l  b e  co l l e c t ed  in  2  r ed  top  tub e s 
4 .B lood  w i l l  b e  a l low ed  to  c lo t  p r io r  to  c en t r i fu g a t ion  a t  4000  x  g  fo r  10  m inu t e s 
5 .B lood  w i l l  b e  s to r ed  a t  -80  d e g r e e s  c en t i g r ad e  un t i l  an a l y s i s  
Bon e  m a r row : 
1 .40m L  o f  Bon e  m a r row  a sp i r a t e  w i l l  b e  co l l e c t ed  f i r s t  in  2  Sod ium  H ep a r in  ( g r e en  top  w i th  10m L 
e a ch )  and  th en  2  l a v end e r  top  co l l e c t ion  tub e s  (10m L  e a ch ) . 
a .S amp l e s  w i l l  und e r go  F i co l l  s ep a r a t ion  fo r  th e  co l l e c t ion  o f  mononu c l e a r  c e l l s .  
Mononu c l e a r  c e l l s  w i l l  b e  g rown  and  an a l y z ed  in  th e  L ip e  l abo r a to r y . 
2 .Bon e  m a r row  s amp l e s  w i l l  b e  co l l e c t ed  and  p ro c e s s ed  in  th e  L ip e  l abo r a to r y . 
49  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 12 REFEREN  CES 
1 .  R a j kum a r ,  S .V . ,  O .  L and g r en ,  and  M . -V .  M a t eo s ,  Smo ld e r ing  mu l t ip l e  m y e loma .  B lood ,  2015 . 
125 (20 ) :  p .  3069 -3075 . 
2 .  B a t a i l l e ,  R . ,  D .  Ch app a rd ,  and  M . F .  B a s l e ,  Quan t i f iab l e  e x c e s s  o f  bon e  r e so rp t ion  in  mono c lona l  
gammopa th y  i s  an  ea r l y  s ymp tom  o f  ma l ignan c y :  a  p ro sp e c t i v e  s tud y  o f  87  bon e  b iop s i e s .  B lood ,  
1996 .  87 (11 ) :  p .  4762 -4769 . 
3 .  V a l l e t ,  S . ,  e t  a l . ,  A  ro l e  fo r  bon e  tu rno v e r  ma r k e r s  b e ta -C ro s s Lap s  (C TX )  and  am ino - t e rm ina l  
p rop ep t id e  o f  t yp e  I  co l lag en  (P INP )  a s  po t en t ia l  ind i ca to r s  fo r  d i s ea s e  p rog r e s s ion  f rom  MGU S  to  
mu l t ip l e  m y e loma .  L eu k  L ymphom a ,  2018 :  p .  1 -8 . 
4 .  S e em an ,  E . ,  e t  a l . ,  M i c roa r ch i t e c tu ra l  d e t e r io ra t ion  o f  co r t i ca l  and  t rab e cu la r  bon e :  d i f f e r ing  
e f f e c t s  o f  d eno sumab  and  a l end rona t e .  J  Bon e  M in e r  R e s ,  2010 .  25 (8 ) :  p .  1886 -94 . 
5 .  Po l i tou ,  M . ,  e t  a l . ,  Ro l e  o f  r e c ep to r  a c t i va to r  o f  nu c l ea r  fa c to r - kappa  B  l igand  (RANK L ) ,  
o s t eop ro t eg e r in  and  ma c rophag e  p ro t e in  1 -a lpha  (M IP -1a )  in  mono c lona l  gammopa th y  o f  
und e t e rm in ed  s ign i f i can c e  (MGU S ) .  B r i t i sh  Jou rn a l  o f  H a em a to lo g y ,  2004 .  126 (5 ) :  p .  686 -689 . 
6 .  G a t t i ,  D . ,  e t  a l . ,  S c l e ro s t in  and  DKK1  in  po s tm enopau sa l  o s t eopo ro s i s  t r ea t ed  w i th  d eno sumab .  J  
Bon e  M in e r  R e s ,  2012 .  27 (11 ) :  p .  2259 -63 . 
7 .  K y l e ,  R .A . ,  e t  a l . ,  C l in i ca l  cou r s e  and  p rogno s i s  o f  smo ld e r ing  (a s ymp toma t i c )  mu l t ip l e  m y e loma .  N  
En g l  J  M ed ,  2007 .  356 (25 ) :  p .  2582 -90 . 
8 .  J am e s ,  A .H . ,  e t  a l . ,  Von  W i l l eb rand  d i s ea s e  and  o th e r  b l e ed ing  d i so rd e r s  in  wom en :  con s en su s  on  
d iagno s i s  and  manag em en t  f rom  an  in t e rna t iona l  e xp e r t  pan e l .  Am e r i c an  Jou rn a l  o f  Ob s t e t r i c s  &  
G yn e co lo g y ,  2009 .  201 (1 ) :  p .  12 . e1 -12 . e8 . 
9 .  p ro g r am ,  N .N . S . ,  can c e r  s ta t  fa c t s :  m y e loma .  s e e r . c an c e r . go v ,  2018 . 
10 .  R a v ind r an ,  A . ,  e t  a l . ,  P r e va l en c e ,  in c id en c e  and  su r v i va l  o f  smo ld e r ing  mu l t ip l e  m y e loma  in  th e  
Un i t ed  S ta t e s .  B lood  C an c e r  Jou rn a l ,  2016 .  6(10 ) :  p .  e486 . 
11 .  K y l e ,  R .A . ,  e t  a l . ,  P r e va l en c e  o f  mono c lona l  gammopa th y  o f  und e t e rm in ed  s ign i f i can c e .  N ew  
En g l and  Jou rn a l  o f  M ed i c in e ,  2006 .  354 (13 ) :  p .  1362 -1369 . 
12 .  L and g r en ,  O . ,  e t  a l . ,  Mono c lona l  gammopa th y  o f  und e t e rm in ed  s ign i f i can c e  (MGU S )  con s i s t en t l y  
p r e c ed e s  mu l t ip l e  m y e loma :  a  p ro sp e c t i v e  s tud y .  B lood ,  2009 .  113 (22 ) :  p .  5412 -5417 . 
13 .  R a j kum a r ,  S .V . ,  e t  a l . ,  In t e rna t iona l  M y e loma  Wo r k ing  G roup  upda t ed  c r i t e r ia  fo r  th e  d iagno s i s  o f  
mu l t ip l e  m y e loma .  Th e  L an c e t  On co lo g y ,  2014 .  15 (12 ) :  p .  e538 - e548 . 
14 .  K y l e ,  R .A . ,  e t  a l . ,  Mono c lona l  gammopa th y  o f  und e t e rm in ed  s ign i f i can c e  (MGU S )  and  smo ld e r ing  
(a s ymp toma t i c )  mu l t ip l e  m y e loma :  IMWG  con s en su s  p e r sp e c t i v e s  r i s k  fa c to r s  fo r  p rog r e s s ion  and  
gu id e l in e s  fo r  mon i to r ing  and  manag em en t .  L eu k em i a ,  2010 .  24 (6 ) :  p .  1121 -1127 . 
15 .  K y l e ,  R .A . ,  e t  a l . ,  Long - t e rm  fo l low -up  o f  241  pa t i en t s  w i th  mono c lona l  gammopa th y  o f  
und e t e rm in ed  s ign i f i can c e :  th e  o r ig ina l  Ma yo  C l in i c  s e r i e s  25  y ea r s  la t e r .  M a yo  C l in  P ro c ,  2004 .  
79 (7 ) :  p .  859 -66 . 
16 .  H jo r th ,  M . ,  e t  a l . ,  In i t ia l  v e r su s  d e f e r r ed  m e lpha lan -p r edn i son e  th e rap y  fo r  a s ymp toma t i c  mu l t ip l e  
m y e loma  s tag e  I - -a  random i z ed  s tud y .  M y e loma  G roup  o f  W e s t e rn  Sw ed en .  Eu r  J  H a em a to l ,  1993 .  
50 (2 ) :  p .  95 -102 . 
50  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 17 .  R i c c a rd i ,  A . ,  e t  a l . ,  Long - t e rm  su r v i va l  o f  s tag e  I  mu l t ip l e  m y e loma  g i v en  ch emo th e rap y  ju s t  a f t e r  
d iagno s i s  o r  a t  p rog r e s s ion  o f  th e  d i s ea s e :  a  mu l t i c en t r e  random i z ed  s tud y .  Coop e ra t i v e  G roup  o f  
S tud y  and  T r ea tm en t  o f  Mu l t ip l e  M y e loma .  B r  J  C an c e r ,  2000 .  82 (7 ) :  p .  1254 -60 . 
18 .  R a j kum a r ,  S .V . ,  e t  a l . ,  Tha l idom id e  fo r  p r e v iou s l y  un t r ea t ed  indo l en t  o r  smo ld e r ing  mu l t ip l e  
m y e loma .  L eu k em i a ,  2001 .  15 (8 ) :  p .  1274 -6 . 
19 .  B a r lo g i e ,  B . ,  e t  a l . ,  S e v en - y ea r  m ed ian  t im e  to  p rog r e s s ion  w i th  tha l idom id e  fo r  smo ld e r ing  
m y e loma :  pa r t ia l  r e spon s e  id en t i f i e s  sub s e t  r equ i r ing  ea r l i e r  sa l vag e  th e rap y  fo r  s ymp toma t i c  
d i s ea s e .  B lood ,  2008 .  112 (8 ) :  p .  3122 -5 . 
20 . W i t z i g ,  T . E . ,  e t  a l . ,  A  pha s e  I I I  random i z ed  t r ia l  o f  tha l idom id e  p lu s  zo l ed ron i c  a c id  v e r su s  zo l ed ron i c  
a c id  a lon e  in  pa t i en t s  w i th  a s ymp toma t i c  mu l t ip l e  m y e loma .  L eu k em i a ,  2013 .  27 (1 ) :  p .  220 -225 . 
21 . M a t eo s ,  M .V . ,  e t  a l . ,  L ena l idom id e  p lu s  d e xam e tha son e  fo r  h igh - r i s k  smo ld e r ing  mu l t ip l e  
m y e loma .  N  En g l  J  M ed ,  2013 .  369 (5 ) :  p .  438 -47 . 
22 .  T e rpo s ,  E . ,  e t  a l . ,  Pa thog en e s i s  o f  bon e  d i s ea s e  in  mu l t ip l e  m y e loma :  f rom  b en ch  to  b ed s id e .  B lood  
C an c e r  Jou rn a l ,  2018 .  8(1 ) :  p .  7 . 
23 .  T e rpo s ,  E . ,  e t  a l . ,  So lub l e  r e c ep to r  a c t i va to r  o f  nu c l ea r  fa c to r  kappaB  l igand -o s t eop ro t eg e r in  ra t io  
p r ed i c t s  su r v i va l  in  mu l t ip l e  m y e loma :  p ropo sa l  fo r  a  no v e l  p rogno s t i c  ind e x .  B lood ,  2003 .  102 (3 ) :  
p .  1064 -1069 . 
24 .  V e ron e s e ,  N . ,  e t  a l . ,  Mono c lona l  gammopa th y  o f  und e t e rm in ed  s ign i f i can c e  and  bon e  h ea l th  
ou t com e s :  a  s y s t ema t i c  r e v i ew  and  e xp lo ra to r y  m e ta -ana l y s i s .  J  Bon e  M in e r  M e t ab ,  2018 .  36 (1 ) :  
p .  128 -132 . 
25 .  G iu l i an i ,  N . ,  e t  a l . ,  Human  m y e loma  c e l l s  s t imu la t e  th e  r e c ep to r  a c t i va to r  o f  nu c l ea r  fa c to r - kappa  
B  l igand  (RANK L )  in  T  l ympho c y t e s :  a  po t en t ia l  ro l e  in  mu l t ip l e  m y e loma  bon e  d i s ea s e .  B lood ,  2002 .  
100 (13 ) :  p .  4615 -21 . 
26 . S t and a l ,  T . ,  e t  a l . ,  O s t eop ro t eg e r in  i s  bound ,  in t e rna l i z ed ,  and  d eg rad ed  b y  mu l t ip l e  m y e loma  c e l l s . 
B lood ,  2002 .  100 (8 ) :  p .  3002 -7 . 
27 .  Bu c k l e ,  C .H . ,  e t  a l . ,  So lub l e  ran k  l igand  p rodu c ed  b y  m y e loma  c e l l s  cau s e s  g en e ra l i s ed  bon e  lo s s  in  
mu l t ip l e  m y e loma .  P Lo S  On e ,  2012 .  7(8 ) :  p .  e41127 . 
28 .  So rd i l lo ,  E .M .  and  R .N .  P e a r s e ,  RANK - F c :  a  th e rap eu t i c  an tagon i s t  fo r  RANK - L  in  m y e loma .  C an c e r ,  
2003 .  97 (3  Supp l ) :  p .  802 -12 . 
29 .  C rou ch e r ,  P . I . ,  e t  a l . ,  O s t eop ro t eg e r in  inh ib i t s  th e  d e v e lopm en t  o f  o s t eo l y t i c  bon e  d i s ea s e  in  
mu l t ip l e  m y e loma .  B lood ,  2001 .  98 (13 ) :  p .  3534 -40 . 
30 . M cC lo s k e y ,  E .V . ,  e t  a l . ,  A  random i z ed  t r ia l  o f  th e  e f f e c t  o f  c lod rona t e  on  s k e l e ta l  mo rb id i t y  in  
mu l t ip l e  m y e loma .  MRC  Wo r k ing  Pa r t y  on  L eu ka em ia  in  Adu l t s .  B r  J  H a em a to l ,  1998 .  100 (2 ) :  p .  
317 -25 . 
31 .  B e r en son ,  J .R . ,  e t  a l . ,  Zo l ed ron i c  a c id  r edu c e s  s k e l e ta l - r e la t ed  e v en t s  in  pa t i en t s  w i th  o s t eo l y t i c  
m e ta s ta s e s .  C an c e r ,  2001 .  91 (7 ) :  p .  1191 -200 . 
32 .  D e r enn e ,  S . ,  e t  a l . ,  Zo l ed rona t e  i s  a  po t en t  inh ib i to r  o f  m y e loma  c e l l  g row th  and  s e c r e t ion  o f  I L -6  
and  MMP -1  b y  th e  tumo ra l  en v i ronm en t .  J  Bon e  M in e r  R e s ,  1999 .  14 (12 ) :  p .  2048 -56 . 
33 .  Sh ipm an ,  C .M . ,  e t  a l . ,  B i spho sphona t e s  indu c e  apop to s i s  in  human  m y e loma  c e l l  l in e s :  a  no v e l  an t i -  
tumou r  a c t i v i t y .  B r  J  H a em a to l ,  1997 .  98 (3 ) :  p .  665 -72 . 
34 .  S an f i l ippo ,  K .M . ,  e t  a l . ,  Compa ra t i v e  e f f e c t i v en e s s  on  su r v i va l  o f  zo l ed ron i c  a c id  v e r su s  
pam id rona t e  in  mu l t ip l e  m y e loma .  L eu k  L ymphom a ,  2015 .  56 (3 ) :  p .  615 -21 . 
51  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 35 . Mo r g an ,  G . J . ,  e t  a l . ,  E f f e c t s  o f  zo l ed ron i c  a c id  v e r su s  c lod ron i c  a c id  on  s k e l e ta l  mo rb id i t y  in  pa t i en t s  
w i th  n ew l y  d iagno s ed  mu l t ip l e  m y e loma  (MRC  M y e loma  IX ) :  s e conda r y  ou t com e s  f rom  a  
random i s ed  con t ro l l ed  t r ia l .  L an c e t  On co l ,  2011 .  12 (8 ) :  p .  743 -52 . 
36 .  D r a k e ,  M . T . ,  B . L .  C l a r k e ,  and  S .  Kho s l a ,  B i sphona t e s :  m e chan i sm  o f  a c t ion  and  ro l e  in  c l in i ca l  
p ra c t i c e .  M a yo  C l in i c  P ro c e ed in g s ,  2008 .  83 :  p .  1032 + . 
37 .  Dun fo rd ,  J . E . ,  e t  a l . ,  S t ru c tu r e -a c t i v i t y  r e la t ion sh ip s  fo r  inh ib i t ion  o f  fa rn e s y l  d ipho spha t e  s yn tha s e  
in  v i t ro  and  inh ib i t ion  o f  bon e  r e so rp t ion  in  v i vo  b y  n i t rog en - con ta in ing  b i spho sphona t e s .  J  
Ph a rm a co l  E xp  Th e r ,  2001 .  296 (2 ) :  p .  235 -42 . 
38 .  B e r en son ,  J .R . ,  e t  a l . ,  Zo l ed ron i c  a c id  ma r k ed l y  imp ro v e s  bon e  m in e ra l  d en s i t y  fo r  pa t i en t s  w i th  
mono c lona l  gammopa th y  o f  und e t e rm in ed  s ign i f i can c e  and  bon e  lo s s .  C l in  C an c e r  R e s ,  2008 .  
14 (19 ) :  p .  6289 -95 . 
39 . Mu s to ,  P . ,  e t  a l . ,  A  mu l t i c en t e r ,  random i z ed  c l in i ca l  t r ia l  compa r ing  zo l ed ron i c  a c id  v e r su s  
ob s e r va t ion  in  pa t i en t s  w i th  a s ymp toma t i c  m y e loma .  C an c e r ,  2008 .  113 (7 ) :  p .  1588 -95 . 
40 .  D 'A r en a ,  G . ,  e t  a l . ,  Pam id rona t e  v e r su s  ob s e r va t ion  in  a s ymp toma t i c  m y e loma :  f ina l  r e su l t s  w i th  
long - t e rm  fo l low -up  o f  a  random i z ed  s tud y .  L eu k  L ymphom a ,  2011 .  52 (5 ) :  p .  771 -5 . 
41 .  D r a k e ,  M . T . ,  Un v e i l ing  S k e l e ta l  F rag i l i t y  in  Pa t i en t s  D iagno s ed  w i th  MGU S :  No  Long e r  a  Cond i t ion  
o f  Und e t e rm in ed  S ign i f i can c e ?  Jou rn a l  o f  bon e  and  m in e r a l  r e s e a r ch  :  th e  o f f i c i a l  jou rn a l  o f  th e  
Am e r i c an  So c i e t y  fo r  Bon e  and  M in e r a l  R e s e a r ch ,  2014 .  29 (12 ) :  p .  2529 -2533 . 
42 .  Q i an g ,  Y . -W . ,  e t  a l . ,  D k k1  b lo c k s  Wn t - indu c ed  o s t eop ro t eg e r in  p rodu c t ion  in  o s t eob la s t  p rog en i to r s  
in  mu l t ip l e  m y e loma .  C an c e r  R e s e a r ch ,  2007 .  67 (9  Supp l em en t ) :  p .  2050 -2050 . 
43 . M ab i l l e ,  C . ,  e t  a l . ,  DKK1  and  s c l e ro s t in  a r e  ea r l y  ma r k e r s  o f  r e lap s e  in  mu l t ip l e  m y e loma .  Bon e ,  
2017 . 
44 .  Zhou ,  F . ,  e t  a l . ,  D i c k kop f -1  i s  a  k e y  r egu la to r  o f  m y e loma  bon e  d i s ea s e :  oppo r tun i t i e s  and  
cha l l eng e s  fo r  th e rap eu t i c  in t e r v en t ion .  B lood  R e v ,  2013 .  27 (6 ) :  p .  261 -7 . 
45 .  Co lombo ,  M . ,  e t  a l . ,  No t ch -d i r e c t ed  m i c ro en v i ronm en t  r ep rog ramm ing  in  m y e loma :  a  s ing l e  pa th  
to  mu l t ip l e  ou t com e s .  L eu k em i a ,  2013 .  27 (5 ) :  p .  1009 -18 . 
46 .  G iu l i an i ,  N . ,  e t  a l . ,  In c r ea s ed  o s t eo c y t e  d ea th  in  mu l t ip l e  m y e loma  pa t i en t s :  ro l e  in  m y e loma -  
indu c ed  o s t eo c la s t  fo rma t ion .  L eu k em i a ,  2012 .  26 (6 ) :  p .  1391 -401 . 
47 .  G iu l i an i ,  N . ,  V .  R i z zo l i ,  and  G .D .  Roodm an ,  Mu l t ip l e  m y e loma  bon e  d i s ea s e :  pa thoph y s io log y  o f  
o s t eob la s t  inh ib i t ion .  B lood ,  2006 .  108 (13 ) :  p .  3992 -3996 . 
48 .  Fow l e r ,  J .A . ,  e t  a l . ,  Bon e  ma r row  s t roma l  c e l l s  c r ea t e  a  p e rm i s s i v e  m i c ro en v i ronm en t  fo r  m y e loma  
d e v e lopm en t :  a  n ew  s t roma l  ro l e  fo r  Wn t  inh ib i to r  D k k1 .  C an c e r  R e s ,  2012 .  72 (9 ) :  p .  2183 -9 . 
49 .  L am y ,  O . ,  e t  a l . ,  S e v e r e  R ebound -A s so c ia t ed  V e r t eb ra l  F ra c tu r e s  A f t e r  D eno sumab  
D i s con t inua t ion :  9  C l in i ca l  Ca s e s  R epo r t .  Th e  Jou rn a l  o f  C l in i c a l  Endo c r ino lo g y  &  M e t abo l i sm ,  
2017 .  102 (2 ) :  p .  354 -358 . 
50 .  R a j e ,  N . ,  e t  a l . ,  D eno sumab  v e r su s  zo l ed ron i c  a c id  in  bon e  d i s ea s e  t r ea tm en t  o f  n ew l y  d iagno s ed  
mu l t ip l e  m y e loma :  an  in t e rna t iona l ,  doub l e -b l ind ,  doub l e -dumm y ,  random i s ed ,  con t ro l l ed ,  pha s e  
3  s tud y .  L an c e t  On co l ,  2018 . 
51 .  An a s t a s i l a k i s ,  A .D . ,  e t  a l . ,  C l in i ca l  F ea tu r e s  o f  24  Pa t i en t s  W i th  R ebound -A s so c ia t ed  V e r t eb ra l  
F ra c tu r e s  A f t e r  D eno sumab  D i s con t inua t ion :  S y s t ema t i c  R e v i ew  and  Add i t iona l  Ca s e s .  Jou rn a l  o f  
Bon e  and  M in e r a l  R e s e a r ch ,  2017 .  32 (6 ) :  p .  1291 -1296 . 
52  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 52 .  Ko s t enu i k ,  P . J . ,  e t  a l . ,  D eno sumab ,  a  fu l l y  human  mono c lona l  an t ibod y  to  RANK L ,  inh ib i t s  bon e  
r e so rp t ion  and  in c r ea s e s  BMD  in  kno c k - in  m i c e  tha t  e xp r e s s  ch im e r i c  (mu r in e /human )  RANK L .  J  
Bon e  M in e r  R e s ,  2009 .  24 (2 ) :  p .  182 -95 . 
53 .  B a ron ,  R . ,  S .  F e r r a r i ,  and  R .G .  Ru s s e l l ,  D eno sumab  and  b i spho sphona t e s :  d i f f e r en t  m e chan i sm s  o f  
a c t ion  and  e f f e c t s .  Bon e ,  2011 .  48 (4 ) :  p .  677 -92 . 
54 . M a s a r a ch i a ,  P . ,  e t  a l . ,  Compa r i son  o f  th e  d i s t r ibu t ion  o f  3H -a l end rona t e  and  3H - e t id rona t e  in  ra t  
and  mou s e  bon e s .  Bon e ,  1996 .  19 (3 ) :  p .  281 -90 . 
55 . M cC lun g ,  M .R . ,  Inh ib i t ion  o f  RANK L  a s  a  t r ea tm en t  fo r  o s t eopo ro s i s :  p r e c l in i ca l  and  ea r l y  c l in i ca l  
s tud i e s .  Cu r r  O s t eopo ro s  R ep ,  2006 .  4(1 ) :  p .  28 -33 . 
56 .  B rown ,  J .P . ,  e t  a l . ,  Compa r i son  o f  th e  e f f e c t  o f  d eno sumab  and  a l end rona t e  on  BMD  and  
b io ch em i ca l  ma r k e r s  o f  bon e  tu rno v e r  in  po s tm enopau sa l  wom en  w i th  low  bon e  ma s s :  a  
random i z ed ,  b l ind ed ,  pha s e  3  t r ia l .  J  Bon e  M in e r  R e s ,  2009 .  24 (1 ) :  p .  153 -61 . 
57 .  K end l e r ,  D . L . ,  e t  a l . ,  E f f e c t s  o f  d eno sumab  on  bon e  m in e ra l  d en s i t y  and  bon e  tu rno v e r  in  
po s tm enopau sa l  wom en  t ran s i t ion ing  f rom  a l end rona t e  th e rap y .  J  Bon e  M in e r  R e s ,  2010 .  25 (1 ) :  
p .  72 -81 . 
58 .  H en r y ,  D .H . ,  e t  a l . ,  Random i z ed ,  Doub l e -B l ind  S tud y  o f  D eno sumab  V e r su s  Zo l ed ron i c  A c id  in  th e  
T r ea tm en t  o f  Bon e  M e ta s ta s e s  in  Pa t i en t s  W i th  Ad van c ed  Can c e r  ( E x c lud ing  B r ea s t  and  P ro s ta t e  
Can c e r )  o r  Mu l t ip l e  M y e loma .  Jou rn a l  o f  C l in i c a l  On co lo g y ,  2011 .  29 (9 ) :  p .  1125 -1132 . 
59 .  P e r e z -P e r son a ,  E . ,  e t  a l . ,  N ew  c r i t e r ia  to  id en t i f y  r i s k  o f  p rog r e s s ion  in  mono c lona l  gammopa th y  o f  
un c e r ta in  s ign i f i can c e  and  smo ld e r ing  mu l t ip l e  m y e loma  ba s ed  on  mu l t ipa ram e t e r  f low  c y tom e t r y  
ana l y s i s  o f  bon e  ma r row  p la sma  c e l l s .  B lood ,  2007 .  110 (7 ) :  p .  2586 -92 . 
60 .   Upda ted  r isk  s t ra t i f ica t ion  mode l  fo r  smo lde r ing  mu l t ip le  mye loma  (SMM )  inco rpo ra t ing  the  rev ised  
IMWG  d iagnos t ic  c r i te r ia .   Je su s  San  M igue l ,  Ma r ia -V i c to r ia  Ma teos ,  Ve ron i ca  Gon za le z ,  Me le t ios  A .  
D imopou lo s ,  E f s ta th io s  Ka s t r i t i s ,  Roman  Ha je k ,  Ca r lo s  Fe rnánde z  de  La r rea  Rod r íguez ,  Ga re th  John  
Mo rgan ,  G iampao lo  Me r l in i ,  S i lv ia  Mang ia ca va l l i ,  Ha r tmu t  Go ld s chm id t ,  M i che le  Ca vo ,  Cha ra lamp ia  
K y r ia kou ,  M ing  Q i ,  Jon  U k rope c ,  B rendan  M .  We is s ,  Ch r i s  Came ron ,  S .  V in cen t  Ra j kuma r ,  B r ian  G .  Du r ie ,  
and  Sha j i  Kuma r .  Jou rna l  o f  C l in i ca l  On co log y  2019  37 :15_ supp l ,  8000 -8000 
53  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 13APPEND IX  A  :  IMWG  RESPONSE  CR IT  ER IA 
IN T ERNA T IONA L  MY E LOMA  WORK ING  GROUP  ( IMWG )  UN I FORM  R E SPON S E  CR I T ER IA  FOR  MU L T IP L E  MY E LOMA 
R e spon s e IMWG  c r i t e r ia 
sCR CR  a s  d e f in ed  b e low  p lu s  no rm a l  F LC  r a t io  and  ab s en c e  o f  c lon a l  c e l l s  in  
bon e  m a r row 3 b y  immunoh i s to ch em i s t r y  o r  immuno f luo r e s c en c e 4
CR N e g a t i v e  immuno f i x a t ion  on  th e  s e rum  and  u r in e  and  d i s app e a r an c e  o f  an y  
so f t  t i s su e  p l a sm a c y tom a s  and  <  5%  p l a sm a  c e l l s  in  bon e  m a r row3 
VGPR S e rum  and  u r in e  M -p ro t e in  d e t e c t ab l e  b y  immuno f i x a t ion  bu t  no t  on  
e l e c t ropho r e s i s  o r  >  90%  r edu c t ion  in  s e rum  M -p ro t e in  p lu s  u r in e  M -p ro t e in  
l e v e l  <  100  m g /24  h 
>  50%  r edu c t ion  o f  s e rum  M -p ro t e in  and  r edu c t ion  in  24  hou r s  u r in a r y  M - 
p ro t e in  b y  >90%  o r  to  <  200  m g /24  h 
I f  th e  s e rum  and  u r in e  M -p ro t e in  a r e  unm e a su r ab l e , ⁵  a  >50%  d e c r e a s e  in  
th e  d i f f e r en c e  b e tw e en  in vo l v ed  and  un in vo l v ed  F LC  l e v e l s  i s  r equ i r ed  in  
p l a c e  o f  th e  M -p ro t e in  c r i t e r i a 
I f  s e rum  and  u r in e  M -p ro t e in  a r e  no t  m e a su r ab l e ,  and  s e rum  f r e e  l i gh t  a s s a y  
i s  a l so  no t  m e a su r e ab l e ,  >  50%  r edu c t ion  in  p l a sm a  c e l l s  i s  r equ i r ed  in  p l a c e  
o f  M -  p ro t e in ,  p ro v id ed  b a s e l in e  bon e  m a r row  p l a sm a  c e l l  p e r c en t a g e  w a s 
>  30% PR 
In  add i t ion  to  th e  abo v e  l i s t ed  c r i t e r i a ,  i f  p r e s en t  a t  b a s e l in e ,  a  >  50%  
r edu c t ion  in  th e  s i z e  o f  so f t  t i s su e  p l a sm a c y tom a s  i s  a l so  r equ i r ed 
MR NA 
No  ch an g e / S t ab l e  d i s e a s e No t  m e e t in g  c r i t e r i a  fo r  CR ,  VGPR ,  PR ,  o r  p ro g r e s s i v e  d i s e a s e 
P l a t e au NA 
54  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a 
D a t e :  15 Ju l2021 P ro g r e s s i v e  D i s e a s e ⁵ In c r e a s e  o f  >  25%  f rom  low e s t  r e spon s e  v a lu e  in  an y  on e  o r  mo r e  o f  th e  
fo l low in g : 
S e rum  M - compon en t  and /o r  ( th e  ab so lu t e  in c r e a s e  mu s t  b e  >0 .5  g /d L ) ⁶  
U r in e  M - compon en t  and /o r  ( th e  ab so lu t e  in c r e a s e  mu s t  b e  >  200  m g /24  h ) 
On l y  in  p a t i en t s  w i thou t  m e a su r ab l e  s e rum  and  u r in e  M -p ro t e in  l e v e l s ;  th e  
d i f f e r en c e  b e tw e en  in vo l v ed  and  un in vo l v ed  F LC  l e v e l s .  Th e  ab so lu t e  
in c r e a s e  mu s t  b e  >  10  m g /d L 
Bon e  m a r row  p l a sm a  c e l l  p e r c en t a g e ;  th e  ab so lu t e  p e r c en t a g e  mu s t  b e  >  
10% ⁷ 
D e f in i t e  d e v e lopm en t  o f  n ew  bon e  l e s ion s  o r  so f t  t i s su e  p l a sm a c y tom a s  o r  
d e f in i t e  in c r e a s e  in  th e  s i z e  o f  e x i s t in g  bon e  l e s ion s  o r  so f t  t i s su e  
p l a sm a c y tom a s 
D e v e lopm en t  o f  h yp e r c a l c em i a  ( co r r e c t ed  s e rum  c a l c ium  >  11 .5  m g /d L  o r 
2 .65  mmo l / L )  th a t  c an  b e  a t t r ibu t ed  so l e l y  to  th e  p l a sm a  c e l l  p ro l i f e r a t i v e  
d i so rd e r 
R e l ap s e C l in i c a l  r e l ap s e  r equ i r e s  on e  o r  mo r e  o f : 
D i r e c t  ind i c a to r s  o f  in c r e a s in g  d i s e a s e  and /o r  end  o r g an  d y s fun c t ion  (CRAB  
f e a tu r e s ) . ⁶  I t  i s  no t  u s ed  in  c a l cu l a t ion  o f  t im e  to  p ro g r e s s ion  o r  p ro g r e s s ion -  
f r e e  su r v i v a l  bu t  i s  l i s t ed  a s  som e th in g  th a t  c an  b e  r epo r t ed  op t ion a l l y  o r  fo r  
u s e  in  c l in i c a l  p r a c t i c e 
D e v e lopm en t  o f  n ew  so f t  t i s su e  p l a sm a c y tom a s  o r  bon e  l e s ion s 
D e f in i t e  in c r e a s e  in  th e  s i z e  o f  e x i s t in g  p l a sm a c y tom a s  o r  bon e  l e s ion s .  A  
d e f in i t e  in c r e a s e  i s  d e f in ed  a s  a  50%  ( and  a t  l e a s t  1  cm )  in c r e a s e  a s  
m e a su r ed 
s e r i a l l y  b y  th e  sum  o f  th e  p rodu c t s  o f  th e  c ro s s -d i am e t e r s  o f  th e  m e a su r ab l e  
l e s ion 
H yp e r c a l c em i a  ( >  11 .5  m g /d L )  [2 .65  mmo l / L ]  D e c r e a s e  in  h emo g lob in  o f  >  2  
g /d L  [1 .25  mmo l / L ] 
R i s e  in  s e rum  c r e a t in in e  b y  2  m g /d L  o r  mo r e  [177  mmo l / L  o r  mo r e ] 
R e l ap s e  f rom  CR 5 ( To  b e  u s ed  
on l y  i f  th e  end  po in t  s tud i ed  i s  
D F S ) 8An y  on e  o r  mo r e  o f  th e  fo l low in g : 
R e app e a r an c e  o f  s e rum  o r  u r in e  M -p ro t e in  b y  immuno f i x a t ion  o r  
e l e c t ropho r e s i s 
D e v e lopm en t  o f  >  5%  p l a sm a  c e l l s  in  th e  bon e  m a r row7 
App e a r an c e  o f  an y  o th e r  s i gn  o f  p ro g r e s s ion  ( i . e . ,  n ew  p l a sm a c y tom a s ,  l y t i c  
bon e  l e s ion ,  o r  h yp e r c a l c em i a ) 
1  BGM  Du r i e  e t  a l .  In t e rn a t ion a l  un i fo rm  r e spon s e  c r i t e r i a  fo r  mu l t ip l e  m y e lom a .  L eu k em i a  (2006 )  1 -7 . 
Ad ap t ed  f rom  Du r i e  BGM ,  e t  a l .  L eu k em i a  2006 ;  20 :  1467 -1473 ;  and  K y l e  RA ,  R a j kum a r  SV .  L eu k em i a  2008 ;23 :3 -9 . 
No t e :  A  c l a r i f i c a t ion  to  IMWG  c r i t e r i a  fo r  cod in g  CR  and  VGPR  in  p a t i en t s  in  whom  th e  on l y  m e a su r ab l e  d i s e a s e  i s  
b y  s e rum  F LC  l e v e l s :  CR  in  su ch  p a t i en t s  i s  d e f in ed  a s  a  no rm a l  F LC  r a t io  o f  0 .26 –1 .65  in  add i t ion  to  CR  c r i t e r i a  l i s t ed  
abo v e .  VGPR  in  su ch  p a t i en t s  i s  d e f in ed  a s  a  >90%  d e c r e a s e  in  th e  d i f f e r en c e  b e tw e en  in vo l v ed  and  un in vo l v ed  
f r e e  l i gh t  ch a in  ( F LC )  l e v e l s . 
3  Con f i rm a t ion  w i th  r ep e a t  bon e  m a r row  b iop s y  no t  n e ed ed . 
4  P r e s en c e / ab s en c e  o f  c lon a l  c e l l s  i s  b a s ed  upon  th e  k app a / l ambd a  r a t io .  An  abno rm a l  k app a / l ambd a  r a t io  b y  
immunoh i s to ch em i s t r y  and /o r  immuno f luo r e s c en c e  r equ i r e s  a  m in imum  o f  100  p l a sm a  c e l l s  fo r  an a l y s i s .  An  
abno rm a l  r a t io  r e f l e c t in g  p r e s en c e  o f  an  abno rm a l  c lon e  i s  k app a / l ambd a  o f  >  4 :1  o r  <  1 :2 . 
5  A l l  r e l ap s e  c a t e go r i e s  r equ i r e  two  con s e cu t i v e  a s s e s sm en t s  m ad e  a t  an y  t im e  b e fo r e  c l a s s i f i c a t ion  a s  r e l ap s e  o r  
d i s e a s e  p ro g r e s s ion  and /o r  th e  in s t i tu t ion  o f  an y  n ew  th e r ap y .  In  th e  IMWG  c r i t e r i a ,  CR  p a t i en t s  mu s t  a l so  m e e t  
th e  c r i t e r i a  fo r  p ro g r e s s i v e  d i s e a s e  shown  h e r e  to  b e  c l a s s i f i ed  a s  p ro g r e s s i v e  d i s e a s e  fo r  th e  pu rpo s e s  o f  
c a l cu l a t in g  t im e  to  p ro g r e s s ion  and  p ro g r e s s ion - f r e e  su r v i v a l .  Th e  d e f in i t ion s  o f  r e l ap s e ,  c l in i c a l  r e l ap s e  and  r e l ap s e  
f rom  CR  a r e  no t  to  b e  u s ed  in  c a l cu l a t ion  o f  t im e  to  p ro g r e s s ion  o r  p ro g r e s s ion - f r e e  su r v i v a l . 
6  Fo r  p ro g r e s s i v e  d i s e a s e ,  s e rum  M - compon en t  in c r e a s e s  o f  >1  gm /d L  a r e  su f f i c i en t  to  d e f in e  r e l ap s e  i f  s t a r t in g  M -  
compon en t  i s  >5  g /d L . 
7  R e l ap s e  f rom  CR  h a s  th e  5%  cu t -o f f  v e r su s  10%  fo r  o th e r  c a t e go r i e s  o f  r e l ap s e . 
8  Fo r  pu rpo s e s  o f  c a l cu l a t in g  t im e  to  p ro g r e s s ion  and  p ro g r e s s ion - f r e e  su r v i v a l ,  CR  p a t i en t s  shou ld  a l so  b e  
e v a lu a t ed  u s in g  c r i t e r i a  l i s t ed  abo v e  fo r  p ro g r e s s i v e  d i s e a s e . 
52  |  P  a  g  e 
D eno sum ab  fo r  Smo ld e r in g  Mu l t ip l e  M y e lom a  
D a t e :  01 F eb2019 
14APPEND IX  B :  ABBREV IA  T IONS 
Abb re v i a t ion Un abb re v i a ted 
A E Ad v e r s e  e v en t s 
BMPC Bon e  m a r row  p l a sm a  c e l l 
Cb c Comp l e t e  b lood  ch em i s t r y 
Cmp Comp r eh en s i v e  m e t abo l i c  p ro f i l e 
C r C r e a t in in e 
CR Comp l e t e  r e spon s e 
CR F C a s e  r epo r t  fo rm 
CR F C a s e  r epo r t  fo rm 
C TCA E Common  T e rm ino lo g y  C r i t e r i a  fo r  Ad v e r s e  
E v en t s 
DKK1 D i c k kop f - r e l a t ed  p ro t e in  1 
d L D e c i l i t e r 
DR Down g r ad e  r a t e 
D SMC D a t a  s a f e t y  mon i to r in g  comm i t t e e 
DXA Du a l  en e r g y  x - r a y  ab ro rp t iom e t r y  s c an 
F LC F r e e  l i gh t  ch a in 
G G r am 
H IV Hum an  immunod e f i c i en c y  v i ru s 
I F E Immuno f i x a t ion 
IMWG In t e rn a t ion a l  m y e lom a  wo r k in g  g roup 
IQR In t e rqu a r t i l e  r an g e 
kD a k i lod a l ton s 
L l i t e r 
M mono c lon a l 
M g M i l l i g r am 
MGU S Mono c lon a l  g ammop a th y  o f  und e t e rm in ed  
s i gn i f i c an c e 
MM Mu l t ip l e  m y e lom a 
Mmo l m i l l imo l e s 
N g N ano g r am s 
ON J O s t eon e c ro s i s  o f  th e  j aw 
OPG o s t eop ro t e g r in 
P F S P ro g r e s s ion  f r e e  su r v i v a l 
P S P e r fo rm an c e  s t a tu s 
Q4w E v e r y  4  w e e k s 
RANK R e c ep to r  a c t i v a to r  o f  nu c l e a r  f a c to r  k app a -B 
RANK L R e c ep to r  a c t i v a to r  o f  nu c l e a r  f a c to r  k app a -B  
l i g and 
SA E S e r iou s  ad v e r s e  e v en t s 
SC sub cu t an eou s 
sCR S t r in g en t  comp l e t e  r e spon s e 
SMM Smo ld e r in g  mu l t ip l e  m y e lom a 
SP EP S e rum  p ro t e in  e l e c t ropho r e s i s 
SR E S k e l e t a l  r e l a t ed  e v en t s 
SU SAR su sp e c t ed  un e xp e c t ed  s e r iou s  ad v e r s e  
r e a c t ion 
U LN Upp e r  l im i t  o f  no rm a l 
uN T x U r in a r y  N - t e lop ep t id e 
UP EP U r in e  p ro t e in  e l e c t ropho r e s i s 
.